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ABSTRACT 
REGULATION OF THE CYSTINE/GLUTAMATE ANTIPORTER AND ITS 
CONTRIBUTION TO NEURONAL DEATH 
 
 
Rebecca Lee Albano, B.S. 
 
Marquette University, 2016 
 
 
The aim of this thesis is to better understand the regulation of the 
cystine/glutamate antiporter (system xc-) and its role in regulating neuronal survival and 
death.  Expressed primarily on astrocytes, system xc- takes up cystine and releases 
glutamate in a 1:1 ratio.  Cystine uptake is the rate-limiting step in glutathione synthesis, 
the brain’s main antioxidant.  Glutamate released into the extrasynaptic space can 
regulate neuronal function; however excessive glutamate release can cause excitotoxicity. 
 
The dual actions of system xc- make it of interest in many neurodegenerative 
diseases where oxidative stress and excitotoxicity are involved.  We investigated the 
regulation of system xc- in SOD1-G93A transgenic mouse model of ALS.  We observed 
an increase in cystine uptake and glutamate release through system xc- in spinal cord 
slices of SOD1-G93A transgenic mice.  We did not observe a change in the function of 
the main glutamate clearance transporter, excitatory amino acid transporter (EAAT).  
This study was the first to show that system xc- activity is dysregulated in an ALS model 
and suggests that the excitotoxicity in the SOD1-G93A transgenic mouse may be due to 
increased system xc- activity. 
 
 Using primary mixed cortical cultures we assessed how different compounds that 
deplete intracellular glutathione (GSH), L-buthionine-sulfoximine (BSO) and diethyl 
maleate (DEM), affect system xc- function.   Both compounds caused significant 
decreases in intracellular GSH levels; however, DEM caused an increase in cystine 
uptake through system xc-, while unexpectedly BSO caused a decrease in uptake.  Also, 
DEM caused a decrease in intracellular cysteine, while BSO increased cysteine levels.  
The results suggest that negative feedback by intracellular cysteine is a more important 
regulator of system xc- than intracellular GSH. 
 
 Transforming growth factor-β1 (TGF-β1) is a cytokine involved in regulating 
many cellular processes, including neuronal survival and death.  We found that TGF-β1 
increased cystine uptake through system xc- in astrocyte-enriched glial cultures via the 
MAPK/ERK pathway.  TGF-β1 increased the export of GSH from astrocytes, which 
suggests a neuroprotective role; however, in mixed cortical cultures TGF-β1 enhanced 
rotenone-induced neurotoxicity through AMPA receptors.  The data suggests that the 
increase in system xc- activity by TGF-β1 may have antioxidant defenses, but also 
exacerbates excitotoxicity. 
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CHAPTER I 
 
 
INTRODUCTION 
 
 
General Introduction 
 
The increase in human lifespan over the past several decades has been 
accompanied by an increase in the prevalence of neurodegenerative diseases.  For 
example, in 2015 it was estimated that 5.3 million Americans had Alzheimer’s disease 
(AD).  Neurodegeneration is characterized by a loss of neuronal structure and function, 
including neuronal death. These diseases include Alzheimer’s disease (AD), Parkinson’s 
disease (PD), amyotrophic lateral sclerosis (ALS), and many more.  Although 
neurodegenerative diseases affect many people the cause of most of these diseases is still 
unknown.   However, they share some common characteristics, including excitotoxicity 
and oxidative stress, which provides hope that a therapeutic treatment targeting these 
factors may be able to help in many of these diseases simultaneously.  
The main focus of this thesis is to better understand the regulation of the 
cystine/glutamate antiporter (system xc-) and the role it plays in regulating neuronal 
survival and death.  Mainly located on astrocytes, system xc- takes up cystine into the 
cell, where it is used to synthesize glutathione, the brain’s main antioxidant (Figure 1.1).  
In exchange for taking up a molecule of cystine, system xc- releases one molecule of 
glutamate.  The glutamate released in the extrasynaptic space by system xc- is able to 
regulate synaptic function.  However, if glutamate levels become too high, they can also 
cause neuronal death through excitotoxicity.  Therefore, the function of system xc- allows 
it to play an important role in both oxidative stress and excitotoxicity and is likely to play 
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a role in neurodegenerative diseases. 
 
		
Figure 1.1 The function of system xc- in astrocytes and the effects it has on 
neurons.  C-C: cystine; Cys: cysteine; GSH: glutathione; Glu: glutamate; xc-: 
system xc-; E: excitatory amino acid transporter; A: AMPA receptor; N: NMDA 
receptor; M: metabotropic glutamate receptor; MRP-1: multidrug resistance 
protein 1 
 
 
GLUTAMATE NEUROTRANSMISSION 
  
 Glutamate is involved in most aspects of normal brain function.  Glutamate is the 
primary excitatory neurotransmitter in the central nervous system (CNS); as such it is 
involved in brain development, cognition, memory, and learning (Erecińska and Silver, 
1990; Meldrum, 2000).  It is also important in many aspects of cellular metabolism, 
including stimulating glycolysis and protein synthesis	(Dingledine	et	al.,	1999)	.  
Glutamate also has a wide array of indirect actions.  It is a precursor to γ-aminobutyric 
acid (GABA) (Petroff, 2002), the main inhibitory neurotransmitter in the brain, and it is 
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one of the three main components of glutathione (GSH) (Meister and Anderson, 1983), 
the main endogenous antioxidant in the CNS. 
 Glutamate has multiple receptors through which it signals, including ionotropic 
and metabotropic receptors (Figure 1.2).  Due to its many functions, glutamate levels are 
tightly regulated.  Multiple transporters are responsible for clearing glutamate from the 
synapse in order to maintain proper glutamatergic signaling and prevent the 
overactivation of glutamate receptors, which can lead to cell death.  Below is a brief 
review of some of these key aspects of glutamate neurotransmission. 
 
		
Figure 1.2 A typical tripartite glutamate synapse. A: AMPA receptor; N: 
NMDA receptor; M: metabotropic glutamate receptor receptor; E: excitatory 
amino acid transporter; Gln: glycine; Gln: glutamate; Sxc: system xc- 
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Glutamate Receptors 
 
 There are two classes of glutamate receptors: ionotropic receptors and 
metabotropic receptors.  Ionotropic receptors open to allow ions to flow in and out of the 
cell and are responsible for quick, short lasting responses.  Metabotropic receptors, on the 
other hand, signal through an intracellular second messenger, which results in slower, 
longer lasting responses.  Glutamatergic ionotropic receptors include 2-amino-3-(5-
methyl-3- oxo-1,2- oxazol-4-yl)propanoic acid (AMPA)/kainate receptors and N-methyl-
D-Aspartate (NMDA) receptors.  There are eight metabotropic glutamate receptors 
(mGluR 1-8) that are divided into three main subgroups.  Each type of receptor is briefly 
described. 
AMPA/Kainate Receptors 
 
 AMPA receptors have a low affinity for glutamate (EC50 value: 200-500µM)  
(Meldrum, 2000) and are composed of a heterotetramer of four subunits (GluR1-4) 
(Meldrum, 2000; Traynelis et al., 2010).  All AMPA receptors are permeable to sodium 
(Na+) and potassium (K+) and the permeability of the receptor to calcium (Ca2+) is 
determined by the GluR2 subunit (Hollmann et al., 1991).  Unlike the other subunits, 
GluR2 can undergo post-transcriptional editing (Sommer et al., 1990).  Edited GluR2 
subunits contain a positively charged arginine (R) residue instead of a neutral glutamine 
(Q) residue and are impermeable to Ca2+ (Sommer et al., 1991).  Most AMPA receptors 
contain the edited GluR2 subunit and therefore are only permeable to Na+ and K+; 
GluR2-lacking AMPA receptors are very permeable to Ca2+ and activation can result in a 
rise in intracellular Ca2+ levels (Isaac et al., 2007; Traynelis et al., 2010). 
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AMPA receptors are not voltage dependent and open and close quickly.  They 
mediate the fast initial part of the excitatory postsynaptic potential (EPSP) and are 
responsible for most of the fast excitatory synaptic transmission in the brain (Zhang and 
Trussell, 1994; Edmonds et al., 1995).  AMPA receptor trafficking into and out of the 
postsynaptic membrane plays a key role in determining the strength of the synapse 
(Malinow and Malenka, 2002; Shepherd and Huganir, 2007; Anggono and Huganir, 
2012). 
 Kainate receptors are composed of a tetramer of four subunits (GluK1-5).  They 
are permeable to Na+ and K+ and are located on both postsynaptic and presynaptic 
neurons (Chittajallu et al., 1999; Dingledine et al., 1999; Meldrum 2000).  The function 
of kainate receptors is not as well defined.  However, it is known that they act as 
modulators of synaptic activity through a variety of mechanisms, including regulating the 
release of both glutamate and GABA from presynaptic neurons and regulating the 
excitability of postsynaptic neurons (Contractor et al., 2011).  
NMDA Receptors 
 
NMDA receptors have a high affinity for glutamate (EC50: 2.5-3µM) (Meldrum, 
2000) They are a heterotetramer composed of two GluN1 and two GluN2 (GluN2A-D) or 
GluN3 subunits; the distribution of isoforms are regionally and developmentally specific 
(Watanabe et al., 1992; Laube et al. 1998; Dingledine et al., 1999).  There are two main 
ways in which NMDA receptors are distinct from AMPA receptors. First, under 
physiological conditions NMDA receptor channels are blocked by magnesium (Mg2+) 
(Nowak et al., 1984; Dingledine et al., 1999).  In order for the Mg2+ block to be removed, 
the cell membrane must first be depolarized by AMPA receptors.  Once the Mg2+ block is 
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removed, Na+, K+, and Ca2+ can flow through the NMDA receptor.  Second, NMDA 
receptor activation requires the binding of the co-agonist glycine or D-serine (Wilcox et 
al., 1996; Laube et al. 1998).  Glutamate/NMDA binds to the GluN2 subunit and 
glycine/D-serine binds to the GluN1 subunit.  NMDA receptors also have multiple 
allosteric modulation sites, which affect the activity of the channel (Dingledine et al., 
1999). 
Due to its slower kinetics the NMDA receptor is responsible for producing the 
slower, longer lasting part of the EPSP (Vargas-Caballero and Robinson, 2004). NMDA 
receptor activation leads to a rise in intracellular Ca2+ concentrations, which can activate 
many signaling pathways and is critical for synaptic plasticity, a mechanism of learning 
and memory (Malenka and Nicoll, 1993; Benfenati, 2007; Lüscher and Malenka, 2012). 
Metabotropic Glutamate Receptors 
 
 Metabotropic receptors consist of an extracellular N-terminus that contains a 
ligand-binding site, seven transmembrane domains, and an intracellular C-terminus that 
couples to a G-protein (Conn and Pin, 1997; Niswender and Conn, 2010).  Activating 
metabotropic receptors leads to the activation of the G-coupled protein and an 
intracellular signaling cascade.  There are eight metabotropic glutamate receptors 
(mGluRs) subdivided into three functional groups (Conn and Pin, 1997; Niswender and 
Conn, 2010; Willard and Koochekpour, 2013).  Group I consists of mGluR1 and mGluR5 
and are coupled to Gq proteins (Hermans and Challiss, 2001; Ribeiro et al., 2010).  Gq 
proteins primarily activate phospholipase C (PLC), which cleave phosphatidylinositol 
4,5-bisphosphate (PIP2) into inositol triphosphate (IP3) and diacyl-glycerol (DAG).  IP3 
releases Ca2+ from the endoplasmic reticulum and DAG stimulates protein kinase C 
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(PKC).  Both Group II (mGluR2 and mGluR3) and Group III (mGluR4-8) metabotropic 
glutamate receptors are coupled to Gi proteins (Conn and Pin, 1997; Niswender and 
Conn, 2010; Willard and Koochekpour, 2013). Activation of Gi proteins primarily 
inhibits adenylyl cyclase (AC), which decreases cyclic adenosine monophosphate 
(cAMP).   
mGluRs are primarily located perisynaptically and extrasynaptically on both 
postsynaptic and presynaptic neurons and modulate synaptic activity (Conn, 2003).  
Activation of postsynaptic mGluRs has been shown to modulate the activity of ion 
channels and presynaptic mGluRs inhibit the release of neurotransmitters (Conn and Pin, 
1997; Conn, 2003; Ribeiro et al., 2010).  mGluRs are also located on glia and their 
activation can lead to the release of glutamate from astrocytes and regulate the expression 
and function of glutamate transporters (D’Antoni et al., 2008). Glutamate binds to each of 
the receptors with varying affinity (Meldrum, 2000). 
Glutamate Clearance 
 
Clearing glutamate from the synapse is very important for terminating excitatory 
transmission and for keeping extracellular concentration of glutamate below excitotoxic 
levels (Nicholls and Attwell, 1990; Kanai and Hediger, 1992; Rothstein et al., 1996; Seal 
and Amara, 1999; Liang et al., 2008).  Excitatory amino acid transporters (EAATs) are 
high capacity glutamate transporters and are the primary mechanism responsible for the 
uptake of glutamate out of the synapse (Kanai and Hediger, 1992; Seal and Amara, 1999; 
Bridges et al., 2012a).  Intracellular glutamate concentrations are in the millimolar range, 
while extracellular concentrations are kept in the low micromolar range (Ronne-
Engström et al., 1995; Baker et al., 2003).  In order to create such a steep glutamate 
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concentration gradient, the uptake of one molecule of glutamate is coupled to the uptake 
of three molecules of Na+ and one molecule of hydrogen (H+) and the efflux of one 
molecule of K+ (Zerangue and Kavanaugh, 1996a).  Five EAATs (EAAT 1-5) have been 
cloned.  EAAT1/GLAST and EAAT2/GLT-1 are located on astrocytes and are 
responsible for the majority of glutamate clearance from the synapse (Rothstein et al., 
1994; Seal and Amara, 1999).  EAAT3 and EAAT4 are located on neurons and EAAT5 
is primarily expressed in the retina (Rothstein et al., 1994; Wersinger et al., 2006). 
Glutamate Microdomains 
 
Along with clearing glutamate from the synapse in order to terminate excitatory 
signaling, EAATs located on astrocytes can prevent glutamate in one synapse from 
diffusing into and activating receptors in neighboring synapses (Rusakov, 2001).  
Similarly, EAATs can also prevent glutamate released into the extrasynaptic space by 
astrocytes from diffusing into the synaptic zone (Jabaudon et al., 1999).  In this way, 
EAATs create microdomains of glutamate (Bridges et al., 2012a).  In the hippocampal 
synapses glutamate levels peak around 1.1mM, but quickly decay (Clements et al., 1992).  
Basal glutamate levels in the extrasynaptic space are 1 to 3µM (Baker et al., 2002), which 
is high enough to activate some types of extrasynaptic receptors. 
Activation of synaptic and extrasynaptic glutamate receptors by these separate 
microdomains of glutamate can lead to different functional outcomes.  One of the most 
well studied examples is the NMDA receptor.  Its activation is critical for neuronal 
survival, but at the same time activation can also lead to cell death.  Evidence suggests 
that this ‘NMDA paradox’ is a result of the receptor’s location (Hardingham and Bading, 
2010).  It is generally accepted that stimulating synaptic NMDA receptors activate 
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intracellular pathways that aid in neuroprotection, while stimulation of extrasynaptic 
NMDA receptors activate pathways that promote cell death (Hardingham et al., 2002; 
Léveillé et al., 2008).  When synaptic NMDA receptors are stimulated the influx of 
calcium into the cell induces cyclic-AMP response element binding protein (CREB) 
(Hardingham et al., 2002), a transcription factor that regulates many cell survival genes 
and has a well-documented role in neuronal protection (Bonni et al., 1999; Mayr and 
Montminy, 2001).  Synaptic NMDA receptor activation also inhibits the apoptotic 
cascade and protects against oxidative stress  (Hardingham and Bading, 2010; Léveillé et 
al., 2010; Papadia et al., 2008).  On the other hand, stimulating extrasynaptic NMDA 
receptors turn off CREB activity and leads to mitochondrial dysfunction (Hardingham et 
al., 2002).  Extrasynaptic NMDA receptor activation also inhibits extracellular signal-
regulated kinase (ERK) (Ivanov et al., 2006; Léveillé et al., 2008), a kinase that has been 
shown to play a role in synaptic NMDA receptor neuroprotection (Hetman and 
Kharebava, 2006). 
Excitotoxicity 
 
 While glutamate is necessary for normal brain function, just a brief exposure of 
mature cortical neurons to high levels of glutamate can cause morphological changes and 
neuronal death occurs within a few hours (Choi et al., 1987).  Under normal 
physiological conditions extracellular glutamate concentrations are tightly regulated, but 
if the regulation is disrupted and extracellular glutamate concentrations rise, 
excitotoxicity can occur.  Excitotoxicity is the damage and death of neurons, caused by 
an over activation of glutamate receptors (Choi et al., 1987).  It is a main pathology in 
many neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), 
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Alzheimer’s disease (AD), multiple sclerosis (MS), and Parkinson’s Disease (PD) (Leigh 
and Meldrum, 1996; Doble, 1999; Koutsilieri and Riederer, 2007; Dong et al., 2009).  It 
is also a key pathology in stroke/ischemia and traumatic brain injury (Choi, 1988; Hayes 
et al., 1988; Yi and Hazell, 2006; Szydlowska and Tymianski, 2010). 
Excitotoxicity is calcium dependent (Choi, 1985, 1987; Tymianski et al., 1993).  
Overactivation of glutamate receptors results in a large influx of calcium into the cell, 
which activates multiple enzymes.  Activation of these enzymes leads to an increase in 
free radicals, protein breakdown, cell membrane degradation, and DNA damage, 
culminating in cell death (Freeman and Crapo, 1982; Mark et al., 2001; Berliocchi et al., 
2005).  Excitotoxicity can occur as a result of NMDA receptor overactivation.  For 
example, in vitro NMDA receptor antagonists significantly block cell death induced by 
glutamate (Choi et al., 1988; Tymianski et al., 1993).  NMDA overactivation is also 
involved in many models of disease.  Microglia treated with amyloid-beta (Aβ), a 
hallmark of AD, have increased glutamate release, which results in enhanced cortical 
neuron toxicity.  Multiple NMDA receptor antagonists can block this enhanced toxicity 
(Qin et al., 2006).  In vivo, excitotoxicity caused by Aβ is blocked by the NMDA receptor 
antagonist, memantine (MEM) (Miguel-Hidalgo et al., 2002).  In clinical trials, MEM has 
been shown to delay clinical signs of AD (Hellweg et al., 2012).  It has also been shown 
to be protective in other models of excitotoxicity, including the 1-methyl-4-
phenylpyridinium (MPP+) toxicity model of Parkinson’s disease and an in vivo model of 
hypoxia-ischemia (Volbracht et al., 2006), suggesting that NMDA receptor 
overactivation is involved. 
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Excitotoxicity can also occur as a result of overactivation of GluR2-lacking 
AMPA receptors.  Motor neurons are vulnerable to kainate toxicity because they have a 
high number of GluR2-lacking AMPA receptors; and calcium entry through these 
receptors is responsible for the toxicity (Carriedo et al., 1996; Van Den Bosch et al., 
2000; Van Damme et al., 2002).  In presymptomatic SOD1-G93A mouse, a model of 
ALS, an increase in GluR2-lacking AMPA receptors has been observed and AMPA 
receptor antagonists have been shown to increase motor neuron survival and prolong the 
survival of these mice (Van Damme et al., 2003; Tortarolo et al., 2006).  Overactivation 
of AMPA receptors may also play a role in MS.  In oligodendrocyte cultures, kainate or 
increasing extracellular glutamate levels leads to excitotoxicity, which can be blocked by 
AMPA receptor antagonists (Yoshioka et al., 1996; Domercq et al., 2005). AMPA 
receptor antagonists have been shown to also improve neurological scores in mice treated 
with autoimmune encephalitis (EAE), a model of MS (Smith et al., 2000).  
NEURON-ASTROCYTE INTERACTION 
 
 Astrocytes, the most common type of glial cell in the brain, are highly organized.  
They ensheath synapses and have non-overlapping domains (Ventura and Harris, 1999; 
Bushong et al., 2002; Nedergaard et al., 2003).  Traditionally, astrocytes are thought of as 
playing a supportive role to neurons; more recently, however, many studies are emerging 
that show astrocytes are a key player in regulating neurotransmission.  Below is a brief 
review of some important aspects of the neuron-astrocyte interaction. 
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Metabolic Coupling and the Glutamate/Glutamine Cycle 
 
 Glucose is the main substrate for energy production in the brain and the astrocyte-
neuron interaction is critical for maintaining energy homeostasis, as well as normal 
glutamatergic transmission.  After glutamate is released into the synapse it is taken up by 
astrocytes through EAATs, along with three molecules of Na+ (Zerangue and Kavanaugh, 
1996a).  The increase in intracellular Na+ concentration activates the Na+/K+ pump, 
which triggers astrocytes to take up glucose from capillaries, which are covered by 
astrocytic end feet.  The activation of the Na+/K+ pump also triggers glycolysis, which 
metabolizes glucose into lactate, a process that yields two molecules of adenosine 
triphosphate (ATP) (Pellerin and Magistretti, 1994; Magistretti and Pellerin, 1999).  The 
lactate is then released by astrocytes and taken up by neurons, where it is converted into 
pyruvate and goes through the tricarboxylic acid (TCA) cycle to supply the neuron with 
energy (Tsacopoulos and Magistretti, 1996; Magistretti and Pellerin, 1999).  The two 
molecules of ATP produced by glycolysis are used to convert glutamate to glutamine by 
the enzyme glutamine synthase.  Glutamine is then released and taken up by neurons, 
where it is converted back into glutamate (Sibson et al., 1998).  This metabolic 
interaction is illustrated in Figure 1.3.  Since this cycle depends on uptake of glutamate 
from the synapse following neurotransmission, EAAT activation is an activity-dependent 
signaling mechanism for the utilization of glucose (Sibson et al., 1998; Magistretti and 
Pellerin, 1999). 
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Figure 1.3 Interaction between astrocytes and neurons: metabolic coupling 
and the glutamate/glutamine cycle.  A: AMPA receptor; N: NMDA receptor; 
M: metabotropic glutamate receptor receptor; E: excitatory amino acid transporter 
Adapted and modified from (Magistretti and Pellerin, 1999) 
 
 
Neuronal Regulation of Astrocytes 
 
Like neurons, astrocytes express a wide variety of ion channels and 
neurotransmitter receptors, including K+ channels, ionotropic glutamate receptors, 
mGluRs, GABA receptors, muscarinic aceylcholine (mAch) receptors and 
endocannabinoid (CB) receptors (Barres, 1991; Newman, 2003; Navarrete and Araque, 
2008).  Neuronal activity can activate these receptors and lead to a wide range of effects.  
For example, astrocyte membranes can be depolarized in response to glutamate or in 
response to high concentrations of extracellular K+ that result from high neuronal activity 
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(Bowman and Kimelberg, 1984; Sontheimer et al., 1988; Usowicz et al., 1989; Murphy et 
al., 1993; Meeks and Mennerick, 2007).  GABA released from neurons has been shown 
to regulate astrocyte morphology through GABAA receptors (Matsutani and Yamamoto, 
1997) .  Although the mechanism is unknown, neurons can also regulate expression of 
glutamate transporter subtypes (Swanson et al., 1997).  Activation of many of the G-
protein coupled receptors on astrocytes leads to increased intracellular concentrations of 
Ca2+  (Porter and McCarthy, 1996; Araque et al., 2002; Newman, 2003; Navarrete and 
Araque, 2008).  
Astrocyte Regulation of Neurons 
 
 Astrocytes are involved in most aspects of synaptic transmission (Araque et al., 
1999; Newman, 2003; Bridges et al., 2012a).  They take part in synaptogenesis by 
influencing synapse formation, axonal pruning, and synapse elimination through secreted 
and cell-surface signals (Ullian et al., 2001; Eroglu and Barres, 2010).  Intracellular Ca2+ 
waves can cause astrocytes to release vesicular gliotransmitters that regulate neuronal 
function and synaptic plasticity (Araque et al., 1999, 2000; Newman, 2003).  For 
example, glutamate release from astrocytes can increase neuronal Ca2+ levels (Parpura et 
al., 1994).  Astrocytes influence synaptic plasticity by enhancing neuronal NMDA 
receptor activation and enabling induction of long-term potentiation (LTP) through 
release of D-serine (Yang et al., 2003) .  Non-vesicular release of glutamate from 
astrocytes through the cystine/glutamate antiporter (system xc-) can also influence 
neuronal transmission through activation of extrasynaptic glutamate receptors (Bridges et 
al., 2012a; 2012b; Massie et al., 2015). 
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Due to its highly branched morphology, one astrocyte is able to interact with tens 
of thousands of synapses (Halassa et al., 2007), which allows them to synchronize 
neuronal activity (Rouach et al., 2008).  It also allows for neurons to influence synaptic 
transmission of neighboring synapses by signaling through astrocytes (Araque et al., 
1999; Angulo et al., 2004; Navarrette and Araque, 2008).  And although astrocytes have 
non-overlapping domains, they are coupled together by gap junctions (Dermietzel et al., 
1991; Giaume et al., 1991), through which signals spread rapidly between astrocytes, 
allowing them to work together as a network (Rouach et al., 2008; Giaume et al., 2010). 
OXIDATIVE STRESS 
  
A common pathology in many neurodegenerative diseases discussed in this thesis 
is oxidative stress.  Oxidative stress is an accumulation of reactive oxygen species (ROS) 
due to an imbalance between the production of ROS and the body’s ability to eliminate 
them.  Common ROS include superoxide (O2-), hydroxyl radical (OH-) and hydrogen 
peroxide (H2O2).  The brain is particularly vulnerable to oxidative stress because of its 
high oxygen consumption. 
Production and Elimination of ROS 
 
There are two main sources of intracellular ROS production.  First, ROS are 
produced during normal mitochondrial oxidative metabolism.  During cellular respiration 
electrons from the mitochondria leak out and react with oxygen, forming O2-, the 
precursor of most other ROS  (Freeman and Crapo, 1982; Kirkinezos and Moraes, 2001; 
Turrens, 2003) .  The second source is from activity of the membrane bound enzyme 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase.  NADPH oxidases are 
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found in neurons, astrocytes, and microglia; and when active they generate O2- as 
electrons cross the cell membrane and couple with oxygen  (Infanger et al., 2006; Sorce 
and Krause, 2009) . 
As seen in Figure 1.4 cells have various defense mechanisms against ROS, 
including superoxide dismutases (SOD), catalase, and glutathione (GSH).  SODs are a 
class of enzymes that catalyze O2- into H2O2 (Fridovich, 1975).  While H2O2 itself is not 
reactive, the bond between the two oxygen atoms is very weak and it can form the highly 
reactive hydroxyl radical OH- via the Fenton reaction (Winterbourn, 1995).  Some H2O2 
reacts with a catalase to form the non-harmful byproducts, water and oxygen (George, 
1947).  The majority of H2O2 is removed by GSH in a reaction catalyzed by glutathione 
peroxidase, which oxidizes GSH into glutathione disulfide (GSSG) and forms water 
(Finley et al., 1981; Winterbourn and Metodiewa, 1994).  GSSG can be converted back 
into GSH by glutathione reductase and the reduced form of NADPH (Simonian and 
Coyle, 1996).  Under normal conditions, 99% of total cellular GSH is in the reduced 
form.  However, when oxidative stress occurs, GSSG is rapidly produced and 
accumulates in the cell (Deneke and Fanburg, 1989). 
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Figure 1.4 Cellular pathways involved in regulating O2. GSH: glutathione; 
GSSG: oxidized glutathione; H2O: water; O2: oxygen: O2-: superoxide; OH-: 
hydroxal radical; H2O2: hydrogen peroxide; Fe: iron 
 
 
Oxidative stress occurs when there is an accumulation of ROS, due to an 
imbalance between ROS production and removal, which can occur through a number of 
mechanisms.  For example, middle cerebral artery occlusion in mice upregulates NADPH 
oxidase expression in the mouse brain resulting in an increase in ROS production  (Vallet 
et al., 2005) .  Mitochondrial dysfunction is a common mechanism behind increased ROS 
production; multiple new therapeutics are aimed at targeting the mitochondria because 
mitochondrial dysfunction is a main pathology in many neurodegenerative diseases  (Lin 
and Beal, 2006; Federico et al., 2012; Lee, 2016).  Decreased ROS removal can also 
make cells more susceptible to oxidative damage.  For example, dopaminergic neurons 
co-cultured with astrocytes show increased toxicity to H202 when the astrocytes have 
been depleted of GSH (Drukarch et al., 1997).  Increased intracellular ROS causes 
damage to DNA, protein oxidation, and damage to the plasma membrane via lipid 
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peroxidation (Freeman and Crapo, 1982; Berliocchi et al., 2005).  Prolonged exposure to 
oxidative stress leads to cell death. 
Glutathione Metabolism 
 
 GSH, a tripeptide composed of cysteine, glutamate, and glycine, is the major 
antioxidant found in the brain.  GSH synthesis occurs intraceullularly in a two-step 
process (Meister and Anderson, 1983).  First, the enzyme glutamate-cysteine ligase 
(GCL) catalyzes glutamate and cysteine to produce the dipeptide, γ-glutamylcysteine 
(γGluCys).  Glycine is then added to the dipeptide by GSH synthase (GS) to form GSH.  
Both steps require ATP and GSH metabolism is dependent upon the availability of 
glutamate, cysteine, and glycine.  Since glutamate and glycine are highly available, the 
uptake of cystine or cysteine into the cell is the rate-limiting step in GSH synthesis 
(Sagara et al., 1993a; Dringen and Hirrlinger, 2003). 
 There are two well characterized mechanisms found on astrocytes and neurons 
that take up cystine or cysteine: system xc- and the glutamate/aspartate/cysteine 
transporter (EAAC1/EAAT3).  Astrocytes transport cystine, mainly through system xc- 
(Sagara et al., 1993a; Kranich et al., 1998; Bridges et al., 2012b).  Once inside the cell, 
cystine is rapidly reduced into two cysteine molecules and metabolized into GSH 
(Dringen and Hirrlinger, 2003).  Neurons, on the other hand, have limited ability to take 
up cystine as a GSH precursor.  Instead neurons rely on cysteine or cysteinylglycine 
(CysGly) provided by astrocytes (Sagara et al., 1993a; Dringen et al., 1999; Wang and 
Cynader, 2000; Dringen and Hirrlinger, 2003).  Astrocytes export GSH into the 
extracellular space through multidrug resistance protein-1 (Mrp-1) (Minich et al., 2006), 
where it can be broken down by γ-glutamyl-transpeptidase into glutamate and CysGly 
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(Hanigan and Rickets, 1993).  Aminopeptidase-N, expressed on the cell membrane of 
neurons, then breaks CysGly down into glycine and cysteine (Dringen et al., 2001).  
Neurons then take up the extracellular cysteine through EAAT3 to synthesize GSH 
(Sagara et al., 1993a; Zerangue and Kavanaugh, 1996b; McBean, 2002).  Without the 
GSH/cysteine supplied by astrocytes, neurons are much more susceptible to oxidative 
insults (Drukarch et al., 1997; Abramov et al., 2003; Shih et al., 2003).  GSH metabolism 
is illustrated in Figure 1.5.  
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Figure 1.5 Interaction between astrocytes and neurons: GSH metabolism. 
Cystine (C-C) enters astrocytes through system xc- and is rapidly reduced to 
cysteine (cys).  Glutamate-cysteine ligase (GCL) catalyzes glutamate and cysteine 
to γ-glutamylcysteine (Cys-Glu).  Glycine (Gly) is added to the dipeptide by GSH 
synthase (GS) to form the tripeptide glutathione (GSH).  Astrocytes then export 
GSH through multidrug resistance protein 1 (MRP-1) into the extracellular space 
where it is broken down into cysteinylglycine (Cys-Gly) by γglutamyltransferase 
(γGT).  It is further broken down into glycine and cysteine by aminopeptidase 
(AP-N).  Cysteine can then be taken up into neurons via EAAT3 (E), where it is 
metabolized into GSH.  Adapted and modified from (Bridges et al., 2012) 
 
 
Although GSH is the main antioxidant in the brain, compared to other tissues the 
concentration of GSH is low.  The concentration also varies between cells types; for 
example, the concentration in neurons is ~2.5mM and in astrocytes it is ~3.8mM  (Rice 
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and Russo-Menna, 1998) .  The brain’s high oxygen consumption and low concentration 
of GSH makes it, particularly the neurons, susceptible to oxidative stress. 
TRANSFORMING GROWTH FACTOR-β1 
 
Transforming growth factor-β1 (TGF-β1), first discovered in the early 1980s, is a 
cytokine with wide ranging effects both in development and in the adult brain, including 
regulating cellular processes like growth and development (Böttner et al., 2000; 
Massagué et al., 2000), differentiation (Ishihara et al., 1994), and apoptosis (Prehn et al., 
1994; Zhu et al., 2001; 2002).  TGF-β1 is one of three TGF-β isoforms and is part the 
TGF-β superfamily, which includes multiple cytokines.  Its expression is very low during 
development and in the adult brain (Flanders et al., 1991; Pelton et al., 1991; Unsicker et 
al., 1991).  While some studies show it is mainly confined to the meninges and choroid 
plexus (Unsicker et al., 1991), others have found it is present in the cerebral cortex 
(Vivien et al., 1998).   
Receptors and Intracellular Signaling 
 
 When TGF-β1 is first synthesized it becomes part of a large latent complex (LLC) 
contained in the cell’s extracellular matrix (Akhurst and Hata, 2012).  The complex is 
composed of a TGF-β1 homodimer, a latency-associated peptide (LAP), and a latent 
TGFβ binding protein (LTBP).  When TGF-β1 is activated the LLC is released from the 
extracellular matrix and the LAP and LTBP are broken down, releasing TGF-β1.  Upon 
its release TGF-β1 is able to interact with its receptors: TGF-β receptor I and II (TGF-
βRI, -II) (Massagué, 1998).  Both TGF-βRI and TGF-βRII are serine/threonine kinases 
and are expressed on neurons, astrocytes, and microglia throughout the brain (Böttner et 
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al., 1996; Vivien et al., 1998; Vivien and Ali, 2006).  There are two TGF-βRI isoforms 
that TGF-β1 signals through: activin receptor-like kinase 1 (ALK1) and ALK5 
(Massagué, 1998; Akhurst and Hata, 2012).  Signaling begins when TGF-β1 binds to 
TGF-βRII, which recruits and phosphorylates TGF-βRI.  Following activation, TGF-βRI 
phosphorylates and activates receptor specific signaling mother against decapentaplegic 
(R-SMAD) proteins, which then associate with its common mediator SMAD (C-SMAD).  
Together R-SMAD and C-SMAD translocate to the nucleus where they regulate gene 
transcription (Figure 1.6). 
 
 
Figure 1.6 The canonical TGF-β1 signaling pathway. Adapted and modified 
from (Massagué, 2000) 
 
 
Recently other signaling pathways of TGF-βRI/II activation have begun to 
emerge (Figure 1.7) (Massagué, 2000; Vivien and Ali, 2006; Akkhurt and Hata, 2012).  
Through crosstalk these non-canonical pathways and the SMAD pathways can modulate 
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each other.  Also, along with being serine/threonine kinases, recently it was discovered 
that TGF-βRI/II can also phosphorylate tyrosine, which plays a role in activating the 
mitogen-activated protein kinase/ extracellular signal-regulated kinase (MAPK/ERK) 
signaling pathway (Lee et al., 2007; Zhang, 2009). 
 
 
Figure 1.7 The non-canonical TGF-β1 signaling pathway. Adapted and 
modified from (Akhurt and Hata, 2012) 
 
 
TGF-β1 in Brain Disorders 
 
While TGF-β1 expression is very low in the adult brain (Flanders et al., 1991; 
Pelton et al., 1991; Unsicker et al., 1991) in response to injury and neurodegeneration 
TGF-β1 is highly upregulated and secreted by many different cell types (Pratt and 
McPherson, 1997; Flanders et al., 1998; Vivien and Ali, 2006), suggesting it plays a role 
in regulating neuronal survival and death.  In fact TGF-β1 knockout mice have 
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widespread neuronal degeneration (Brionne et al., 2003), which reveals a role for TGF-β1 
in regulating neuronal survival. Below is a brief description of some of the diseases TGF-
β1 has been shown to be upregulated in and the role it plays in neuronal survival/death. 
Amyotrophic Lateral Sclerosis 
 
 TGF-β1 is increased in both the SOD1-G93A mouse model of amyotrophic lateral 
sclerosis (ALS) and in the cerebral spinal fluid (CSF), plasma, and ventral horn of ALS 
patients; levels of TGF-β1 are positively correlated with the duration of the disease (Houi 
et al., 2002; Iłzecka et al., 2002; Endo et al., 2015).  In SOD1-G93A mutant mice, 
overproduction of TGF-β1 in astrocytes resulted in a decreased inflammatory reaction by 
microglia, which accelerated disease progression in a non-cell autonomous manner (Endo 
et al., 2015).  This suggests that TGF-β1 negatively regulates disease progression.  In 
further support of this, inhibiting TGF-β1 signaling led to a decrease in disease 
progression and extended the survival time in SOD1-G93A mice (Endo et al., 2015).   
Alzheimer’s Disease 
 
 While increased levels of TGF-β1 have been observed in in the CSF, serum, and 
even in the amyloid-β (Aβ) plaques of patients with Alzheimer’s disease (AD) (van der 
Wal et al., 1993; Chao et al., 1994; Zetterberg et al., 2004), the effects of this increase are 
unknown.  In fact, there is conflicting data as to whether increased TGF-β1 plays a role in 
driving disease pathology or is neuroprotective.  Overexpression of TGF-β1 in mice has 
been shown to lead to overexpression of amyloid precursor protein (APP), which drives 
Aβ production in astrocytes (Lesné et al., 2003) and increases Aβ deposition in cerebral 
blood vessels and meninges (Wyss-Coray et al., 1997).  These studies suggest that TGF-
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β1 may enhance AD pathology.  However, TGF-β1 has also been shown to be protective 
against Aβ toxicity in hippocampal cultures (Ren and Flanders, 1996) and in Aβ-induced 
AD mouse models (Shen et al. 2014; Chen et al., 2015).  Beneficial effects of TGF-β1 in 
these models included decreases in production of pro-inflammatory cytokines (Chen et 
al., 2015), cognitive deficits, glial activation, APP expression, and neuronal loss (Shen et 
al., 2014).  Other protective effects of TGF-β1 on Aβ toxicity include preserving 
mitochondrial potential (Prehn et al., 1996), inhibiting apoptosis by regulating gene 
expression to favor the anti-apoptotic pathway (Kim et al., 1998), and even increasing the 
clearance of Aβ (Wyss-Coray et al., 2001). 
Ischemia 
 
 TGF-β1 has been well studied in models of ischemia.  It is upregulated in the 
infarct and the area surrounding the vessel occlusion (penumbra) in the brains of stroke 
patients (Krupinski et al., 1996).  Similarly, following models of focal ischemia in rats 
TGF-β1 is also upregulated (Lehrmann et al., 1998; Ruocco et al., 1999) and exerts 
neuroprotective effects.  For example, injection of TGF-β1 into the ventricles before the 
induction of ischemia decreased brain lesion size (Prehn et al., 1993; Henrich-Noack et 
al., 1996).  TGF-β1 overexpression decreased chemokine expression and infarct size 
following middle cerebral artery occlusion (MCAO) and reperfusion (Pang et al., 2001), 
while blocking endogenously released TGF-β1 following MCAO increased infarct size 
(Ruocco et al., 1999). 
 Two of the key mechanisms involved in cell death following ischemia are 
excitotoxicity and apoptosis.  The effects TGF-β1 exerts on insults that induce 
excitoxicity or apoptosis have been studied in vitro, in order to better understand the 
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mechanism behind its effects on neuronal death.  TGF-β1 exerts opposite effects on 
slowly-triggered vs rapidly-triggered excitotoxicity.  TGF-β1 is protective against short 
applications of high doses of glutamate or NMDA (rapidly-triggered excitotoxicity) in 
hippocampal and cortical neurons (Prehn and Krieglstein, 1994; Prehn and Miller, 1996; 
Bruno et al., 1998).  However, TGF-β1 exacerbates the toxicity of long applications of 
low doses of glutamate (slowly-triggered excitotoxicity) (Prehn and Miller, 1996).  TGF-
β1’s protection against NMDA receptor mediated toxicity involves upregulation of type 1 
plasminogen activator inhibitor (PAI-1) (Buisson et al., 1998; Docagne et al., 1999).  The 
protection by PAI-1 is due to its inhibition of tPA, a protein that increases NMDA 
toxicity by cleaving the NR1 subunit leading to increased NMDA induced calcium influx 
(Nicole et al., 2001).   The mechanism behind exacerbation of slowly-triggered 
excitotoxicity is unknown. 
TGF-β1 protects against apoptosis by regulating the expression of apoptotic 
genes.  For example, TGF-β1 pretreatment increased expression of the anti-apoptotic 
gene, B-cell lymphoma 2 (Bcl2) and Bcl-xl, in hippocampal neurons deprived of trophic 
factors (Prehn et al., 1994).  TGF-β1 is also able to inhibit the pro-apoptotic gene 
caspase-3 and protect hippocampal neurons from staurosporine-induced apoptosis (Zhu et 
al., 2001).  In vivo, TGF-β1 is able to reduce ischemic lesions and neurological deficits 
by inhibiting the pro-apoptotic genes Bad and caspase-3 induced by MCAO; TGF-β1’s 
effects are through activation of the MAPK/ERK pathway (Zhu et al., 2002). 
SYSTEM XC- 
 
 The cystine/glutamate antiporter (system xc-) is a sodium-independent, chloride-
dependent amino acid transporter system localized in the plasma membrane.  First 
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characterized in human fibroblast cell cultures, system xc-, is an antiporter that mediates 
the uptake of cystine into cells in exchange for exporting glutamate from the cell in a 1:1 
ratio (Bannai and Kitamura, 1980; Bannai, 1986). 
Structure of System xc- 
 
 System xc- is a member of the solute carrier (SLC) 7 family of amino acid 
transporters and is a heterodimer composed of two subunits: a 502 amino acid short chain 
protein xCT and 4F2hc, the heavy chain subunit.  4F2hc is found in multiple members of 
the SLC7 family of transporters and is responsible for the transport of the antiporter to 
the plasma membrane (Estévez et al., 1998; Sato et al., 1999; Bassi et al., 2001; Verrey et 
al., 2004).  The 4F2hc subunit is linked by a disulfide bridge to the xCT subunit (Torrents 
et al., 1998; Shih et al., 2006).  xCT is encoded by the SLC7a11 gene (Bassi et al., 2001) 
and is the functional subunit that confers substrate specificity of the transporter (Sato et 
al., 1999; Bassi et a., 2001).  It is composed of 12 transmembrane domains and both the 
N- and C-terminus are located in the cytoplasm (Gasol et al., 2004) (Figure 1.8). 
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Figure 1.8 The structure of system xc-. Adapted and modified from (Shih et al., 
2006) 
 
 
Function of System xc- 
 
 System xc- has three main functions.  Due to its dual action of importing one 
molecule of cystine in exchange for exporting one molecule of glutamate, it is able to    
1) regulate intracellular GSH levels and 2) regulate extracellular glutamate 
concentrations.  Often overlooked because of its first two functions, system xc- also 3) 
plays a role in regulating the redox environment of the cell.  Each of these functions is 
described in more detail below. 
Regulation of GSH Levels 
 
As previously described, GSH is essential for the reduction of ROS in the brain 
and protection from oxidative stress; system xc- not only provides astrocytes with the 
substrate to synthesize GSH, but it is also critical for GSH synthesis in neurons.  Certain 
cells rely heavily on system xc- to protect them from oxidative glutamate toxicity.  
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Oxidative glutamate toxicity occurs when high levels of extracellular glutamate are 
applied to cells that lack glutamate receptors; instead of causing excitotoxicity, high 
levels of glutamate competitively inhibit the uptake of cystine through system xc-, 
causing GSH depletion, resulting in oxidative stress and cell death  (Miyamoto et al. 
1989; Murphy et al. 1989; 1990; Sagara et al. 1993b; Ratan et al. 1994).  Overexpression 
of xCT on astrocytes can protect immature cortical neurons from oxidative glutamate 
toxicity (Shih et al., 2006). 
 System xc- activity is also needed in order to maintain the high levels of GSH 
necessary for glioma cells to grow (Chung et al. 2005; Chung and Sontheimer 2009); that 
is why when cellular GSH levels are depleted by diethyl maleate (DEM) treatment, 
glioma cells increase xCT expression and system xc- activity  (Kim et al. 2001).  
Upregulation of system xc- can also protect cells from different types of oxidative stress.  
For example, insulin-like growth factor 1 (IGF-1) and TGF-β upregulate system xc- 
activity and protect dental pulp cells against oxidative stress induced by dental materials 
(Pauly et al., 2011).  Interleukin-1β (IL-1β) upregulates system xc- activity, which 
protects astrocytes from ROS-inducing FeSO4 and tert-butyl hydroperoxide (tBOOH) 
exposure (He et al., 2015).  On the other hand, astrocytes derived from mice with the 
subtle gray pigmentation mutant phenotype (sut/sut), an xCT loss of function mutation, 
have reduced proliferation as a result of decreased GSH and increased oxidative stress 
(Shih et al., 2006).  Together these studies show that upregulating system xc- confers 
protection against oxidative stress in the cells in which it is upregulated by increasing 
cystine uptake, which leads to the production of the antioxidant GSH. 
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Extracellular Glutamate Regulation 
 
The second main function of system xc- is the regulation of extracellular 
glutamate concentrations.  Non-vesicular release of glutamate through system xc- is the 
major source of extracellular glutamate in several rodent brain regions (De Bundel et al., 
2011; Massie et al., 2011; Baker et al. 2002) and it is able to regulate neuronal activity 
through extrasynaptic glutamate receptors.  For example, glutamate released by system 
xc- can activate presynaptic mGluR2/3 receptors and inhibit synaptic glutamate release 
(Baker et al., 2002; Moran et al., 2005).  It can also change receptor levels in the synapse, 
which can affect synaptic strength (Augustin et al., 2007; Williams and Featherstone, 
2014).  Sut/sut mice have impaired long-term potentiation (LTP) and deficits in their 
long-term memory (Li et al., 2012) and xCT-/- mice have decreased extracellular 
glutamate and impaired spatial working memory (De Bundel et al., 2011). 
In contrast to the possible neural protective mechanism of system xc- against 
oxidative stress, it has been shown that glutamate release via system xc- can cause 
excitotoxicity and lead to neuronal death.  The strongest evidence comes from studies 
involving glial cells.  Activation of microglia can increase glutamate release through 
system xc- causing toxicity to cerebellar granule cells (Piani and Fontana, 1994), cortical 
neurons (Qin et al., 2006), and oligodendrocytes (Domercq et al. 2007).  System xc- on 
astrocytes has also been shown to play a role in neuronal death.  Activation of astrocytes 
with IL-1β leads to increased system xc- mediated glutamate release causing enhanced 
excitotoxicity of cortical neurons exposed to hypoxia or glucose deprivation (Fogal et al., 
2007; Jackman et al., 2010).  And long-term exposure to fibroblast growth factor-2 (FGF-
2) upregulates system xc- activity and causes AMPA receptor mediated excitotoxicity in 
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cortical neurons (Liu et al., 2012; 2014).  Together these studies show that system xc- can 
increase extracellular glutamate levels, which can lead to excitotoxicity. 
Regulation of the Redox Environment 
 
 Finally, system xc- is involved in regulating the redox environment around the cell 
membrane by maintaining proper levels of GSH and cystine/cysteine (Conrad and Sato, 
2012; Lewerenz et al., 2013).  GSH is exported from the cell by MRP-1 and contributes 
to the reduced extracellular environment (Wang and Cynader 2000; Dringen and 
Hirrlinger 2003).  Likewise cysteine can also be directly exported from the cell via 
system ASC and oxidized to cystine.  System xc- drives this cystine/cysteine cycle, which 
helps maintain the redox environment independent of the GSH (Bannai and Ishii 1982; 
Anderson et al. 2007).  The redox state of the cell is important because it can play a large 
role on cell signaling.  For example, the NMDA receptor has an extracellular redox site 
and changes in the redox environment can affect the open-channel frequency and 
potentiate or decrease the magnitude of the response (Aizenman et al., 1989; Tang and 
Aizenman, 1993).  The redox state can also impact enzyme and transcription factor 
activity (Janssen-Heininger et al., 2008). 
xCT knockout mice (xCT-/-) provide evidence for the involvement of system xc- 
in redox balance.  Sato et al. (2005) found that the plasma in xCT-/- mice is more 
oxidized, as a result of higher levels of cystine and lower levels of GSH.  Also, 
fibroblasts cultured from these mice died unless the reducing agent 2-mercaptoethanol 
was added.  If 2-mercaptoethanol was removed cysteine and GSH levels decreased and 
cells began to die within 24 hours. 
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Regulation of System xc- 
 
 System xc- has similar affinities for transport of both cystine and glutamate; 
therefore, the concentration gradient of these substrates determines the direction of 
transport (Lewerenz et al., 2013).  Physiologically, cystine is found at very low 
concentrations inside the cell, while glutamate has high intracellular and low extracellular 
concentrations thus, intracellular concentrations of glutamate drive the release of 
glutamate from the cell through system xc-, which leads to the import of cystine 
(Lewerenz et al., 2013).  EAATs regulate intracellular/extracellular glutamate 
concentrations and, therefore, regulate system xc- activity (Rimaniol et al., 2001; 
Lewerenz et al., 2006).  Since system xc- can transport glutamate both directions, 
increases in extracellular glutamate can act as a competitive inhibitor of cystine uptake 
(Bannai, 1986). 
 Regulation of xCT subunit expression is more important in determining system 
xc- activity than the 4F2hc subunit (Lewerenz et al., 2013).  The factors that regulate xCT 
and mechanisms behind its regulation are still largely unknown.  Given its role in 
oxidative stress and excitotoxicity, along with its emerging role in many 
neurodegenerative diseases, understanding what regulates system xc- is important and 
may one day help in developing therapeutic agents for some of these diseases.  Below is a 
brief description of the nuclear factor erythroid 2-related factor 2 (Nrf2)-antioxidant 
responsive element (ARE) and the eukaryotic initiation factor-2 (eIF2α)-activating 
transcription factor (ATF) 4- amino acid response element (AARE) pathways, which 
regulate system xc- expression (Figure 1.9).   
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Figure 1.9 Factors and pathways that regulate the transcription of xCT. 
Adapted and modified from (Lewerenz et al., 2012) 
 
 
Nrf2-ARE Pathway 
 
Oxidative stress is one of the main regulators of system xc-.  Xanthine/xanthine 
oxidase induced oxidative stress in Müller glial cells causes an upregulation of system xc- 
activity (Mysona et al., 2009).  Also, oxidative stress and nitric oxide upregulate system 
xc- activity in a retinal ganglion cell line (RGC-5) (Dun et al., 2006), while oxidative 
stress induced by exposure to DEM increases system xc- function in human glioma cells 
(Kim et al., 2001). 
In response to oxidative and electrophilic stress cells activate the Nrf2-ARE 
pathway, which increases the cell’s antioxidant defenses (Itoh et al., 1997), including 
intracellular and extracellular GSH levels (Sasaki et al., 2002; Shih et al, 2006).  Under 
normal conditions, Nrf2 is bound to kelch-like ECH-associated protein 1 (Keap1), which 
retains Nrf2 in the cytoplasm.  However, in response to ROS and electrophiles Nrf2 
dissociates from Keap1 and translocates to the nucleus where it binds to ARE sequences, 
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also known as electrophile response elements (EpRE), and activates gene transcription 
(Itoh et al., 2004; Taguchi et al., 2011; Kansanen et al., 2013).  The Nrf2-ARE pathway is 
responsible for activating multiple genes involved in neuronal survival.  Many of the 
genes activated are involved in the metabolism of GSH, including glutamate-cysteine 
ligase, glutathione synthetase, glutathione S-transferase, glutathione reductase, and 
multidrug resistance protein 1 (Sasaki et al., 2002; Lee and Johnson, 2004; Shih et al., 
2006).  Transcription of xCT, which contains four ARE sequences in the 5’ end of its 
gene, is also activated (Sasaki et al., 2002). 
Studies show that the Nrf2-ARE pathway can upregulate system xc- in response to 
a wide variety of stress agents, including diethyl maleate, H2O2, cadmium, and oxidative 
glutamate toxicity in different types of cells (Ishii et al., 2000; Sasaki et al., 2002; 
Lewerenz et al., 2009).  It is important to note that the Nrf-2-ARE pathway is 
preferentially activated in astrocytes (Shih et al., 2006; Johnson et al., 2008) and 
upregulation of system xc- through this pathway not only protects astrocytes from 
oxidative stress, but also protects neighboring neurons (Shih et al. 2003). 
eIF2α-ATF4-AARE Pathway 
 
Amino acid deprivation causes an increase in system xc- activity through 
activation of the ATF4-AARE pathway (Sato et al., 2004).  Low levels of amino acids 
activate the general control non-derepressible-2 (GCN2) protein kinase, which 
phosphorylates eIF2α (Zhang et al., 2002; Wek et al., 2006). Composed of eIF2α, eIF2β, 
and eIF2γ, eIF2 is part of the initiating complex for most protein synthesis.  
Phosphorylation of eIF2α leads to global inhibition of protein synthesis in order to slow 
down cellular activity and protect the cell (Wek et al., 2006; Kilberg et al., 2009).  While 
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translation of most proteins is inhibited, eIF2α phosphorylation induces translation of 
select transcripts, like ATF4 (Vattem and Wek, 2004; Wek et al., 2006; Kilberg et al., 
2009).  ATF4 binds to the AARE sequence and results in translation of the gene (Kilberg 
et al., 2009).  The 5’ end of xCT contains two AARE sequences, thus ATF4 binding 
results in increased xCT transcription (Sato et al., 2004). 
The ATF4-AARE pathway can also be activated by phosphatidylinositide 3-
kinase (PI3K) in glioblastomas (Lewerenz et al., 2014).  High frequency neuronal 
activation in vitro activates PI3K, which generates 3,4,5-triphosphate (PIP3) through 
phosphorylation of inositol lipids in the membrane (Lewerenz et al., 2014).  PIP3 
activation leads to Akt activation, which phosphorylates and inhibits glycogen synthase 
kinase 3β (GSK-3β) (Hers et al., 2011; Matsuda et al., 2013; Lewerenz et al., 2014).  In 
turn, inhibition of GSK-3β leads to GCN2 activation and the eIF2α-ATF4-AARE 
pathway continues as previously described (Lewerenz et al., 2014). 
In embryonic fibroblasts, mutation of the eIF2α phosphorylation site results in 
decreased ATF4 expression and system xc- activity (Lewerenz and Maher, 2009).  
Likewise, increasing eIF2α phosphorylation in hippocampal HT22 cells increases ATF4 
expression and system xc- activity.   The increase in system xc- activity led to increased 
GSH levels and protected against oxidative glutamate toxicity (Lewerenz and Maher, 
2009).  Together these studies show that basal levels of eIF2α phosphorylation help 
determine basal system xc- activity (Lewerenz and Maher, 2009). 
Growth Factors and Other Peptides 
 
Growth factors and other peptides also regulate system xc- activity.  Our lab has 
previously shown that FGF-2 upregulates system xc- activity in astrocytes; upregulation 
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was through FGF receptor 1 (FGFR1) and both the MEK/ERK and PI3-kinase pathways 
(Liu et al., 2012).  We have also shown that IGF-1 and TGF-β upregulate system xc- 
activity in dental pulp cells (Pauly et al., 2011).   
Interleukin-1β (IL-1β) upregulates system xc- activity, specifically in cortical 
astrocytes, through the IL-1 receptor (Jackman et al., 2010).  The same lab also showed 
that IL-1β upregulates GSH synthesis in astrocytes through nuclear factor-kappaB (NF-
κB) activity (He et al., 2015).  While the 5’ end of the xCT gene contains a NF- κB 
binding site (Sato et al., 2001), there is no direct evidence that IL-1β increases system xc- 
activity through the NF- κB pathway. 
Similar to FGF-2 and IL-1β, pituitary adenylate cyclase-activating polypeptide 
(PACAP) increases system xc- activity in cortical cultures.  The pathway has been 
partially determined.  Applying PACAP for at least 6 hours induces system xc- activity 
through VPAC1R, the vasoactive intestinal peptide (VIP) receptor, and a protein kinase 
A (PKA)-dependent pathway (Resch et al., 2014).  It has also been shown that inhibiting 
PKA decreases system xc- activity in ex vivo striatal punches rapidly (Baker et al. 2002). 
The differences in the time course of the two studies suggest that PKA may regulate 
system xc- through multiple mechanisms (Massie et al., 2015).  More direct evidence is 
needed to understand the mechanism(s) behind PKA’s regulation of system xc- 
expression and activity. 
 Intracellular GSH levels can also increase system xc- activity.  Depleting GSH 
from astrocytes that have been treated with dibutyryl-cyclic AMP (dbcAMP) upregulates 
system xc- activity.  The exact mechanism is unknown, but it is independent of the Nrf2 
pathway (Seib et al., 2011). 
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Potential Role of System xc- in Brain Disorders 
 
 Oxidative stress and excitotoxicity are two of the key mechanisms in many 
neurodegenerative diseases (Coyle and Puttfarcken, 1993; Simonian and Coyle, 1996; 
Doble, 1999).  The dual nature of system xc- suggests that it may provide antioxidant 
protection during times of increased oxidative stress; however, by releasing glutamate 
into the extrasynaptic space it also has the potential to contribute to neuronal death 
through excitotoxicity.  In this thesis we analyze the function of system xc- in the SOD1-
G93A mutant mouse model of ALS.  However, the pathology of many neurodegenerative 
diseases suggests that system xc- may also play an important role in them, so we briefly 
review what is known about system xc- in these diseases as well. 
Amyotrophic lateral sclerosis 
 
ALS is the most common paralytic disease in adults, characterized by the loss of 
motor neurons in the motor cortex, brainstem, and spinal cord, which results in loss of 
motor function. It is believed that approximately 10% of ALS cases are inherited, while 
the majority of cases are sporadic, and are of unknown cause.  The mutation involved in 
approximately 10-20% of genetic cases involves copper/zinc superoxide dismutase type 1 
(SOD-1).  Interestingly, silencing the SOD-1 gene does not produce ALS symptoms 
(Shefner et al., 1999), but rather it appears to be a gain-of-function mutation as mice 
expressing the human SOD-1 mutation do develop ALS-like symptoms (Gurney et al. 
1994).  Also, motor neuron death occurs through a non-cell autonomous mechanism with 
glial cells (Clement et al., 2003; Boillée et al., 2006; Yamanaka et al., 2008).  Although it 
is unclear what causes ALS, it is clear that oxidative stress is a key mechanism involved 
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in the pathology of the disease.  Elevated levels of protein carbonyl groups, markers of 
oxidative damage, have been found in post mortem tissue from ALS patients (Bowling et 
al., 1993; Ferrante et al., 1997); and increased production of both oxygen and hydroxyl 
free radicals have been found in transgenic mice with the human SOD1-G93A mutation 
(Yim et al., 1996; Bogdanov et al., 1998; Liu et al., 1998). 
 Another key mechanism in the pathology of ALS is excitotoxicity.  Elevated 
levels of glutamate have been found in patients with ALS (Spreux-Varoquaux et al., 
2002).  Previous research has shown that the increase in glutamate levels may be 
attributed to a decrease in EAAT2/GLT-1, the main mechanism by which glutamate is 
taken up out of the extrasynaptic space and into astrocytes.  Decreased levels of GLT-1 
have been reported in both the brain and spinal cord in post mortem tissue of ALS 
patients (Rothstein et al., 1995) and in the ventral horn of SOD1-G93A transgenic rat and 
mouse spinal cords (Canton et al., 1998; Warita et al., 2002; Bendotti et al., 2001).  While 
impaired glutamate transports seem to play an important role in the increased 
extracellular glutamate levels seen in ALS, decreases in the glutamate transporter do not 
appear until after the onset of symptoms in the mouse models and, therefore, are probably 
not the primary cause of motor neuron loss (Canton et al., 1998; Warita et al., 2002; 
Bendotti et al., 2001).   
Elevated levels of glutamate could also occur as a result of increased system xc- 
function and/or expression.  Prior to our work done in ex vivo slice from SOD1-G93A 
mice (Chapter II), the function of system xc- had not been assessed in ALS.  Following 
our study, system xc- function was also examined in the SOD1-G37R mouse model, a 
much slower progression model of the disease.  In the SOD1-G37R model xCT mRNA 
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increased in the spinal cord over the course of the disease, specifically in microglia 
(Mesci et al., 2015).  Post-mortem spinal cord tissue from ALS patients also expressed 
xCT mRNA that correlated with a marker for macrophage inflammation (Mesci et al., 
2015).  Interestingly, deletion of xCT in the SOD1-G37R mouse led to an earlier onset of 
symptoms followed by a prolonged symptomatic stage; at end stage of the disease there 
were more surviving motor neurons (Mesci et al., 2015).  The implications of the findings 
in this study will be discussed further in the context of our discoveries in the SOD1-
G93A model (Chapter V). 
Alzheimer’s disease  
 
 AD is the most common neurodegenerative disease.  It is characterized by 
degeneration in the hippocampus and cerebral cortex, which leads to impairments in 
memory and cognition.  Two of the main hallmarks of AD are the formation of 
extracellular Aβ plaques and intracellular tangles of phosphorylated tau protein.  Aβ is 
derived from cleavage of the amyloid precursor protein (APP) (Selkoe, 1994) and 
abnormal accumulation can lead to cell death by inducing oxidative stress (Varadarajan et 
al., 2000; Butterfield et al. 2002; Butterfield and Lauderback, 2002). 
Reactive microglia are found in the plaques of AD patients.  Therefore, the first 
studies that analyzed system xc- function in AD looked at the effects of soluble APP 
(sAPP) and Aß1-40 on primary microglia cultures.  Both sAPP and Aß1-40 peptide 
increased glutamate release from microglia through system xc- (Barger and Basile, 2001; 
Qin et al., 2006).  The sAPP induced increase in glutamate release caused increased 
calcium elevation in hippocampal neurons and compromised their synaptic density 
(Barger and Baile, 2001), while Aß1-40 induced glutamate release caused NMDA receptor 
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mediated excitotoxicity and masked the protective effects of microglia release of 
apolipoprotein E (apoE) (Qin et al., 2006).  These studies suggest that increased system 
xc- activity in microglia has detrimental effects on neurons in AD.  Another study, 
however, found that increasing system xc- by activating the eIF2α-ATF4-AARE pathway 
made PC12 cells more resistant to Aß1-42 peptide toxicity (Lewerenz and Maher, 2009). 
To date there are only a couple of in vivo studies that have assessed system xc- in 
AD.  In 18-month old AßPP23 mice expression of xCT, as assessed by western blot, is 
increased in the cortex.  At this same time point, GLT-1 expression was decreased and 
there were increased levels of extracellular glutamate (Schallier et al., 2011).  Transgenic 
mice expressing human APP and wild-type mice injected with Aβ1-40 have increased xCT 
mRNA levels in microglia in amyloid plaques (Qin et al., 2006).   
There have been some AD studies assessing the effects of N-acetylcysteine 
(NAC).  NAC is a pro-cysteine drug that drives system xc- activity (Kupchik et al. 2012).    
In one double-blind study where AD patients were given NAC, they showed beneficial 
trends in all areas tested, particularly in cognitive tasks (Adair et al., 2001).  NAC 
pretreatment was also shown to protect SHS5Y neuroblastoma cells from Aβ1-42 and 
Aβ25-35 (Olivieri et al., 2001), an effect associated with decreased Aβ secretion and tau 
phosphorylation; they did not assess system xc- function in these cells.  Therefore, while 
these studies show beneficial effects of NAC in AD none of those benefits have been 
directly linked to increased system xc- activity.  Further studies using xCT knockout mice 
in AD mouse models may help to better clarify the role of system xc- in AD.  
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Parkinson’s Disease 
 
 Parkinson’s disease (PD) is a neurodegenerative disease characterized by a loss of 
dopaminergic neurons in the substantia nigra.  Loss of dopaminergic neurons leads to a 
progressive loss of motor function; symptoms include stiff gait, tremors, impaired 
balance, slow movement, and eventually muscle atrophy (Beitz, 2014).  While the cause 
of dopaminergic cell death is unknown, oxidative stress (Hwang, 2013) and 
excitotoxicity (Caudle and Zhang, 2009) play a role in the pathology of PD.  
Determining the effects of system xc- in PD models has led to mixed results.  In 
the hemi-Parkinson rat model, injection of 6-hydroxydopamine (6-OHDA) caused an 
ipsilateral increase in xCT protein in the striatum three weeks after injection; twelve 
weeks after injection xCT levels were back down to normal (Massie et al., 2008).  In a 
follow up study dopaminergic neurons in the substantia nigra pars compacta were 
protected from 6-OHDA injection in xCT-/- mice compared to wild-type mice (Massie et 
al., 2011).  GSH levels were unaffected and oxidative stress was not elevated in the xCT-
/- mice; however, extracellular glutamate levels were significantly reduced (Massie et al., 
2011).  Taken together the data suggests that system xc- may contribute to the 
neurodegeneration seen in PD.  A more recent study has yielded different results in the 6-
OHDA model of PD.  The anti-epileptic drug levetiracetam (LEV) increased xCT 
expression and GSH levels in astrocytes cultured from the striatum.  Culture medium 
taken from LEV treated astrocytes was able to protect dopaminergic neurons from 6-
OHDA toxicity, an affect that was blocked by xCT inhibitor SSZ (Miyazaki et al., 2016).  
In vivo LEV also increased xCT expression in striatal astrocytes and significantly 
decreased dopaminergic cell loss in mice injected with 6-OHDA (Miyazaki et al., 2016). 
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The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of PD has also 
yielded different results regarding the actions of system xc-.  xCT expression was 
increased in the striatum, but decreased in the substantia nigra pars compacta following 
MPTP injection (Bentea et al., 2015).  Also, MPTP injection resulted in similar levels of 
dopaminergic cell loss and similar behavioral deficits in both xCT-/- mice and wild-type 
mice (Bentea et al., 2015), which suggests system xc- does not affect neurodegeneration 
of dopamine neurons.  Given the differences seen between different models of PD and 
even within the same model, further studies need to be performed in order to gain a better 
understanding of system xc-’s role in PD. 
Multiple Sclerosis 
 
 Multiple sclerosis (MS) is an autoimmune demyelinating disease.  Pathology of 
the disease includes white matter scar formation, inflammation, disruption in the blood 
brain barrier, and glutamate dysregulation (Werner et al., 2001; Minagar and Alexander, 
2003; Goldenberg, 2012).  Dysregulation of glutamate contributes to the death of 
oligodendrocytes, myelin-producing cells in the CNS, however the source of this 
glutamate is unknown (Werner et al., 2001). 
 In microglia-oligodendrocyte cocultures, activation of microglia by 
lipopolysaccharide (LPS) caused an increase in glutamate release through system xc-, 
resulting in increased extracellular glutamate and oligodendrocyte toxicity (Domercq et 
al., 2007).  Similarly, CD4+ T helper cells provoke microglia to release glutamate 
through system xc- resulting in oligodendrocyte excitotoxicity (Evonuk et al., 2015). 
 Microglia cells from the spinal cord of rats treated with experimental autoimmune 
encephalomyelitis (EAE), a model of MS, have increased xCT mRNA and protein levels 
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(Pampliega et al., 2011).  This finding correlates with increased xCT mRNA levels found 
in the leukocytes and optic nerve tissue from human MS patients (Pampliega et al., 
2011).  Blocking system xc- in both the chronic and relapse-remitting EAE models of MS 
decreased the clinical severity of the disease and decreased spinal cord demyelination 
(Evonuk et al., 2015).  Likewise, mice that contain inactive system xc- due to a mutation 
in the xCT gene (sut/sut mice) are resistant to EAE treatment (Evonuk et al., 2015).  
Together this data suggests that increased glutamate release though system xc- may 
contribute to the degeneration of oligodendrocytes and that decreasing system xc- activity 
may be a therapeutic target for the treatment of MS. 
Huntington’s Disease 
 
Huntington’s disease (HD) is a fatal neurodegenerative disease caused by a 
polyglutamine expansion in the huntingtin (htt) gene.  This autosomal dominant mutation 
leads to the death of GABAergic medium spiny neurons, mainly in the striatum; the 
mechanism of this selective neuronal death is unknown (Vonsattel and DiFiglia, 1998).  
However, there is strong evidence that there is mitochondrial dysfunction, resulting in 
defects in energy metabolism, oxidative stress, and excitotoxicity (Browne and Beal, 
2004). 
 Little is known about system xc- activity in HD.  In the striatal cell line 
STHdhQ111/Q111, a model of HD, system xc- mRNA levels and protein expression were 
decreased, which resulted in decreased system xc- function (Frederick et al., 2014).  
These cells also have decreased GSH levels, increased levels of ROS, and are more 
sensitive to oxidative stress caused by DEM (Frederick et al., 2014).  System xc- mRNA 
and protein levels were also decreased in the striatum of R6/2 mutant htt exon 1 
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transgenic mice, another model of HD (Frederick et al., 2014).  Administration of NAC 
in the R6/1 model of HD resulted in delayed symptom onset and progression of motor 
deficits (Wright et al., 2015).  The mechanism behind the benefits of NAC was not 
determined.  Ceftriaxone, an antibiotic that increases xCT and EAAT2/GLT-1 expression 
(Lewerenz et al., 2009), also attenuated the R6/2 behavioral phenotype (Miller et al., 
2008).  The authors attributed ceftriaxone’s positive effects to restoring basal levels of 
glutamate in the striatum through increased in GLT-1 expression, however, they did not 
assess xCT levels, so an increase in system xc- activity contributing to the effects cannot 
be ruled out. 
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CHAPTER II 
 
 
REGULATION OF SYSTEM XC- IN THE SOD1-G93A MOUSE MODEL OF ALS 
 
 
Abstract 
 
 
The cystine/glutamate antiporter (system xc-) is critical for the generation of the 
antioxidant glutathione by transporting cystine into the cell.  At the same time, system xc- 
also releases glutamate, which can potentially lead to excitotoxicity. The dual actions of 
system xc- make it of great interest in any disease, like amyotrophic lateral sclerosis 
(ALS), in which there is evidence of the involvement of both oxidative stress and 
excitotoxicity.  The present study investigated the regulation of system xc- in the spinal 
cord of the SOD1-G93A transgenic mouse model of ALS. In spinal cord slices of 70 day 
old SOD1-G93A transgenic mice cystine uptake by system xc- was significantly 
increased compared to age matched nontransgenic mice; but it was not significantly 
different at 55, 100, or 130 days.  The spinal cord slices of 70 day old SOD1-G93A 
transgenic mice also showed significantly increased glutamate release in the presence of 
cystine.  In contrast, in glial cells cultured from postnatal day 1-3 mice there was no 
difference in cystine uptake in cultures from SOD1-G93A mice; and it was actually less 
when oxidative stress was induced by exposure to iron.  D-aspartate uptake through 
excitatory amino acid transporters (EAATs), the main mechanism by which glutamate is 
cleared from the extracellular space was also examined. In spinal cord slices of 70 day 
old SOD1-G93A mice no change in D-aspartate uptake was found.  Together, these 
findings suggest that at 70 days of age, SOD1-G93A transgenic mice have increased 
system xc- activity, but no change in EAAT function.  These results raise the possibility 
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that excitotoxicity in the SOD1-G93A transgenic mouse, at least at early time points, may 
be due to increased system xc- activity and not decreased EAAT function. 
Introduction 
 
 
Amyotrophic lateral sclerosis is the most common paralytic disease in adults, 
characterized by the loss of motor neurons in the motor cortex, brainstem, and spinal 
cord, which results in atrophy and loss of motor function.  It is believed that 
approximately 10% of ALS cases are inherited, while the majority of cases are sporadic.  
The mutation involved in approximately 10-20% of genetic cases involves copper/zinc 
superoxide dismutase type 1 (SOD-1).  Interestingly, silencing the SOD-1 gene does not 
produce ALS symptoms (Shefner et al., 1999), but mice expressing the human SOD-1 
mutation do develop ALS like symptoms (Gurney et al., 1994).  Although it is unclear 
what causes ALS, it appears that oxidative stress plays a key role in the pathology of the 
disease.  Elevated levels of protein carbonyl groups, markers of oxidative damage, have 
been found in post mortem tissue from ALS patients (Bowling et al., 1993; Ferrante et 
al., 1997); and increased production of oxygen free radicals have been found in 
transgenic mice with the human SOD1-G93A mutation (Yim et al., 1996; Bogdanov et 
al., 1998; Liu et al., 1998). 
 Another key mechanism in the pathology of ALS is excitotoxicity.  Elevated 
levels of glutamate have been found in patients with ALS (Rothstein et al., 1990; Spreux-
Varoquaux et al., 2002).  Previous research has shown that the increase in glutamate 
levels may be attributed to a decrease in the high affinity glutamate transporter 
(EAAT2/GLT-1), the main mechanism by which glutamate is taken up from the 
extrasynaptic space and into astrocytes.  Decreased levels of EAAT2/GLT-1 have been 
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reported in both the brain and spinal cord of post mortem tissue of ALS patients 
(Rothstein et al., 1995) and in the spinal cord of SOD1-G93A transgenic rats (Howland et 
al., 2002) and mice (Bendotti et al., 2001). 
 The cystine/glutamate antiporter (system xc-) is a sodium-independent amino acid 
transporter that may play a key role in both oxidative stress and excitotoxicity due to its 
dual function.  System xc- mediates the transport of cystine into the cell in exchange for 
releasing glutamate into the extrasynaptic space.  After being taken up into the cell, 
cystine is reduced to cysteine and used in the synthesis of glutathione (GSH), an 
abundant and important antioxidant in the brain (Dringen and Hirrlinger, 2003).  This 
activity occurs mainly on non-neuronal cells and the release of GSH by these cells can be 
protective to neurons (Shih et al., 2003).   
Not only does system xc- act to prevent oxidative stress, but such stress appears to 
be the main trigger for its upregulation.  Oxidative stress induced by exposure of Muller 
glial cells to xanthine/xanthine oxidase causes an upregulation of system xc- activity 
(Mysona et al., 2009).  Also, oxidative stress and nitric oxide upregulates system xc- 
activity in a retinal ganglion cell line (RGC-5) (Dun et al., 2006), while oxidative stress 
induced by exposure to diethylmaleate increases system xc- function in human glioma 
cells (Kim et al., 2001).  Thus, it appears that upregulation of system xc- may act as a 
mechanism of cellular protection against oxidative stress. 
In contrast to the possible neural protective mechanism of system xc- against 
oxidative stress, it is known that glutamate release via system xc- can cause excitotoxicity 
and lead to neuronal death.  The strongest evidence comes from studies involving glia.  
Glutamate release via system xc- from microglia kills cerebellar granule cells (Piani and 
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Fontana, 1994).  Also, activation of microglia by amyloid-β causes increased glutamate 
release and neuronal death in cortical cultures (Qin et al., 2006).  System xc- on 
astrocytes may also play a role in neuronal death.  Activation of astrocytes with IL-1β 
leads to increased system xc- mediated glutamate release causing enhanced excitotoxicity 
of cortical neurons exposed to hypoxia or glucose deprivation (Fogal et al., 2007; 
Jackman et al., 2010).    
Due to the complex nature of the pathology of ALS, and the ability of system xc- 
to alter both oxidative stress and excitotoxicity, the current studies were designed to 
evaluate the function of system xc- in spinal cord slices of the SOD1-G93A transgenic 
mouse.  Since oxidative stress is a main factor that can lead to the upregulation of system 
xc- it was our prediction that system xc- would be upregulated in these mice.  We also 
evaluated the function of EAATs since no functional analysis of EAATs has been 
previously performed in spinal cord slices of SOD1-G93A transgenic mice.  Finally, we 
cultured spinal cord glial cells to further characterize the regulation of system xc- in 
SOD1-G93A mice. 
Materials and Methods 
 
 
Materials 
 Male B6SJL-TgN(SOD1-G93A)1Gur/J and female B6SJLF1/J mice were 
obtained from Jackson Laboratory (Bar Harbor, ME). 14C-cystine was from PerkinElmer 
(Waltham, MA).  All other chemicals were from Sigma (St. Louis, MO). 
Animals 
Male B6SJL-TgN(SOD1-G93A)1Gur/J autosomal hemizygous mice were bred 
with female B6SJLF1/J hybrid non-affected control mice.  At 3 weeks of age, pups were 
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separated and housed individually.  Mice were handled in accordance with a protocol 
approved by our institutional animal care committee. 
Genotyping 
The presence of the human G93A transgene was confirmed using PCR of DNA 
extracted from ear punch samples or tail snips.  Ear punches and tail snips were dissolved 
in 50mM Tris, 2mM NaCl, 10mM EDTA, 1% sodium dodecyl sulfate (SDS), and 
1mg/mL Proteinase K in a 56ºC water bath.  They were then heat shocked for 8 minutes 
at 100ºC and immediately put on ice.  250µL of water was added and samples were 
stored overnight at 4ºC.  PCR was then performed to identify transgenic littermates 
(Transgene forward primer: CAT CAG CCC TAA TCC ATC TGA; Transgene reverse 
primer: CGC GAC TAA CAA TC A AAG TGA). 
Neurological Scoring 
 Neurological scoring was performed three times a week, starting around day 55 
and was performed as recommended by the Jackson Labs guide “Working with ALS 
mice”.  The score criteria was as follows: 
Score of 0:  Full extension of hind legs away from lateral midline when mouse is 
 suspended by its tail, and mouse can hold this for two seconds, suspended two 
 to three times. 
Score of 1:  Collapse or partial collapse of leg extension towards lateral midline or 
 trembling of hind legs during tail suspension. 
Score of 2:  Toes curl under at least twice during walking of 12 inches, or any part of foot 
 is dragging along cage bottom/table. 
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Score of 3:  Rigid paralysis or minimal joint movement, foot not being used for 
 generating forward motion. 
Score of 4:  Mouse cannot right itself within 30 seconds after being placed on either side. 
A score of 0 is pre-symptomatic.  A score of 1 is early symptomatic. A score of 2 or 3 is 
symptomatic and a score of 4 results in termination. 
Spinal Cord Removal and Slice Preparation 
Experiments were performed using spinal cord slices from transgenic and 
littermate nontransgenic mice.  Male and female mice of various ages were euthanized by 
cervical dislocation following isoflurane anesthesia.  The entire vertebral column from 
just below the skull to the hips was removed and placed into ice cold slice buffer (119 
mM NaCl, 3mM KCl, 1.4mM KH2PO4, 2.7mM MgSO4, 26mM NaHCO3, 7.8mM 
glucose, 2.4mM CaCl2).  A 16-gauge beveled needle was inserted into the lumbar end of 
the column and the spinal cord was ejected from the vertebral column by injecting slice 
buffer into the vertebral column (Meikel and Martin, 1981).  Using a McIlwain tissue 
chopper, the spinal cord was cut transversely into 400µm slices and placed onto nylon 
mesh platforms in ice cold slice buffer.  Slices from the cervical, thoracic, and lumbar 
levels of the spinal cord were used for experiments.  Slices were then incubated in slice 
buffer with 95% O2 and 5% CO2 at 37°C for 30 minutes before uptake or release 
experiments.  Alternating slices were used for the different experimental conditions, with 
2-3 slices for each condition being used to generate each “n” value; multiple animals 
were used. 
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Spinal Cord Cell Culture 
Astrocyte-enriched glial cultures from the spinal cord were prepared from 
postnatal day 1-3 SOD1-G93A mice as previously described, with modifications  
(Kerstetter and Miller, 2012).   Briefly, dissociated spinal cord cells were plated on 24-
well plates (2.0 cm2 surface area per well) coated with poly-D-lysine and laminin in 
Eagles’ Minimal Essential Medium (MEM, Earle’s salts, supplied glutamine-free) 
supplemented with 5% (v/v) heat-inactivated horse serum, 5% (v/v) fetal bovine serum, 2 
mM glutamine and D-glucose (total 21 mM).  Cultures were maintained in humidified 
5% CO2 incubators at 370C with experiments performed on cultures DIV 13-15.   
14C-Cystine Uptake 
Radiolabeled cystine uptake into spinal cord slices was measured by exposure to 
slice buffer containing 14C-cystine (0.15µCi/ml) for 30 minutes at 37°C, in the presence 
or absence of 300µM of the system xc- inhibitor sulfasalazine (SSZ).  The slices were 
then washed for 2 minutes in ice cold slice buffer and dissolved in 250µL 1% SDS.  A 
100µL aliquot was removed and added to scintillation fluid for counting.  Another 100µL 
aliquot was removed to measure cellular protein levels using the BCA assay.  14C-cystine 
uptake values were normalized to cellular protein levels. 
Radiolabeled cystine uptake in spinal cord glial cultures was performed as 
previously described, with modifications (Liu et al., 2009).  Cultures were exposed to 
media with or without 100µM iron sulfate for 24 hours.  After the drug exposure cultures 
were washed into HEPES buffered saline solution and immediately exposed to 14C-
cystine (0.025µCi/mL, 200nM total cystine) for 20 minutes.  Following 14C-cystine 
exposure, cultures were washed with ice cold HEPES buffered saline solution and 
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dissolved in 250µl warm sodium dodecyl sulfate (0.1%).  An aliquot (200µl) was 
removed and added to scintillation fluid for counting.  A 30µL aliquot was removed to 
measure cellular protein levels using the BCA assay.  14C-cystine uptake values were 
normalized to cellular protein levels. 
Analysis of Glutamate Release 
To measure glutamate released from spinal cord slices, slices were exposed to 
slice buffer in the presence or absence of 100µM cystine for 30 minutes at 37°C. The 
slices were then removed and dissolved in 250µL of 1% SDS. A 100µL aliquot was 
removed for the BCA protein assay. Also, the media the slices were bathed in was 
collected and analyzed for glutamate by HPLC (Agilent 1100), using a Hypersile-ODS 
reverse phase column, and ultraviolet detection at a 254nm wavelength, as previously 
described (Rush et al., 2010).  Briefly, 200µL of media was derivatized with 100µL of 
phenylisothiocyanate (PITC), methanol, triethylamine (TEA) and dried under vacuum.  
Samples were then reconstituted in solvent consisting of 0.14M sodium acetate, 0.05% 
TEA, 6% acetonitrile, and brought to a pH of 6.4 with glacial acetic acid.  The solvent 
was also used as the mobile phase, with the column being washed in 60% acetonitrile and 
40% water between each sample run.  Media glutamate concentrations were calculated by 
normalizing to glutamate standards ranging from 1-100µM. Glutamate values were then 
normalized to cellular protein levels. 
3H-D-Aspartate Uptake 
To assess EAAT function, uptake of radiolabeled D-aspartate into spinal cord 
slices was measured.  Slices were exposed to slice buffer containing 3H-D-aspartate 
(0.25µCi/ml) for 30 minutes in the presence or absence of 100µM of the general EAAT 
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inhibitor DL-threo-β-Benzyloxyaspartic acid (TBOA).  The slices were then washed for 2 
minutes in ice cold slice buffer and dissolved in 250µL 1% SDS.  A 100µL aliquot was 
removed and added to scintillation fluid for counting. Another 100µL aliquot was 
removed to measure cellular protein levels using the BCA assay.  3H-D-aspartate uptake 
values were normalized to cellular protein levels. 
EAAT function was also assessed in spinal cord glial cultures using radiolabeled 
D-aspartate. Cultures were exposed to media with or without 100µM iron citrate for 24 
hours.  Cultures were then washed with HEPES buffered saline solution and immediately 
exposed to 3H-D-asparate (0.25µCi/ml) for 20 min.  Following 3H-D-aspartate exposure, 
cultures were washed, dissolved, and scintillation counted as for 14C-cystine studies.  A 
30µL aliquot was removed to measure cellular protein levels using the BCA assay.  3H-
D-asparate uptake values were normalized to cellular protein levels. 
Assay of neuronal death 
 
Cell death was assessed in spinal cord glia cultures by the measurement of lactate 
dehydrogenase (LDH), released from damaged or destroyed cells, in the extracellular 
fluid 24 hours after exposure to varying concentrations of iron citrate.  Control LDH 
levels were subtracted from insult LDH values, and results normalized to 100% cell death 
caused by 10 µM A23187.  Control experiments have shown previously that the efflux of 
LDH occurring from either necrotic or apoptotic cells is proportional to the number of 
cells damaged or destroyed (Lobner, 2000; Koh and Choi, 1987). 
l2’,7’-dichlorofluorescein (DCF) assay of oxidative stress 
 
Oxidative stress was assayed by measuring DCF oxidation using a fluorescent 
plate reader following a modification of a previous method (Wang and Joseph, 1999; 
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Lobner et al., 2007).  Briefly, cultures were exposed to 100µM iron citrate for the 
indicated time, after which they were exposed to 5-(and –6)-carboxy-2’7’-
dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA) (10µM).  The carboxy-
H2DCFDA is de-esterified within cells to form a free acid that can then be oxidized to the 
fluorescent 2’7’-dichlorofluorescein (DCF).  After a 1-hour exposure to carboxy-
H2DCFDA, cultures were washed 3 times with culture media lacking serum and 
dissolved in DMSO.  A 200µL aliquot was taken and fluorescence was measured using a 
Fluoroskan Ascent fluorescence plate reader (ThermoLabsystems).  The excitation filter 
was set at 485 nm and emission filter at 538 nm.  A 30µL aliquot was removed to 
measure cellular protein levels using the BCA assay.  Background fluorescence (no 
carboxy-H2DCFDA added) was subtracted and the results normalized to cellular protein 
levels.  
Monochlorobimane (MCB) assay of cellular reduced GSH 
 
Cellular GSH levels were measured by MCB fluorescence.  MCB forms a 
fluorescent compound when it reacts with GSH through a reaction catalyzed by 
glutathione-S-transferase.  As previously described (Pauly et al., 2011) with modification, 
cultures were exposed to 100µM iron citrate for the indicated time, after which they were 
exposed to MCB (10µM).  After 30 minutes the cultures were washed with ice cold 
HBBSS and dissolved in DMSO.  A 200µL aliquot was taken and excited at a 
wavelength of 355 nm and emission measured at a wavelength of 460 nm using a Thermo 
Labsystems Fluoroskan microplate reader.  A 30µL aliquot was removed to measure 
cellular protein levels using the BCA assay.  Background (no MCB added) was 
subtracted and the results normalized to cellular protein levels. 
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Statistical analysis 
Differences between test groups were examined for statistical significance by 
means of a t-test and one-way ANOVA followed by the Bonferroni post-hoc analysis, 
with a p-value <0.05 being considered significant. 
Results 
 
 
 We first tested whether cystine uptake was altered in spinal cord slices in mice 
prepared from SOD1-G93A compared to nontransgenic littermate mice.  Cystine uptake 
was the same in 55 day old mice, but in 70 day old mice there was significantly higher 
cystine uptake in the SOD1-G93A mice.  This difference disappeared in the 100 day old 
mice (Figure 2.1).  At all three of these time points mice were presymptomatic 
(neurological score of 0).  Cystine uptake was also measured in 130 day old mice, which 
were early symptomatic (each with a neurological score of 1).  Similar to the 100 day old 
mice, there was no significant difference in cystine uptake in the 130 day old mice.   
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Figure 2.1 14C-cystine uptake in spinal cord slices of SOD1-G93A mice is significantly 
increased compared to nontransgenic (NonTG) mice at 70 days, but not at 55, 100, or 130 
days of age.  Bars show the counts per minute (cpm) of radiolabeled cystine per µg 
protein (mean ± s.e.m, n=10-16; 2-5 animals were used for each experimental group) 
during a 30 minute uptake assay in spinal cord slices. * indicates a significant difference 
within an age group, t-test (p < 0.05). 
 
 
There are multiple mechanisms by which cystine may enter cells, to determine if 
the change in uptake was due to increased system xc- activity, we tested the inhibitor of 
this system, sulfasalazine (SSZ).  SSZ blocked about 30% of cystine uptake in 
nontransgenic mice, but completely blocked the increased cystine uptake in 70 day old 
SOD1-G93A mice (Figure 2.2A).  Graphing only the SSZ dependent cystine uptake 
showed that it was this component that was elevated in the SOD1-G93A mice (Figure 
2.2B).   
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Figure 2.2 The increased 14C-cystine uptake in spinal cord slices of SOD1-G93A mice is 
through system xc-. A) At 70 days of age, 14C-cystine uptake into spinal cord slices is 
significantly blocked by the system xc- inhibitor, sulfasalazine (SSZ) in both SOD1-
G93A and NonTG mice. B) The amount of cystine uptake through system xc- is 
significantly higher at 70 days in SOD1-G93A mice compared to NonTG mice. Bars 
show the cpm of radiolabeled cystine per µg protein (mean ± s.e.m, n=16-20; 3-4 animals 
were used for each experimental group) during a 30 minute uptake assay in the presence 
or absence of 300µm SSZ.  * indicates a significant difference from the NonTG mice. # 
indicates a significant difference within a group, t-test (p < 0.05).   
 
 
Since each time system xc- transports one cystine molecule into the cell it also 
transports one glutamate molecule out of the cell, it would also be expected to increase 
	 58	
glutamate release in the slices from 70 day old SOD1-G93A mice.  Under conditions 
with no added extracellular cystine, the glutamate accumulation was slightly elevated in 
slices from SOD1-G93A mice.  However, with 100µM cystine present in the media, there 
was significantly greater glutamate accumulation in the media from SOD1-G93A mouse 
slices (Figure 2.3).   
 
 
Figure 2.3 70 day old SOD1-G93A mice have higher glutamate release from spinal cord 
slices than NonTG mice; this release can be driven by cystine. Bars show the 
extracellular glutamate levels per µg protein (mean ± s.e.m, n=4-6; 2-3 animals were 
used for each experimental group) released from spinal cord slices during a 30 minute 
release assay in the presence or absence of 100µM cystine. * indicates a significant 
difference from the NonTG mice. # indicates a significant difference within a group, t-
test (p < 0.05).   
 
 
It is well known that glutamate uptake is decreased in both ALS patients and 
SOD1-G93A mice.  However, glutamate uptake in spinal cord slices has not previously 
been tested in any ALS model.  We found that glutamate uptake, measured by 3H-D-
aspartate uptake, was not changed in either the presymptomatic 55, 70, or 100 day old 
SOD1-G93A mice or in the early symptomatic 130 day old mice (Figure 2.4).  To 
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determine whether the D-aspartate uptake was actually measuring transport by EAATs 
we tested the effect of the general EAAT inhibitor TBOA.  TBOA blocked about 80% of 
3H-D-aspartate uptake in both nontransgenic and SOD1-G93A 70 day old mice (Figure 
2.5A) and there was no difference in the amount of TBOA dependent uptake (Figure 
2.5B). 
 
 
Figure 2.4 There is no significant difference in 3H-D-aspartate uptake between NonTG 
and SOD1-G93A mice at 55, 70, 100, or 130 days of age (t-test performed).  Bars show 
the cpm of radiolabeled D-aspartate per µg protein (mean ± s.e.m, n=11-16; 2-5 animals 
were used for each experimental group) during a 30 minute uptake assay in spinal cord 
slices. 
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Figure 2.5 3H-D-aspartate uptake through EAATs is not significantly different between 
NonTG and SOD1-G93A mice.  A) At 70 days of age, 3H-D-aspartate uptake into spinal 
cord slices is significantly blocked by the excitatory amino acid transporter (EAAT) 
inhibitor, DL-threo-β-Benzyloxyaspartic acid (TBOA) in both NonTG and SOD1-G93A 
mice. B) The amount of D-aspartate uptake mediated by EAATs is not significantly 
different at 70 days in SOD1-G93A mice compared to NonTG mice. Bars show the cpm 
of radiolabeled D-aspartate per µg protein (mean ± s.e.m, n=8-11; 3-4 animals were used 
for each experimental group) taken up during a 30 minute uptake assay in the presence or 
absence of 100µm TBOA. * indicates a significant difference, t-test (p < 0.05). 
 
 
 Astrocytes carrying the SOD1-G93A mutation have been shown to promote 
motor neuron degeneration 	(Cassina	et	al.,	2008;	Fritz	et	al.,	2013;	Papadeas	et	al.,	
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2011).	 Since system xc- is mainly found on astrocytes  (Fritz et al., 2013) and has the 
potential to lead to excitotoxicity through increased glutamate release, we wanted to 
further characterize system xc- and its regulation in SOD1-G93A astrocyte-enriched glial 
spinal cord cells.  First, we tested whether cystine uptake was altered compared to 
nontransgenic littermates.  Cystine uptake was the same under control conditions (Figure 
2.6).  In order to see if cystine uptake changed in response to oxidative stress we 
challenged the cells with 100µM iron citrate (Fe).  As expected, cystine uptake increased 
significantly.  Interestingly, the increase in SOD1-G93A mice was significantly lower 
than in nontransgenic littermates.  Based upon what we observed in the spinal cord slices 
from SOD1-G93A mice, these results were the opposite of what we hypothesized.  
 
 
Figure 2.6 24-hour application of 100µM iron (Fe) increases 14C-cystine uptake more in 
NonTG glial cells than in SOD1-G93A glial cells.  Bars show the cpm of radiolabeled 
14C-cystine per µg protein (mean ± s.e.m, n=8-11) taken up during a 20 minute uptake 
assay. * indicates a significant difference from control; # indicates a significant 
difference from NonTG, t-test (p < 0.05). 
 
 To better understand what may be causing the difference in cystine uptake with 
iron application seen between cultured SOD1-G93A spinal cord cells and nontransgenic 
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littermates, GSH levels were measured in the presence and absence of 100µM Fe using 
MCB, which fluoresces when it reacts with GSH.  SOD1-G93A mice did not have altered 
GSH levels under control conditions and 24-hour application of Fe significantly 
decreased GSH levels in both SOD1-G93A mice and nontransgenic littermates (Figure 
2.7). 
 
 
Figure 2.7 100µM Fe causes a similar time-dependent decrease in cellular glutathione 
levels in SOD1-G93A and NonTG glial cells.  Cultures were exposed to 100µM Fe for 1, 
6, 12, or 24 hours, after which cellular reduced glutathione was determined by MCB 
fluorescence.  Bars show MCB fluorescence normalized to cellular protein levels (mean 
± s.e.m, n=8-16).  * indicates significant difference from control, one-way ANOVA       
(p < 0.05). 
 
Another potential mechanism that may be causing the difference in cystine uptake 
is the level of oxidative stress generated by iron.  To assess this cellular oxidative stress 
was measured with the l2’,7’-dichlorofluorescein (DCF), which fluoresces when 
oxidized.  Under control conditions, oxidative stress levels were the same; however, after 
a 24-hour application of 100µM Fe, oxidative stress increased significantly more in the 
nontransgenic littermate cultures than in SOD1-G93A cultures (Figure 2.8). 
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Figure 2.8 100µM Fe causes greater increase in cellular oxidative stress as measured by 
DCF fluorescence after 24-hour treatment in NonTG glial cells than in SOD1-G93A glial 
cells.  Bars show DCF fluorescence normalized to cellular protein levels (mean ± s.e.m, 
n=8-16).  * indicates significant difference from control, one-way ANOVA (p < 0.05);    
# indicates significant difference from NonTg littermate at the same timepoint, t-test         
(p < 0.05). 
 
 
 Since a large difference in oxidative stress induced by iron was observed, we 
wanted to see if iron application had different effects on glial toxicity.  100µM Fe, which 
is the concentration at which cystine uptake is altered, was not significantly toxic to 
SOD1-G93A or nontransgenic glial cells.  Surprisingly, even though oxidative stress was 
higher in nontransgenic glial cells, a higher concentration of Fe (300µM) was more toxic 
to SOD1-G93A glial cells (Figure 2.9). 
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Figure 2.9 Greater toxicity is observed in SOD1-G93A cells treated with Fe than in 
NonTG cells.  Concentration response curve for 24 hr exposure to varying concentrations 
of Fe on LDH release in primary glial cultures.  Results are expressed as mean ± s.e.m 
(n=8-16).  * indicates significant difference from untreated control, one-way ANOVA   
(p < 0.05). 
 
 
  Since we observed a difference in cystine uptake in the spinal cord glial cultures 
compared to uptake in spinal cord slices, we wanted to determine if 3H-D-aspartate might 
also be different.  In contrast to what was observed in slices, cultured SOD1-G93A spinal 
cord cells have significantly lower 3H-D-aspartate uptake under control conditions.  
Interestingly, when challenged with 100µM Fe, 3H-D-aspartate uptake does not decrease 
any further in SOD1-G93A mice (Figure 2.10). 
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Figure 2.10 SOD1-G93A glial cells have lower 3H-D-aspartate uptake than NonTG cells 
under control conditions.  24-hour application of 100µM Fe decreases 3H-D-aspartate 
uptake in NonTG cells, but not in SOD1-G93A cells.  Bars show the cpm of radiolabeled 
14C-cystine per µg protein (mean ± s.e.m, n=8-11) taken up during a 20 minute uptake 
assay. * indicates a significant difference from NonTG control, t-test (p < 0.05). 
 
Discussion 
 
 
The present study is the first to evaluate the function of system xc- in the spinal 
cord of any model of ALS.  The role of system xc- in neuronal death is complex; it has 
potentially damaging effects due to its ability to release glutamate while also having 
potentially protective effects due to its ability to take up cystine, leading to enhanced 
antioxidant capabilities.  The relative contribution of excitotoxicity and oxidative stress in 
ALS is not certain, and the potential for crosstalk between the two mechanisms exists. 
For example, neuronal death induced by excitotoxicity can involve oxidative stress 
(Dugan et al., 1996) and oxidative stress can induce glutamate release (Globus et al., 
1995).  A previous study by Liu et al. (1998) showed that in the spinal cord of SOD1-
G93A transgenic mice there is a significant increase in oxidative stress beginning at day 
60.  In this study we observed a significant enhancement in cystine uptake in spinal cord 
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slices from presymptomatic, 70 day old SOD1-G93A transgenic mice compared to 
nontransgenic mice.  This increase was not present at day 55 and was no longer present at 
day 100.  We also did not observe a difference in cystine uptake in 130 day old, early 
symptomatic SOD1-G93A transgenic mice compared to their nontransgenic littermates.  
The enhanced uptake in the 70 day SOD1-G93A was significantly blocked by 
sulfasalazine (SSZ), the system xc- inhibitor, suggesting that the increase in cystine 
uptake was through system xc-.    
 There was also increased cystine driven glutamate release in the spinal cord slices 
of 70 day old SOD1-G93A mice. These findings suggest the possibility that the oxidative 
environment found in the spinal cord of SOD1-G93A transgenic mice may upregulate 
system xc-.  This is a potential protective mechanism as it leads to increased cystine 
uptake and glutathione synthesis.  However, it will also cause increased glutamate release 
which can induce excitotoxicity.  To date the only FDA approved drug for the treatment 
of ALS is the anti-excitotoxic compound, riluzole (Miller et al., 2002).  The high 
sensitivity of motor neurons to excitotoxicity is likely due to their expression of high 
numbers of calcium permeable AMPA receptors (Carriedo et al., 1996) and low 
expression of calcium binding proteins (Alexianu et al., 1994).  Therefore, it is possible 
that the combination of oxidative stress and the glutamate released by system xc-, along 
with other potential factors, causes excitotoxicity in these mice. 
 The results in the SOD1-G93A astrocytes-enriched glial cells yield different 
results than those observed in slices.  In culture, no differences in radiolabeled cystine 
uptake under control conditions were observed.  Surprisingly, however, applying iron 
caused a significantly larger increase in system xc- function in the nontransgenic cells 
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than in the SOD1-G93A cells.  Iron caused similar levels of GSH depletion in both 
SOD1-G93A cells and nontransgenic cells.  However, the DCF assay revealed that iron 
caused a significantly larger increase in oxidative stress levels in nontransgenic cells, 
which may explain the larger increase in system xc- function observed in nontransgenic 
cells. 
 The SOD1-G93A mutation makes motor neurons more vulnerable to oxidative 
stress  (Bridges et al., 2012a; Papadeas et al., 2011)  In the current study we observe that 
the SOD1-G93A mutation also makes glial cells more vulnerable.  300µM Fe caused 
toxicity in the SOD1-G93A cells; however, 300µM Fe did not cause toxicity in 
nontransgenic cells, even though we observe higher levels of oxidative stress in these 
cells.  Therefore, while SOD1-G93A cells do appear to be more sensitive, it does not 
appear to be due to increased oxidative stress.  This finding is in agreement with a study 
that found transfecting astrocytes with SOD1-G93A did not cause an increase in 
oxidative stress	(Boillée	et	al.,	2006)	.  The increased toxicity in the SOD1-G93A glial 
cells is not due to depleted GSH levels either, but rather through a mechanism we were 
unable to detect. 
 It is interesting that system xc- function appears to decrease with age in 
nontransgenic mice.  To our knowledge, this is the first study measuring system xc- 
activity over a range of ages.  Decreased system xc- function with age could potentially 
be a contributing factor to the increased levels of oxidative stress observed with age 
(Liochev, 2013). 
 Previous studies have shown decreased expression of EAAT2 in ALS animal 
models.  Decreased EAAT2 expression was found beginning at 14 weeks (98 days) in 
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SOD1-G93A transgenic rats (Howland et al., 2002) and mice (Bendotti et al., 2001), 
although another study involving these mice did not show a decrease until 35 weeks of 
age (Warita et al., 2002).  Also, studies of functional glutamate uptake using 
synaptosomal preparations from SOD1-G93A transgenic mice did not indicate a 
significant decrease in glutamate uptake until mice were 150 days old (Canton et al., 
1998). A potential mechanism for the decreased glutamate uptake observed in ALS is that 
caspase 3 is able to cleave and inactivate EAAT2 (Boston-Howes et al., 2006).  A 
cleaved form of EAAT2 is found in spinal cords of SOD1-G93A mice (Boston-Howes et 
al., 2006) and caspase 3 is highly activated in these mice at the time point of ALS-like 
symptoms (Pasinelli et al., 2000).  Since caspase 3 is activated in cells undergoing 
apoptosis, these findings suggest that cell death may be triggered before the inactivation 
of EAAT2. 
In the current study we did not observe a significant decrease in radiolabeled D-
aspartate uptake in spinal cord slices from SOD1-G93A transgenic mice at 55, 70, 100, or 
130 days of age.  D-aspartate uptake was significantly blocked in both 70 day old SOD1-
G93A transgenic mice and nontransgenic mice by the EAAT inhibitor TBOA, showing 
that the uptake of D-aspartate was through EAATs.  However, the amount of D-aspartate 
uptake blocked by TBOA was not significantly different between SOD1-G93A 
transgenic mice or nontransgenic littermate mice, suggesting that there was no change in 
EAAT function in SOD1-G93A transgenic mice at this age.  Taken together, our results 
that system xc- mediated glutamate release is increased long before any potential decrease 
in glutamate uptake, suggest the possibility that this glutamate release may contribute to 
early excitotoxicity in SOD1-G93A mice. 
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However, the radiolabeled D-aspartate uptake results in cultured spinal cord glial 
cells are quite different than what was observed in the spinal cord slices.  In glial cell 
cultures from SOD1-G93A mice there is a significant decrease in EAAT function in 
control conditions.  This would suggest that very early on these cells have an impaired 
ability to handle glutamate, which could cause the increased levels of extracellular 
glutamate and contribute to excitotoxicity seen in ALS patients.  The reason why iron 
application does not decrease EAAT function in SOD1-G93A cells further is unknown. 
 There have been a number of studies testing the effects of using N-acetylcysteine 
(NAC) to drive system xc- as a potential treatment for ALS.  NAC prevents increased 
oxidative stress and mitochondrial dysfunction in human neuroblastoma cells (SH-SY5Y) 
expressing the SOD1-G93A mutation (Beretta et al., 2003).  In animal models of ALS the 
results have been mixed.  In the SOD1-G93A mouse, one study found that NAC 
prolonged survival and delayed onset of motor impairment (Andreassen et al., 2000), 
while in another study it did not alter survival or disease onset (Jaarsma et al., 1998).  
There is one well controlled study using NAC in human ALS patients.  In this 
randomized, double-blind, controlled trial it was found that NAC provided a small, non-
significant increase in survival, with no evidence of reduction in disease progression 
(Louwerse et al., 1995).  Interestingly, in subgroups of patients, those with disease of the 
limbs onset showed increased survival, while those with bulbar onset had decreased 
survival.  This type of variability in effects may be expected given the dual actions of 
driving system xc-.  Supporting this view, riluzole provides greater survival promoting 
benefit in ALS patients with bulbar symptoms (Bensimon et al., 1994; Zoccolella et al., 
2007), suggesting that excitotoxicity plays a greater role in these patients, which would 
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be consistent with NAC having a negative effect in these patients.  It is possible that 
increased system xc- function may be particularly pronounced in these patients in which 
case further driving system xc- could lead to excitotoxicity that overwhelms the benefit of 
increased cystine uptake. 
 The data presented from spinal cord slices show there is enhanced system xc- 
function occurring at 70 days of age in the SOD1-G93A mouse, possibly due to the 
oxidative stress observed in these mice.  This increased activity could be a protective 
mechanism in that the increased cystine uptake would maintain glutathione levels even 
under conditions of oxidative stress.  Previously, it was found that in the spinal cord of 
SOD1-G93A mice reduced glutathione levels were decreased at 110 days of age, but not 
at 45 or 80 days (Chi et al., 2007).  Interestingly, this study also found that oxidized 
glutathione was increased at both 80 and 110 days of age.  These results suggest that 
glutathione production is increased at the 80 day timepoint, but high levels of oxidative 
stress are causing the formation of increased oxidized glutathione.  These results are 
consistent with the elevated system xc- activity we found in 70 day old SOD1-G93A mice 
being induced by oxidative stress and that upregulation acts as a mechanism to maintain 
glutathione levels.  However, the increased function of system xc- will also lead to 
increased glutamate release, which may contribute to the eventual neurological deficits.   
The studies done in spinal cord glial cells seem to conflict with the results we see 
from spinal cord slices.  The major difference in the ages of the mice used for these two 
sets of experiments is likey a factor in these conflicting results. Spinal cord slice 
experiments were performed in mice between the ages of 55 and 130 days old, while glial 
cultures were made from postnatal 1-3 day old pups. Major changes occur in the SOD1- 
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G93A mice as they age that cannot be replicated in culture.  These are not the only 
discrepancies seen between in vitro and in vivo work done in SOD1-G93A mice.  
Tortarolo et al. (2004) saw a decrease in GLT-1 expression and function in primary 
astrocytes only four days after they are transfected with the SOD1-G93A gene.  
However, in vivo decreases in GLT-1 expression and function are not seen in the SOD1-
G93A mouse until at least the symptomatic stages of the disease  (Tortarolo et al., 2004) .  
The discrepancies seen between these studies highlight the differences between work 
done in vitro and in vivo.  While in vitro studies are useful to determine mechanisms, the 
limitations of work done in vitro must be taken into consideration when translating them 
in vivo.  With this in mind, further studies will be required to determine the net effects of 
system xc- activity in the SOD1-G93A mouse model and in human ALS patients. 
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CHAPTER III 
 
 
REGULATION OF SYSTEM XC- BY PHARMACOLOGICAL  
MANIPULATION OF CELLULAR THIOLS 
 
 
Abstract 
 
 
The cystine/glutamate exchanger (system xc-) mediates the transport of cystine 
into the cell in exchange for glutamate.  By releasing glutamate, system xc- can 
potentially cause excitotoxicity.  However, through providing cystine to the cell it 
regulates the levels of cellular glutathione (GSH), the main endogenous intracellular 
antioxidant, and may protect cells against oxidative stress.  We tested two different 
compounds that deplete primary cortical cultures containing both neurons and astrocytes 
of intracellular GSH, L-buthionine-sulfoximine (BSO) and diethyl maleate (DEM).  Both 
compounds caused significant, concentration and time-dependent decreases in 
intracellular GSH levels.  However, DEM caused an increase in radiolabeled cystine 
uptake through system xc-, while unexpectedly BSO caused a decrease in uptake.  The 
compounds caused similar low levels of neurotoxicity, while only BSO caused an 
increase in oxidative stress.  The mechanism of GSH depletion by these two compounds 
is different, DEM directly conjugates to GSH, while BSO inhibits γ-glutamylcysteine 
synthetase, a key enzyme in GSH synthesis.  As would be expected from these 
mechanisms of action, DEM caused a decrease in intracellular cysteine, while BSO 
increased cysteine levels.  The results suggest that negative feedback by intracellular 
cysteine is a more important regulator of system xc- than intracellular GSH in this culture 
system. 
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Introduction 
 
 
Under normal physiological conditions, the cystine/glutamate exchanger (system 
xc-) mediates the transport of cystine into the cell in exchange for releasing glutamate 
into the extrasynaptic space.  The exchange of extracellular cystine and intracellular 
glutamate occurs in a one to one ratio.  The function of system xc- makes it likely to play 
an important role in regulating neuronal survival and death.  By releasing glutamate, 
system xc- can increase extracellular glutamate levels and potentially cause 
excitotoxicity.  Release of glutamate via system xc-, from both microglia and astrocytes 
has been shown to enhance excitotoxicity of cortical neurons. (Qin et al., 2006; Fogal et 
al, 2007; Jackman et al, 2010; Liu et al., 2014) However, through providing cystine to the 
cell, it regulates the levels of intracellular glutathione (GSH), the main endogenous 
intracellular antioxidant, and in this way may protect cells against oxidative stress 
(Murphy et al., 1989; Shih et al., 2006). 
Not only does system xc- act to prevent oxidative stress, but it appears that such 
stress is an important trigger for its upregulation.  Direct induction of oxidative stress has 
been shown to upregulate system xc- function in a retinal ganglion cell line (Dun et al., 
2006) and in retinal Muller glial cells (Mysona et al., 2009).  Compounds that deplete 
cellular GSH levels upregulate system xc- function in a glioma cell line (Kim et al., 2001) 
and in primary astrocytes (Seib et al., 2011), although there is not always a correlation 
between depletion of GSH and upregulation of system xc- (Sasaki et al., 2002).   
  The first step in the production of GSH in the brain is believed to involve uptake 
of cystine, primarily into astrocytes (Kranich et al., 1998).  Most of the cystine 
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transported into cortical astrocytes appears to be through system xc- (Lobner, 2009).  
Once in the astrocytes cystine is immediately broken down by thioredoxin reductase 1 
into two cysteine molecules (Arrick et al., 1985).  GSH is synthesized via a two-step 
reaction (Beutler, 1989; Deneke and Fanburg, 1989).  First, glutamate and cysteine are 
catalyzed to γ-glutamylcysteine by γ-glutamylcysteine synthetase.  Then glutathione 
synthetase combines glycine with γ-glutamylcysteine forming GSH.  Both glutamate and 
glycine are highly available in the cells, so the rate-limiting factor in the production of 
GSH is the levels of cysteine present in the cell (Dringen and Hirrlinger, 2003). 
   Glutathione can be utilized by cells to reduce reactive oxygen species; for 
example, superoxide produced as a byproduct of mitochondrial energy production rapidly 
reacts to form hydrogen peroxide which is then reduced by GSH to form glutathione-
disulfide (GSSG) and water in a reaction catalyzed by glutathione peroxidase.  
Glutathione may also be utilized as a xenobiotic detoxicant as has been well 
characterized involving chemotherapeutics in cancer treatment (Salinas and Wong, 
1999).  That is, GSH can be directly conjugated to exogenous substrates via a disulfide 
bond with the free sulfhydryl groups; these reactions are directed by a class of enzymes 
known as glutathione-S-transferases (GSTs) (Dringen and Hirrlinger, 2003; Dringen, 
2000).  GSH, GSSG and the glutathione-conjugates are then exported from the cell in a 
glutathione-dependent manner via multi-drug resistance proteins (MRP), specifically 
MRP1 in the CNS (Hirrlinger and Dringen, 2005; Minich et al., 2006).  GSH molecules 
produced by astrocytes can then be broken down in the extracellular space by glutathione 
reductase, amino-peptidase N, or γ-glutamyl transpeptidase.  This metabolism produces 
the substrate cysteine, which can be taken up and utilized by neurons to produce their 
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own GSH (Fellin and Carmignoto, 2004; Stipursky et al., 2011; Yoshiba-Suzuki et al., 
2011).  In this way, neurons are dependent on astrocytes to supply the substrate for their 
GSH production (Dringen et al., 1999).  The importance of cysteine uptake into neurons 
is indicated by the finding that knocking out the excitatory amino acid transporter-3 
(EAAT3) greatly reduces neuronal cysteine uptake and intracellular GSH levels, resulting 
in decreased viability of hippocampal neurons against hydrogen peroxide insults (Chen 
and Swanson, 2003; Aoyama et al., 2006). 
The current studies used mixed cultures of neurons and astrocytes to be able to 
incorporate the important interaction between these cell types.  The studies involve 
assessing the effects of two different approaches to depleting cellular GSH.  Diethyl 
maleate (DEM) directly conjugates to GSH while buthionine sulfoximine (BSO) inhibits 
γ-glutamylcysteine synthetase preventing the production of GSH.  The studies were 
designed to determine the effects of these different mechanisms of GSH depletion on 
system xc- function.    
Materials and Methods 
 
 
Materials 
 
Timed pregnant Swiss Webster mice were obtained from Charles River 
Laboratories (Wilmington, DE, USA).  Serum was from Atlanta Biologicals (Atlanta, 
GA, USA).  NADPH was from Applichem (Darmstadt, Germany).  Radiolabeled 14C-
Cystine was purchased from PerkinElmer (Boston, MA, USA).  DCF was from 
Molecular Probes (Eugene, OR, USA).  All other chemicals were from Sigma-Aldrich 
(St. Louis, MO, USA).  
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Cortical Cell Cultures 
 
Mixed cortical cell cultures containing glial and neuronal cells were prepared 
from fetal (15-16 day gestation) mice as previously described (Lobner, 2000).  
Dissociated cortical cells were plated on 24-well plates (2.0 cm2 surface area per well) 
coated with poly-D-lysine and laminin in Eagles’ Minimal Essential Medium (MEM, 
Earle’s salts, supplied glutamine-free) supplemented with 5% (v/v) heat-inactivated horse 
serum, 5% (v/v) fetal bovine serum, 2 mM glutamine and D-glucose (total 21 mM).  
Cultures were maintained in humidified 5% CO2 incubators at 370C with experiments 
performed on cultures DIV 13-15.  Mice were handled in accordance with a protocol 
approved by our institutional animal care committee and in compliance with the Public 
Health Service Policy on Humane Care and Use of Laboratory Animals.  All efforts were 
made to minimize animal suffering and reduce the number of animals used.  Experiments 
were performed in media lacking serum (MS) but otherwise identical to the growth 
media. 
Assay of neuronal death 
 
Cell death was assessed in cultures by the measurement of lactate dehydrogenase 
(LDH), released from damaged or destroyed cells, in the extracellular fluid 24 hours after 
the beginning of the insult.  Control LDH levels were subtracted from insult LDH values, 
and results normalized to 100% neuronal death caused by 500 µM NMDA.  Control 
experiments have shown previously that the efflux of LDH occurring from either necrotic 
or apoptotic cells is proportional to the number of cells damaged or destroyed (Lobner, 
2000; Koh and Choi, 1987).  Cultures were also examined visually following trypan blue 
staining. 
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2’,7’-dichlorofluorescein (DCF) assay of oxidative stress 
 
Oxidative stress was assayed by measuring DCF oxidation using a fluorescent 
plate reader following a modification of a previous method (Wang and Joseph, 1999; 
Lobner et al., 2007).  Briefly, cultures were exposed to 100µM DEM or BSO for the 
indicated period of time after which they were exposed to 5-(and –6)-carboxy-2’7’-
dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA) (10 mM).  The carboxy-
H2DCFDA is de-esterfied within cells to form a free acid that can then be oxidized to the 
fluorescent 2’7’-dichlorofluorescein (DCF).  After a 30 minute exposure to carboxy-
H2DCFDA, cultures were washed 3 times with culture media lacking serum.  
Fluorescence was then measured using a Fluoroskan Ascent fluorescence plate reader 
(ThermoLabsystems).  The excitation filter was set at 485 nm and emission filter at 538 
nm.   Background fluorescence (no carboxy-H2DCFDA added) was subtracted and the 
results normalized to control conditions (carboxy-H2DCFDA added but no DEM or 
BSO).  
Monochlorobimane (MCB) assay of cellular reduced GSH 
 
 Cellular GSH levels were measured by MCB fluorescence.  MCB forms a 
fluorescent compound when it reacts with GSH through a reaction catalyzed by 
glutathione-S-transferase (Pauly et al., 2011).  Cultures were exposed to the indicated 
concentrations of DEM or BSO for the indicated period of time after which they were 
exposed to MCB (10 mM).  After 30 minutes the cultures were excited at a wavelength of 
355 nm and emission measured at a wavelength of 460 nm using a Thermo Labsystems 
Fluoroskan microplate reader.  Background (no MCB added) was subtracted and the 
results normalized to control (MCB added but no DEM or BSO). 
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HPLC analysis of cellular cysteine levels 
 
 To assess cysteine concentrations, cultures were exposed to MS containing the 
indicated drug for 6 or 24 hours. After the indicated time, cultures were washed with 
balanced salt solution (BSS) and then scraped into 250µL HPLC mobile phase.  Cells 
were collected into microcentrifuge tubes, sonicated using a probe sonicator and analyzed 
for protein content using the common BCA method.  Once the protein content was 
determined, the homogenized samples were spun through a centrifugal filter and the 
resulting protein free sample was injected onto a Shimadzu HPLC system coupled with 
an electrochemical detector.  Separation was obtained with a reverse phase C-18 column 
and an ion-pairing mobile phase (50 mM citric acid, 10 mM octane sulfonic acid, pH 
2.80, 1% acetonitrile).  Resulting cysteine concentrations were normalized by the protein 
content and values are reported as percent control. 
14C-Cystine Uptake 
 
Radiolabeled cystine uptake was performed as previously described with 
modifications (Liu et al., 2009).  Cultures were exposed to MS containing the indicated 
drug treatments for 40 min, 6 hrs, or 24 hrs.  After the drug exposure cultures were 
washed into HEPES buffered saline solution and immediately exposed to 14C-cystine 
(0.025 µCi/mL, 200 nM total cystine) for 20 minutes.  Following 14C-cystine exposure, 
cultures were washed with ice cold HEPES buffered saline solution and dissolved in 
250µl warm sodium dodecyl sulfate (0.1%).  An aliquot (200µl) was removed and added 
to scintillation fluid for counting.  Values were normalized to control. 
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Statistical Analysis 
 
Differences between test groups were examined for statistical significance by 
means of one-way ANOVA followed by the Bonferroni post-hoc analysis, with p<0.05 
being considered significant. 
Results 
 
 
 We set out to determine whether depleting cellular GSH alters system xc- activity 
as assessed by measuring 14C-cystine uptake in mixed cortical cell cultures.  We have 
shown previously that the large majority of 14C-cystine uptake in mixed cortical cultures 
is mediated by system xc- uptake into astrocytes (Lobner, 2009).  In the current studies 
cellular GSH levels were depleted using two compounds with different mechanisms of 
action.  DEM directly conjugates to GSH, while BSO inhibits GSH synthesis.  Varying 
concentrations of DEM were added to mixed cortical cultures for 40 min, 6 hr, or 24 hrs, 
with 14C-cystine uptake measured for 20 minutes following the exposure.  DEM caused a 
significant increase in 14C-cystine uptake at all timepoints at a concentration of 100µM, 
and at 6 and 24 hrs at the 10µM concentration (Figure 3.1).  In contrast to DEM, when 
cultures were exposed to BSO at the same concentrations it did not cause an increase in 
14C-cystine uptake at any concentration or timepoint.  In fact, BSO at a concentration of 
100µM caused a significant decrease in 14C-cystine uptake after 6 hr treatment, while 
both 10 and 100µM BSO caused a decrease at 24 hrs (Figure 3.1).  
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Figure 3.1 Diethyl maleate (DEM) exposure causes an increase, while buthionine 
sulfoximine (BSO) exposure causes a decrease, in 14C-cystine uptake in mixed cortical 
cultures.   Cultures were exposed to varying concentrations of DEM or BSO for A) 40 
min, B) 6 hrs, or C) 24 hrs, after thorough washing, 14C-cystine uptake was measured for 
20 minutes.   Results are expressed as mean ± s.e.m (n=8-16) after normalizing to 
untreated control uptake. * indicates significant difference from DEM control; # indicates 
significant difference from BSO control, one-way ANOVA (p < 0.05). 
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 To test whether the increased uptake induced by DEM treatment was mediated by 
system xc-, the inhibitor of that system, sulfasalazine (SSZ), was added during the uptake 
period following exposure to 100µM DEM.  The SSZ treatment completely blocked the 
increased 14C-cystine uptake induced by DEM (Figure 3.2).  
 
 
Figure 3.2 DEM induced increase in 14C-cystine uptake is mediated by system xc-.  
Cultures were exposed to 100µM DEM for 40 min, 6 hrs, or 24 hrs, after thorough 
washing, 14C-cystine uptake was measured for 20 minutes with or without the system xc- 
inhibitor    sulfasalazine (SSZ) present.  Results are expressed as mean ± s.e.m (n=8-16) 
after normalizing to untreated control uptake.  * indicates significant difference from 40 
min control; # indicates significant difference from 6 hour control; @ indicates 
significant difference from 24 hour control, one-way ANOVA (p < 0.05). 
 
 
 A potential cause for altered 14C-cystine uptake could be toxicity of DEM or 
BSO.  DEM and BSO both caused a small, but significant level of neurotoxicity after 24 
hours at the 100µM concentrations (Figure 3.3).  Trypan blue staining indicated that the 
death was selective for neurons (data not shown). 
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Figure 3.3 DEM and BSO cause similar low levels of neurotoxicity.  Concentration 
response curve for 24-hour exposure to DEM and BSO on LDH release in primary 
cortical cultures.  Results are expressed as mean ± s.e.m (n=8-16).  * indicates significant 
difference from untreated control, one-way ANOVA (p < 0.05). 
 
 
 A potential mechanism by which DEM may have caused increased system xc- 
activity is through inducing oxidative stress, which has been shown to upregulate system 
xc- (Dun et al., 2006; Mysona et al., 2009).  We measured cellular oxidative stress with 
the compound DCF, which becomes fluorescent when oxidized.  Somewhat surprisingly 
we did not see enhanced DCF fluorescence following 100µM DEM treatment, while 
100µM BSO only caused an increase following 24 hr treatment (Figure 3.4). 
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Figure 3.4 BSO, but not DEM, causes an increase in cellular oxidative stress after a 24-
hour treatment.  Bars show % DCF fluorescence normalized to control fluorescence 
(mean ± s.e.m, n=8-16).  * indicates significant difference from control, one-way 
ANOVA (p < 0.05).  
 
 
 Another potential mechanism by which DEM may be causing increased system 
xc- function is through causing decreased GSH levels.  DEM and BSO treatment both 
caused a decrease in cellular GSH levels (Figure 3.5).  There were some differences in 
the decrease; DEM caused a more rapid decrease in GSH, with a significant decrease at 
the 40 minute timepoint, while BSO did not cause a significant decrease until the 6 hr 
timepoint.  The GSH levels with DEM treatment actually increased from the 6 hr 
timepoint to the 24 hr timepoint, so that at 24 hrs, BSO caused a greater decrease in GSH 
levels than DEM.  
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Figure 3.5 DEM and BSO cause a concentration dependent decrease in cellular 
glutathione levels.  Cultures were exposed to varying concentrations of DEM or BSO for 
A) 40 min, B) 6 hrs, or C) 24 hrs, after which cellular reduced glutathione was 
determined by MCB fluorescence.  Bars show % MCB fluorescence normalized to 
control fluorescence (mean ± s.e.m, n=8-16).  * indicates significant difference from 
DEM control; # indicates significant difference from BSO control, one-way ANOVA (p 
< 0.05). 
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 While DEM and BSO both act to decrease GSH levels they do so by different 
mechanisms suggesting the possibility that they may alter cellular cysteine levels 
differently.  We found that 100µM DEM caused a significant decrease in cellular cysteine 
levels after 6 hr treatment with the effect disappearing at 24 hours, while 100µM BSO 
caused a significant increase in cellular cysteine after 6 and 24 hr treatment (Figure 3.6). 
 
 
Figure 3.6 DEM causes an early decrease in cellular cysteine levels, while BSO causes 
an early and late increase in cellular cysteine levels.  Cultures were exposed to varying 
concentrations of DEM or BSO for A) 6 hrs or B) 24 hrs, after which cellular cysteine 
levels were determined by HPLC.  Bars show % cellular cysteine normalized to control 
(mean ± s.e.m, n=8).  * indicates significant difference from DEM control; # indicates 
significant difference from BSO control, one-way ANOVA (p < 0.05). 
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Discussion 
 
 
 The regulation of system xc- function is proving to be complicated, likely because 
of its varied functions.  Upregulation of system xc- by oxidative stress has been well 
established and this regulation is mechanistically understandable considering that system 
xc- is important for cystine uptake and therefore GSH production.  However, system xc- 
function has also been shown to be upregulated by a diverse array of compounds 
including IL-1b (Fogal et al., 2007), erythropoietin (Sims et al., 2010), FGF-2 (Liu et al., 
2012), IGF-1 (Pauly et al., 2011; Yang and Yee, 2014), TGF-b (Pauly et al., 2011), and 
PACAP (Resch et al., 2014).  While system xc- function has been shown to be decreased 
by dexamethasone (Piani and Fontana, 1994), regulation by these diverse compounds 
may reflect the importance of system xc- in regulating not only oxidative stress but also 
extracellular glutamate.  For example, it has been shown that cocaine addiction is 
associated with impaired system xc- function leading to decreased activation of 
presynaptic group II mGluRs leading to increased synaptic release of glutamate (Baker et 
al., 2002; Baker et al., 2003).  It is likely that the regulation of system xc- by these 
compounds reflects the importance of regulating both intracellular GSH and extracellular 
glutamate.  Another factor to consider is that there is an interaction between system xc- 
and excitatory amino acid transporters (EAATs) (Lewerenz et al., 2009). The possibility 
that altered EAAT function could change glutamate concentrations and in this way 
change system xc- function exists. 
The goal of the current study was to examine in more detail the regulation of 
system xc- by agents that deplete GSH.  The previous thinking about such agents is that 
they upregulated system xc- by depletion of cellular GSH, and either this depletion 
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directly stimulated system xc-, or the resulting increased oxidative stress caused the 
upregulation.  Our results indicate another potential mechanism of regulation.  In our 
studies, simple depletion of cellular GSH did not appear to be the trigger for upregulation 
of system xc-.  While there were some differences in the time course and concentration 
dependence of the effects of DEM and BSO treatment on GSH levels, they both caused 
depletion of GSH and yet they had opposite effects on system xc- function.  These results 
are difficult to explain by the different time courses in effects on GSH levels.  If BSO 
caused no effect on system xc- function this could potentially be explained by its slower 
depletion of GSH, but the fact that it actually caused a decrease in system xc- activity 
seems unlikely to be explained by the slower loss of GSH with BSO treatment than with 
DEM treatment.  Interestingly, the GSH levels following DEM treatment actually 
increased from the 6 hr timepoint to the 24 hr timepoint (Figure 3.5).  This increase is 
likely due to the upregulation of system xc- under these conditions leading to increased 
cystine uptake and additional substrate for GSH production. 
Toxicity due to treatment with DEM or BSO could be a potential confound when 
assessing cystine uptake.  However, both compounds caused only a small degree of 
neurotoxicity (10-15%) after 24 hours.  This toxicity seems unlikely to play a major role 
in the results for three reasons.  First, DEM and BSO caused similar toxicity but had 
opposite effects on cystine uptake.  Second, the levels of cell death were small compared 
to the magnitude of changes in cystine uptake.  Third, the cell death was selective for 
neurons, while most the cystine uptake in this culture system is into astrocytes (Lobner, 
2009). 
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The result that DEM did not induce oxidative stress, as measured by DCF 
fluorescence, suggests that increased oxidative stress is not the mechanism by which 
DEM upregulates system xc- function, particularly since BSO did induce oxidative stress 
while it actually decreased system xc- function.  However, it was somewhat surprising 
that DEM did not induce oxidative stress since it did decrease the levels of GSH.  There 
are a number of possible explanations for this result.  First, GSH is not the only 
antioxidant present in the brain.  Under the conditions we were studying it is possible that 
decreased GSH levels would not lead to enhanced oxidative stress in the cells.  Second, 
the DCF assay does not detect all forms of free radicals (Gomes et al., 2005) and it may 
be less effective in detecting mitochondria selective oxidative stress (Karlsson et al., 
2010).  Therefore while we cannot absolutely conclude that oxidative stress is not the 
trigger for upregulation of system xc- by DEM, the fact that BSO caused a marked 
increase in oxidative stress while DEM did not, and yet BSO caused a decrease in system 
xc- function, suggests that factors other than oxidative stress are more important in 
regulation of system xc- in this system.  
 Our results suggest that, at least for our cell culture system, cysteine is a more 
important regulator of system xc- function than GSH.  DEM caused both a decrease in 
cysteine and GSH levels, consistent with its action to conjugate GSH leading to constant 
use of cellular cysteine.  Therefore, either the decrease in cysteine or GSH could be 
responsible for the upregulation of system xc-.  However, BSO also decreased GSH, but 
increased cysteine levels, consistent with its action to inhibit γ-glutamylcysteine 
synthetase leading to GSH depletion but buildup of cysteine, and it caused a 
downregulation of system xc- function.  In this case, the most likely explanation for the 
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effect is that the buildup of cysteine provides negative feedback on system xc- function.  
This type of regulation makes sense physiologically.  The levels of cysteine in the cell are 
more directly related to the uptake of cystine than they are to the levels of GSH.  
Glutathione levels in cells could be altered by changes in the function of γ-
glutamylcysteine synthetase or glutathione synthetase, or potentially the availability of 
glycine or glutamate.  Therefore, if system xc- was upregulated by GSH depletion it could 
be in response to conditions unrelated to the availability of cystine.  Additionally, 
cysteine levels in the brain are 100 times lower than GSH levels (Slivka and Cohen, 
1993) and therefore, rapid changes in their levels are more likely to occur than changes in 
GSH levels. 
 Our results are in contrast to those of Seib et al. (2011), who found a large 
increase in system xc- function in astrocytes after treatment with BSO.  There are two 
major differences in the culture systems used for the studies. First, we used a mixed 
neuronal and astrocyte culture, while in the Seib et al. study they used a pure astrocyte 
culture. The possibility exists that the interaction of neurons with the astrocytes alters the 
how-cells-regulate system xc-. Second, their cultures received long-term treatment with a 
cell permeant form of cAMP prior to the BSO treatment. From their studies, it is clear 
that GSH levels can also be an important regulator of system xc-, but that the status of the 
cells likely determines the relative importance of cysteine or GSH in the regulation.   We 
cannot exclude the possibility that GSH plays a role in regulating system xc- even in our 
culture conditions, but it appears that cysteine levels have a greater effect than GSH on 
system xc- function.  The implications this finding has for the role of system xc- in 
disease conditions is not certain.  Cysteine levels are not as commonly measured as GSH 
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levels.  For example, we have found that system xc- function is increased at 70 days of 
age in the G93A-SOD1 mouse model of ALS (Albano et al., 2013), a timepoint at which 
GSH levels are not yet decreased (Chi et al., 2007), but intracellular cysteine levels are 
unknown.  
In conclusion, our studies indicate that, at least under some conditions, 
intracellular levels of cysteine are a more important regulator of system xc- than 
intracellular levels of GSH. We did not determine the mechanism of regulation by 
cysteine, but the redox sensitive transcription factor Nrf2 has been shown to be the main 
regulator of system xc- (Sasaki et al., 2002; Shih et al., 2003). This finding puts system 
xc- in the context of it being one factor in the role of Nrf2 as the master regulator of the 
cellular response to oxidative stress (Ishii and Mann, 2014). In conclusion, studies 
involving assessment of levels of cysteine, GSH, and system xc- function during disease 
conditions will be required to determine the most important regulator of system xc- 
function in disease states. 
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CHAPTER IV 
 
TGF-β1 INDUCED UPREGULATION OF SYSTEM XC- IN ASTROCYTES 
ENHANCES NEURONAL DEATH 
 
 
Abstract 
 
System xc-, the cystine/glutamate exchanger, mediates the transport of one cystine 
molecule into the cell in exchange for the release of one glutamate molecule into the 
extrasynaptic space.  Cystine transported into the cell is converted to glutathione (GSH), 
the main antioxidant in the brain, which protects the cell from oxidative stress.  However, 
the release of glutamate into the extrasynaptic space can lead to excitotoxicity.  
Transforming growth factor-β1 (TGF-β1) is a cytokine involved in regulating many 
cellular processes, including neuronal survival and death.  In this study we determined 
whether TGF-β1 regulates system xc- function and if system xc- plays a role in the effects 
of TGF-β1 activity on neuronal survival/death. We found that TGF-β1 increased 14C-
cystine uptake through system xc- in astrocyte-enriched glial cultures, which required 
both TGF-β1 receptors ALK5 and ALK1 and was mediated through the MAPK/ERK 
pathway.  TGF-β1 increased xCT mRNA levels and the increased uptake was blocked by 
the protein synthesis inhibitor cycloheximide.  Interestingly, TGF-β1 increased the export 
of GSH from astrocytes to be utilized by neurons, which would suggest a neuroprotective 
role for TGF-β1.  However, in mixed cortical cultures TGF-β1 enhanced rotenone-
induced toxicity, an effect mediated through AMPA receptors.  Together the data 
suggests that the increase in system xc- activity by TGF-β1 may have antioxidant 
defenses, but can also exacerbate excitotoxicity. 
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Introduction 
 
 
 Transforming growth factor-β1 (TGF-β1) is a cytokine with wide ranging effects 
in the CNS, including regulating cellular processes like growth and development (Böttner 
et al., 2000; Massagué et al., 2000), differentiation (Ishihara et al., 1994), and apoptosis 
(Prehn et al., 1994; Zhu et al., 2001; 2002).  TGF-β1 is one of three TGF-β isoforms and 
is part the TGF-β superfamily, which includes multiple cytokines.  While its receptors, 
TGF-β receptor I and II (TGF-βRI, -II), are found throughout the brain and are expressed 
on neurons, astrocytes, and microglia (Böttner et al., 1996; Vivien et al., 1998; Vivien 
and Ali, 2006), TGF-β1 expression is very low during development and in the adult brain 
(Flanders et al., 1991; Pelton et al., 1991; Unsicker et al., 1991).  While some studies 
show it is mainly confined to the meninges and choroid plexus (Unsicker et al., 1991), 
others have found it is present in the cerebral cortex (Vivien et al., 1998).  However, in 
response to injury and neurodegeneration TGF-β1 is highly upregulated and secreted by 
many different cell types (Pratt and McPherson, 1997; Flanders et al., 1998; Vivien and 
Ali, 2006), which makes its potential role in neuronal protection and death of interest. 
 TGF-β1 has been well studied in models of focal and global ischemia, where it is 
upregulated in the infarct and penumbral areas (Krupinski et al., 1996) and has protective 
effects (Prehn et al., 1993; Henrich-Noack et al., 1996; Pang et al., 2001).  It is also 
protective against β-amyloid toxicity (Prehn et al., 1996; Ren and Flanders, 1996), MPP+ 
toxicity to dopaminergic neurons (Krieglstein et al., 1995), apoptosis (Prehn et al., 1994; 
Zhu et al., 2001; 2002) and oxidative stress mediated neuronal death (Henrich-Noack et 
al., 1996).  Interestingly, while TGF-β1 has been shown to be neuroprotective in acute 
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excitotoxicity models, in chronic excitotoxicity models TGF-β1 enhances toxicity (Prehn 
and Kriedglstein, 1994; Prehn and Miller, 1996). 
 The cystine/glutamate antiporter (system xc-) is a sodium-independent amino acid 
transporter found on astrocytes, which takes up one molecule of cystine into the cell in 
exchange for one molecule of glutamate (Bannai and Kitamura, 1980; Bannai, 1986).  
The cystine that is imported is quickly reduced to cysteine and used to synthesize 
glutathione (GSH) (Bannai and Kitamura, 1980).  GSH is the main endogenous 
antioxidant in the brain and protects against oxidative stress; it can be released by 
astrocytes and used to protect neurons (Shih et al., 2003).  Cysteine can also be released 
by astrocytes and taken up by surrounding neurons to synthesize GSH (Lewerenz et al., 
2006; Wang and Cynader, 2000).  In exchange for taking up one molecule of cystine, 
system xc- releases one molecule of glutamate into the extrasynaptic space and is the 
major source of extracellular glutamate in several rodent brain regions (De Bundel et al., 
2011; Massie et al., 2011; Baker et al. 2002).  The glutamate released by system xc- can 
activate extrasynaptic receptors and regulate synaptic function (Baker et al., 2002; 
Williams and Featherstone, 2014).  However, high extracellular levels of glutamate 
released via system xc- can also lead to excitotoxicity (Fogal et al., 2007; Hardingham 
and Bading, 2010; Liu et al., 2014).  The dual function of system xc- makes it likely to 
play an important role in regulating neuronal survival and death. 
 Both TGF-β1 and system xc- are known to play a role in oxidative stress and 
excitotoxicity, key players in many neurodegenerative diseases.  TGF-β1 and system xc- 
are also upregulated in neurodegenerative diseases (Flanders et al., 1998; Vivien and Ali, 
2006; Massie et al., 2015).  It is our hypothesis that TGF-β1 upregulates system xc- on 
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astrocytes and some of the actions of TGF-β1 may be due its effects on system xc-.  In 
this present study we used primary astrocyte-enriched glial cortical cultures to study the 
effects of TGF-β1 on system xc- and then used primary mixed cortical cultures to 
investigate TGF-β1’s effect on neuronal survival/death in concert with an increase in 
oxidative stress, a hallmark of many neurodegenerative diseases. 
Materials and Methods 
 
 
Materials 
 
 Timed pregnant Swiss Webster mice were obtained from Charles River 
Laboratories (Wilmington, DE). Serum was from Atlanta Biologicals (Lawrenceville, 
GA).  TGF-β1 was from Prospec (East Brunswick, NJ) and 14C-cystine was from 
PerkinElmer (Waltham, MA). TRIzol was obtained from Life Technologies (Grand 
Island, NY).  The reverse transcription kit was from Promega (Madison, WI) and the 
PerfeCTa SYBR Green FastMix with ROX from Quanta Biosciences (Gaithersburg, 
MD).  Primers were obtained from Integrated DNA Technologies (Coralvilla, IA).  All 
other chemicals were obtained from Sigma (St. Louis, MO). 
Cortical cell cultures 
 
Mixed cortical cell cultures containing glial and neuronal cells were prepared 
from fetal (15-16 day gestation) mice as previously described (Lobner, 2000).  
Dissociated cortical cells were plated on 24-well plates coated with poly-D-lysine and 
laminin in Eagles’ Minimal Essential Medium (MEM, Earle’s salts, supplied glutamine-
free) supplemented with 5% heat-inactivated horse serum, 5% fetal bovine serum, 2mM 
glutamine and glucose (total 21 mM).  Neuron-enriched cultures were prepared exactly as 
above with the addition of 10µM cytosine arabinoside 48 hours after plating to inhibit 
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glial replication.  In these cultures <1% of cells are astrocytes (Dugan et al., 1995; Rush 
et al., 2010).  Astrocyte-enriched glial cultures were prepared as described for mixed 
cultures except they are from cortical tissue taken from post-natal day 1-3 mice (Choi et 
al., 1987; Schwarts and Wilson, 1992; Rush et al., 2010).  Pure astrocyte cultures were 
prepared from astrocyte-enriched glial cultures as described by Hamby et al. (2006).  
Microglia cultures were prepared by first growing astrocyte enriched glial cultures, then 
shaking the microglia free and plating them in media containing 10 ng/ml colony 
stimulating factor (CSF) (Barger and Basile, 2001).  Cultures were maintained in 
humidified 5% CO2 incubators at 37°C.  Mice were handled in accordance with a 
protocol approved by our institutional animal care committee and in compliance with the 
Public Health Service Policy on Humane Care and Use of Laboratory Animals.  All 
efforts were made to minimize animal suffering and reduce the number of animals used. 
14C-Cystine Uptake  
 
System xc- mediated uptake of radiolabeled cystine was assayed as previously 
described with modifications (Liu et al., 2009).  Astrocyte-enriched glial cultures were 
exposed to media lacking serum (MS) containing 100ng/mL TGF-β1 for the indicated 
time in humidified 5% CO2 incubators at 37°C.  In experiments where inhibitors were 
used, the inhibitors were added 1 hour prior to the addition of TGF-β1 and remained in 
the media for the duration of the incubation time.  After the indicated time, cultures were 
washed with HEPES buffered saline solution and immediately exposed to 14C-cystine 
(0.025µCi/mL) for 20 minutes.  In experiments where 14C-cystine uptake through system 
xc- was blocked, 300µM sulfasalazine (SSZ) was added just prior to radiolabeled cystine.  
Following 14C-cystine exposure, all cultures were washed with HEPES buffered saline 
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solution and dissolved in 250µL warm sodium dodecyl sulfate (0.5%).  A 200µL aliquot 
was removed and added to scintillation fluid for counting.  Values were normalized to 
14C-cystine uptake in untreated controls on the same experimental plate.  
Assay of neuronal death 
 
Mixed and astrocyte-enriched glial cultures were washed with MS containing 
100ng/mL TGF-β1 for 24 hours. 100nM rotenone was then added, either with or without 
the other inhibitors indicated for another 24 hours. Cell death was assessed in mixed and 
astrocyte-enriched glial cultures by the measurement of lactate dehydrogenase (LDH) 
released from damaged or destroyed cells, in the extracellular fluid 48 hours after the 
beginning of the insult.  Control LDH levels were subtracted from insult LDH values and 
results normalized to 100% neuronal death caused by 500 µM NMDA for mixed cultures 
or 100% astrocyte death caused by 20µM of the calcium ionophore A23187, added 24 
hours before the assay.  Control experiments have shown previously that the efflux of 
LDH occurring from either necrotic or apoptotic cells is proportional to the number of 
cells damaged or destroyed (Koh and Choi, 1987; Lobner, 2000). 
Monochlorobimane (MCB) assay of cellular reduced GSH 
 
 Cellular GSH levels were measured by MCB fluorescence.  MCB forms a 
fluorescent compound when it reacts with GSH through a reaction catalyzed by 
glutathione-S-transferase (Pauly et al., 2011).  Astrocyte-enriched glial cultures were 
exposed to MS containing 100ng/mL TGF-β1 for 24 hours.  MCB (final concentration of 
10µM) was added to each sample 30 minutes prior to the end time. A 200µL sample was 
taken from the media.  The cells were then washed three times with cold HBBSS and 
dissolved with 250µL DMSO.  A 200µL sample was placed into a 96-well plate.  
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Samples were read at 355/460 with a Fluoroskan Ascent Microplate Fluorometer 
(Thermo LabSystems). Results were normalized to control conditions.  
Reverse transcription quantitative real-time PCR (RT-qPCR) 
 
Transcriptional expression of xCT in astrocyte-enriched glial cultures after 
stimulation with TGF-β1 was examined using RT-qPCR. Briefly, after treating cells with 
TGF-β1 for various time points, cells were washed 3 times with cold PBS.  Total RNA 
was isolated with TRIzol extraction (Invitrogen; Carlsbad, CA) according to 
manufacturer’s protocol.  RNA quality was determined using spectrophotometry with a 
260/280 ratio of >1.8.  cDNA was synthesized using the Reverse Transcription System 
(Promega; Madison, WI) from 1 mg of total RNA following the manufacturer’s protocol. 
All products were amplified on a StepOne real-time PCR system (Applied Biosystems; 
Carlsbad, CA) using 100 ng of cDNA, PerfeCTa SYBR Green FastMix with ROX 
(Quanta Biosciences; Gaithersburg, MD), and the following primers designed using 
Primer3 software:  gapdh mouse forward-AAG GGC TCA TGA CCA CAG TC; gapdh 
mouse reverse-GGA TAC AGG GAT GAT GTT CT; xCT mouse forward- TCA CTT 
TTT GGA GCC CTG TC; xCT mouse reverse- ACC CAG ACT CGA ACA AAA GC. 
Relative quantification of xCT transcripts was analyzed via the 2-∆∆Ct method normalized 
to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
Statistical analysis 
 
 Differences between test groups were examined for statistical significance by 
means of t-test or one-way ANOVA followed by the Bonferroni correction post-hoc test, 
with p<0.05 being considered significant. 
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Results 
 
We first tested the effects of TGF-β1 on 14C-cystine uptake in purified cultures of 
astrocytes, microglia, and neurons.  A 24-hour treatment with TGF-β1 caused a 
significant increase in 14C-cystine uptake in pure astrocyte cultures, but not in microglia 
or pure neuronal cell cultures (Figure 4.1).  The following experiments, unless otherwise 
noted, were performed in astrocyte-enriched glial cultures.  We next tested if the TGF-β1 
induced increase in 14C-cystine uptake was mediated by system xc-; addition of the 
system xc- inhibitor, sulfasalazine (SSZ), blocked the TGF-β1 induced increase in 14C-
cystine uptake (Figure 4.2). 
 
 
 
 
 
 
 
Pure Astrocyte Culture  A Microglial Culture B 
Figure 4.1 Transforming growth factor β1 
(TGF-β1) causes an increase in 14C-cystine 
uptake in A) pure astrocyte cultures, but not 
in B) microglial cultures or C) neuronal 
enriched cultures.  Cultures were exposed 
to TGF-β1 (100ng/mL) for 24 hours. TGF-
β1 was washed out and 14C-cystine uptake 
was measured for 20 minutes.   Results are 
expressed as mean ± s.e.m (n=8-16) after 
normalizing to untreated control uptake.     
* indicates significant difference from 
control, t-test (p < 0.05). 	
Neuronal Enriched Culture C 
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Figure 4.2 TGF-β1 increases 14C-cystine uptake through system xc-. Astrocyte 
enriched cultures were exposed to TGF-β1 (100ng/mL) for 24 hours and after 
thorough washing, 14C-cystine uptake was measured for 20 minutes with or 
without the system xc- inhibitor sulfasalazine (SSZ, 300mM) present. Results are 
expressed as mean ± s.e.m (n=8-16) after normalizing to untreated control uptake. 
* indicates significant difference from control; # indicates significant difference 
from TGF-β1 alone, one-way ANOVA (p < 0.05). 
 
 
The increased system xc- mediated 14C-cystine uptake could be mediated by 
alteration of function of already present system xc- or increased system xc- protein.  To 
assess this, we first performed a time course of TGF-β1’s effects on 14C-cystine uptake.  
TGF-β1 caused no increase in 14C-cystine uptake with treatment up to 12 hours (Figure 
3A).  The long duration exposure for increased uptake suggests new protein synthesis is 
required.  To test this we added the protein synthesis inhibitor cycloheximide (CHX), 
which completely blocked the TGF-β1 induced increase, during a 24-hour treatment 
(Figure 3B).  Since there are questions regarding antibody reliability (Massie et al., 2015) 
we did not perform western blotting for the functional subunit of system xc-, xCT.  
However, we performed qPCR and found that 24-hour application of TGF-β1 increased 
xCT mRNA levels (Figure 3C). 
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B 
C 
A 
Figure 4.3 TGF-β1 induces a time 
and protein synthesis dependent 
increase in 14C-cystine uptake and 
increases xCT mRNA expression. A) 
TGF-β1 (100ng/mL) was applied for 
various times to astrocyte-enriched 
cultures. Cultures were then washed 
and a 20 min 14C-cystine uptake assay 
was performed. B) Cultures were 
exposed to TGF-β1 with or without 
the protein synthesis inhibitor 
cycloheximide (CHX, 200ng/mL) for 
24 hours and after thorough washing, 
14C-cystine uptake was measured for 
20 minutes. Results are expressed as 
mean±SEM (n=8-16) after 
normalizing to untreated control 
uptake. C) Astrocyte-enriched 
cultures were exposed to TGF-β1 for 
the duration indicated.  RNA was 
extracted using TRIzol and RT-PCR 
was used to determine mRNA 
expression.  Results were normalized 
to controls (set to 1) and presented as 
mean ± s.e.m (n=4-5). * indicates 
significant difference from control; # 
indicates significant difference from 
TGF-β1 alone, one-way ANOVA (p 
< 0.05). 	
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TGF-β1 acts by binding to TGF-β receptor II (TGF-βRII), which then recruits and 
phosphorylates a second receptor, TGF-βRI.  There are two TGF-βRI isoforms that TGF-
β1 signals through: activin receptor-like kinase 5 (ALK5) and ALK1 (Massagué, 1998).   
We tested the ALK 5 inhibitor LY364947 and the ALK1 inhibitor K02288.  Each of the 
inhibitors caused a partial decrease in the TGF-β1 enhancement of 14C-cystine uptake, 
with application of both inhibitors causing a near complete inhibition (Figure 4.4A).   
TGF-β1 activates multiple intracellular pathways (Massagué, 2000).  We tested the role 
of the MEK/ERK pathway in the upregulation of system xc-.  We found that the 
MEK/ERK pathway inhibitor U0126 largely blocked the effect of TGF-β1 (Figure 4.4B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 TGF-β1 induced increase in 14C-cystine uptake is mediated by 
activation of both ALK5 and ALK1 and the MAPK/ERK pathway. A) Astrocyte-
enriched cultures were treated with the ALK5 inhibitor LY364947 (LY, 10µM) 
and/or the ALK1 inhibitor K02288 (K, 10µM) for 1 hour prior to and during 
TGF-β1 (100ng/mL) exposure for 24 hours. After a thorough washing, 14C-
cystine uptake was measured for 20 minutes. B) Cultures were exposed to the 
MAPK/ERK pathway inhibitor U0126 (10µM) 1 hour prior and during exposure 
to TGF-β1 for 24 hours and after thorough washing, 14C-cystine uptake was 
measured for 20 minutes.  Results are expressed as mean ± s.e.m (n=8-16) after 
normalizing to untreated control uptake. * indicates significant difference from 
control; # indicates significant difference from TGF-β1 alone, one-way ANOVA 
(p < 0.05). 
A B 
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The increase in cystine uptake would be expected to cause an increase in 
intracellular GSH.  However, in astrocyte-enriched cultures 24-hour treatment with TGF-
β1 actually caused a decrease in cellular GSH (Figure 4.5A).  There was also a small 
decrease in pure neuronal cultures, but no effect in mixed cultures (Figure 4.5A).  Testing 
the levels of GSH in the media, we found an increase in the media from astrocyte 
cultures, and small decrease in pure neuronal and mixed cultures (Figure 4.5B).  The 
results suggest that TGF-β1 may be stimulating the astrocytes to release glutathione, 
which in turn supplies substrate for glutathione production in neurons.  To test this 
neurons were grown on culture inserts in the presence of astrocytes; after TGF-β1 
treatment cultures were separated in order to test GSH levels in each cell type 
individually. TGF-β1 treatment caused a decrease in cellular GSH in the astrocytes, but 
no change in neurons (Figure 4.6). 
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Figure 4.5 TGF-β1 decreases intracellular GSH levels in astrocyte-enriched (glia) 
and neuronal-enriched (PNC) cultures, but not in mixed cultures; TGF-β1 
increases extracellular GSH levels in astrocyte-enriched cultures. TGF-β1 
(100ng/mL) was applied to the indicated culture system for 24 hours.  30 minutes 
prior to the end time 1mM MCB was applied.  Both the A) intracellular and B) 
extracellular GSH levels were measured.  Results are expressed as mean ± s.e.m 
(n=8-16) after normalizing to untreated control. * indicates significant difference 
from control, t-test (p < 0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 In an insert system, TGF-β1 decreases intracellular GSH levels in 
astrocyte-enriched (glia) cultures, but not in neuronal-enriched (PNC) cultures. 
TGF-β1 (100ng/mL) was applied for 24 hours to astrocytes and neurons that had 
been cultured together using an insert system. 30 minutes prior to the end time 
1mM MCB was applied.  The astrocytes and neurons were then separated so 
intracellular GSH levels could be measured in each cell type separately. Results 
are expressed as mean ± s.e.m (n=8-16) after normalizing to untreated control.     
* indicates significant difference from control, t-test (p < 0.05). 
A Intracellular B 
Extracellular 
Insert System 
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Upregulation of system xc- can have complicated effects on cell death due to its 
dual role of providing cystine for GSH production, but also releasing glutamate, which 
can cause excitotoxicity.  We found that treatment of mixed cultures with TGF-β1 for up 
to 48 hours did not cause any cell death (Figure 4.7).  However, when cultures were 
treated with TGF-β1 for 24 hours prior to and during 24-hour exposure to the 
mitochondrial inhibitor rotenone (100nM) the TGF-β1 treatment enhanced the toxicity of 
rotenone (Figure 4.7).  The neuronal death induced by exposure to TGF-β1 and rotenone 
was attenuated by treatment with the AMPA/kainate receptor antagonist, NBQX, (Figure 
4.8A) but not by the NMDA antagonist,  memantine (MEM), (Fig 4.8B) or the calcium 
permeable AMPA receptor antagonist NASPM (Figure 4.8C).  The toxicity was purely 
neuronal, as the same treatment did not cause LDH release in astrocyte cultures (Figure 
4.9). However, TGF-β1 did enhance rotenone-induced astrocyte toxicity when higher 
levels of rotenone were applied (Figure 4.9). 
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Figure 4.7 TGF-β1 enhances rotenone-induced toxicity in neurons. TGF-β1 
(100ng/mL) was applied for 48 hours to mixed cortical cultures. 24 hours after 
TGF-β1 application, 100nM rotenone was applied.  Bars show % death (mean ± 
s.e.m, n=8-16) quantified by measuring LDH release, 48 hours after the beginning 
of the treatment with TGF-β1. * indicates significant difference from control; # 
indicates significant difference from 100nM rotenone alone, one-way ANOVA (p 
< 0.05). 
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A 
B 
C 
Figure 4.8 AMPA receptor 
antagonist, NBQX, blocks 
TGF-β1 enhanced rotenone-
toxicity; NMDA receptor 
antagonist, MEM, and Ca2+-
permeable AMPA receptor 
antagonist, NASPM, do not. 
TGF-β1 (100ng/mL) was 
applied for 48 hours to mixed 
cortical cultures. 24 hours 
after TGF-β1 application, 
rotenone (100nM) and A) 
NBQX (7.5µM), B) MEM 
(10µM), or C) NASPM 
(10µM) were applied.  Bars 
show % neuronal death (mean 
± s.e.m, n=8-16) quantified by 
measuring LDH release, 48 
hours after the beginning of 
the treatment with TGF-β1. * 
indicates significant 
difference from control; # 
indicates significant 
difference from 100nM 
rotenone alone, one-way 
ANOVA (p < 0.05). 	
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Figure 4.9 TGF-β1 enhances rotenone-induced toxicity in astrocytes. TGF-β1 
(100ng/mL) was applied for 48 hours to astrocyte-enriched cultures. 24 hours 
after TGF-β1 application, the indicated amount of rotenone was applied.  Bars 
show % death (mean ± s.e.m, n=8-16) quantified by measuring LDH release, 48 
hours after the beginning of the treatment with TGF-β1. * indicates significant 
difference from control; # indicates significant difference from TGF-β1 alone, 
one-way ANOVA (p < 0.05). 
 
 
Discussion 
 
 
TGF-β1 is known to have many diverse effects on the central nervous system 
(Flanders et al., 1998) and this current study adds a novel effect of TGF-β1 to the 
literature.  Our results show that 24-hour application of TGF-β1 increased cystine uptake 
through system xc- on astrocytes. The timecourse of system xc- upregulation by TGF-β1 
suggests that new protein is being made; in support of this hypothesis, the protein 
synthesis inhibitor, cycloheximide, blocked the TGF-β1 mediated increase in system xc- 
function.  Also, TGF-β1 increased xCT mRNA levels in a time dependent manner.  
Together these data suggest that cystine uptake is increased through system xc- due to 
increased system xc- expression. 
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 TGF-β1 can signal through multiple pathways and involves two receptors, TGF-
βRI and TGF-βRII.  Both receptors I and II are serine/threonine kinases and TGF-βRI has 
multiple isoforms.  TGF-β1 signaling begins when TGF-β1 binds to TGF-βRII, which 
recruits and phosphorylates TGF-βRI.  TGF-βRI then initiates the intracellular signaling 
cascade (Massagué, 1998).  Interestingly, in this study the TGF-β1 induced increase in 
system xc- activity requires both TGF-βRI isoforms, ALK1 and ALK5.  Inhibiting one 
receptor only partially blocked the increase in cystine uptake, while blocking both 
receptors completely blocked the increase.  Activation of both ALK1 and ALK 5 
signaling has been observed previously, and certain biological responses have been 
shown to be dependent upon recruitment of both isoforms (Goumans et al., 2003; König 
et al., 2005). 
  Following TGF-βRI activation, TGF-βRI phosphorylates and activates signaling 
mother against decapentaplegic (SMAD) proteins.  SMAD proteins are transcription 
factors and are the main signal transducers of TGF-β receptor activation (Massagué, 
2000).  More recently, however, other signaling pathways of TGF-βRI/II activation are 
beginning to emerge (Massagué, 2000; Vivien and Ali, 2006).  Along with being 
serine/threonine kinases, recently it was discovered that TGF-βRI/II can also 
phosphorylate tyrosine, which plays a role in activating the MAPK/ERK signaling 
pathway (Lee et al., 2007; Zhang, 2009).  In this study when added one hour prior to 
TGF-β1, U0126 blocked the increase in system xc- activity, showing that the 
MAPK/ERK signaling pathway was necessary for the increase system xc- activity.  We 
did not test inhibitors of other known TGF-β1 signaling pathways and therefore cannot 
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rule out the involvement of these other pathways in TGF-β1’s affects on system xc- 
activity.  
Given the function of system xc-, one would hypothesize that increased system xc- 
activity would also lead to increased intracellular GSH levels.  However, our data 
indicate the situation is complicated.  Increased system xc- activity on astrocytes actually 
led to decreased GSH levels in astrocytes.  This appears to be due to TGF-β1 treatment 
not only increasing cystine uptake into astrocytes, but also stimulating astrocytes to 
release more GSH.  When TGF-β1 was applied to pure neuronal cultures there was a 
decrease in both intracellular and extracellular GSH production.  However, when 
astrocytes and neuronal cells were cultured together using an insert system and GSH was 
measured in each cell population separately, TGF-β1 application still led to a decrease in 
GSH levels in astrocytes, but GSH levels in the neurons were slightly higher than control 
levels.  This finding suggests that TGF-β1 leads to the export of GSH from astrocytes so 
that it can be utilized by neurons.  This is consistent with the well described function of 
astrocytes as a source of substrate for neuronal GSH production (Dringen and Hirrlinger, 
2003). 
This release of GSH is likely a benefit to neurons.  Decreased cellular glutathione 
has been shown to occur in schizophrenia (Yao et al., 2006), depression (Godlewska et 
al., 2015), and neurodegenerative diseases (Schulz et al., 2000).  In these cases it would 
be expected that upregulation of system xc- would be beneficial.  For example, the 
protective effects of TGF-β1 against oxidative stress mediated insults, such as amyloid-β 
toxicity (Ren and Flanders, 1996; Shen et al., 2014) could be mediated by the increased 
production of GSH.  However, with increased system xc- activity the potential for 
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increased excitotoxicity also exists.  In our mixed cortical cultures excitotoxicity masked 
any of TGF-β1’s potentially protective effects against an oxidative insult.  48-hour 
application of TGF-β1 alone was not toxic to neurons.  However, when cultures were 
treated with TGF-β1 for 24 hours and then rotenone was co-applied for 24 hours, which 
interferes with mitochondria and increases reactive oxygen species (ROS), TGF-β1 
exacerbated the rotenone-induced toxicity.  We were able to block this toxicity with the 
general AMPA receptor antagonist NBQX, but not the calcium-permeable AMPA 
receptor antagonist NASPM or the NMDA receptor antagonist memantine.   
These results indicate a specific enhancement of AMPA receptor mediated 
excitotoxicity.  This finding is consistent with previous studies.  TGF-β1 has been shown 
to be protective against NMDA receptor mediated excitotoxicity, while it has been shown 
to enhance the toxicity of AMPA/kainate receptor mediated excitotoxicity (Prehn and 
Miller, 1996).  TGF-β1 protection against NMDA receptor mediated toxicity involves 
upregulation type 1 plasminogen activator inhibitor (PAI-1) (Buisson et al., 1998; 
Docagne et al., 1999).  The protection by PAI-1 is due to its inhibition of tPA, which 
increases NMDA toxicity by cleaving the NR1 subunit leading to increased NMDA 
induced calcium influx (Nicole et al., 2001).   The injury promoting effect could be due 
to TGF-β1 upregulating AMPA receptor subunits.  Interestingly, upregulation of GluA2, 
but not the GluA4 subunits has been observed (Bae et al., 2011).  Since lack of a GluA2 
subunit allows calcium permeability (Hollmann et al., 1991), the upregulation of the 
GluA2 subunit is consistent with the results that the toxicity of TGF-β1 treatment in 
combination with rotenone is mediated by general AMPA receptors and not calcium 
permeable AMPA receptors.  Another possibility is that TGF- β1 effects glutamates 
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affinity for AMPA receptors.  Altering subunit composition or phosphorylation of the 
AMPA receptor could change affinity for the receptor and changes in affinity could play 
a role in the AMPA receptor mediated death. 
The potentiation of toxicity could also be caused by changes in excitatory amino 
acid transporter (EAAT) function.  EAATs are the mechanism by which glutamate is 
removed from the extracellular space and decreased EAAT function can lead to 
excitotoxicity (O’Shea, 2002).  However, there were no changes in EAAT function, as 
measured by radiolabeled D-aspartate uptake (data not shown).  This finding is consistent 
with other studies that show TGF-β1 does not effect EAAT function (Piani et al., 1993; 
Brown, 1999). 
In the current study TGF-β1 effects on astrocytes not only led to enhanced rotenone 
toxicity in neurons, but it also enhanced rotenone toxicity in astrocytes.  The current 
study provides interesting differences and similarities to that of He et al. (2015).  In that 
paper the authors found that treating cultured cortical astrocytes with IL-1β caused an 
upregulation of system xc-.  They also observed increased release of GSH, but in contrast 
to the current study they found an increase in intracellular GSH.  What is unusual in the 
current study is that TGF-β1 stimulates the release of GSH in astrocytes to such an extent 
that GSH levels in astrocytes actually decrease below control levels and can lead to 
enhanced rotenone toxicity.  This suggests a function of astrocytes in which their purpose 
of providing GSH to neurons takes precedence over maintaining their own GSH levels. 
The most important implication of the current study is the possibility that some of 
the known actions of TGF-β1 are mediated by its regulation of system xc-.  In a similar 
study, treatment with TGF-β1 was shown to induce death of immature cerebellar neurons 
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co-cultured with cerebral astrocytes (Brown, 1999).  The mechanism of the toxicity 
appeared to be increased release of glutamate from the astrocytes as there was increased 
glutamate in the media.  Astrocyte conditioned media also was toxic to the neurons and 
that toxicity was blocked by an NMDA receptor antagonist.  In retrospect, the increased 
glutamate release was likely due to upregulation of system xc-.  We do not observe 
toxicity in our mixed cortical cultures with TGF-β1 treatment without the added insult of 
rotenone, possibly due to a high rate of glutamate uptake in our culture system. 
TGF-β1 is increased in both the SOD1-G93A mouse model of ALS and in human 
ALS patients, and TGF-β1 levels are positively correlated with the duration of the disease 
(Houi et al., 2002; Iłzecka et al., 2002; Endo et al., 2015).  More specifically, 
overproduction of TGF-β1 in astrocytes has been found to accelerate disease progression 
in a non-cell autonomous way and inhibiting TGF-β1 signaling can extend survival time 
of SOD1-G93A mice (Endo et al., 2015).  Interestingly, system xc- is increased in 
multiple ALS mouse models, including the SOD1-G93A model (Albano et al., 2013; 
Mesci et al., 2015).  Similar to inhibiting TGF-β1, deleting xCT in the SOD1 mutant 
mouse slows disease progression (Mesci et al., 2015).  It is possible that increased TGF-
β1 production is responsible for increased system xc- activity in ALS and both may be 
potential therapeutic targets. 
System xc- is known to be upregulated in gliomas with the consequence of 
making the gliomas resistant to oxidative stress (Singer et al., 2015) and the added 
problem of increased release of glutamate causing neuronal death surrounding the glioma 
leading to increased growth (Ye and Sontheimer, 1999).  Because of these actions 
inhibitors of system xc- are being proposed as treatment for gliomas (Chung et al., 2005; 
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Lo et al., 2008).  TGF-β1 is also known to play an important role in promoting glioma 
growth and antagonists of TGF-β1 signaling are being tested in clinical trials for the 
treatment of gliomas (Joseph et al., 2013; Kaminska et al., 2013).  Given our results it is 
interesting to speculate that some part of TGF-β1’s stimulation of glioma growth may be 
due to its upregulation of system xc-.  This undoubtedly would not be the only 
mechanism of TGF-β1 action as it has also been shown to promote tumor development 
by contributing to angiogenesis (Ueki et al., 1992). 
Another possibility is that in certain disease states there is compromised TGF-β1 
signaling leading to decreased system xc- function, decreased cellular GSH and therefore 
disrupted function.  This may be the case in Huntington’s disease.  TGF-β1 is decreased 
in post-mortem brain tissue from Huntington’s disease patients, in the R6/2 HD mutant 
mouse model of Huntington’s disease, and in cultured astrocytes expressing the mutated 
form of the huntington gene (Battaglia et al., 2011).  Interestingly, xCT levels are also 
decreased in the R6/2 HD mouse and cells with the huntington gene mutation have 
increased oxidative stress in response to system xc- inhibition (Frederick et al., 2014).  
These results raise the possibility that the oxidative stress observed during Huntington’s 
disease (Li et al., 2010) may be mediated by decreased system xc- activity as a result of 
decreased levels of TGF-β1. 
In astrocyte cultures TGF-β1 increases system xc- activity through the 
MAPK/ERK pathway.  It also decreases GSH levels in astrocytes by increasing GSH 
export, even to the detriment of the astrocytes. The exported GSH may be utilized by 
neurons; however, TGF-β1 enhances rotenone-induced excitotoxicity in neurons, through 
AMPA receptors.  Dysregulation of TGF-β1 and system xc- occur in many of the same 
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diseased states and it is possible that some of the known actions of TGF-β1 may be 
mediated by its regulation of system xc-. 
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CHAPTER V 
 
 
DISCUSSION 
 
 
General Discussion 
 
 The dual actions of system xc- make it of great interest in many neurodegenerative 
diseases where oxidative stress and excitotoxicity are involved.  The studies described in 
this thesis were the first to observe that system xc- is dysregulated in an ALS model and 
that intracellular cysteine levels may play an important role in regulating system xc- 
function.  We also show that TGF-β1 upregulates system xc-, but that this many have 
negative consequences on cell death under conditions of high oxidative stress.  The 
following section discusses some of the major findings of this thesis and the broader 
implications of how regulating system xc- affects neuronal death.  It also discusses the 
limitations of the work done, as well as future studies that are needed in order to further 
our understanding of system xc-. 
THE REGULATION OF SYSTEM XC- 
 
The Age Factor 
 
 While studying system xc- function in SOD1-G93A mutant mice, we observed 
that its activity decreased with age in non-transgenic littermates (Chapter IV).  The role 
system xc- plays in development and aging is largely unknown.  Glutathione (GSH) 
levels are high in neuronal and non-neuronal cells in the immature brain, as well as in 
developing neurons of the mature brain  (Lowndes et al., 1994; Shih et al., 2006; Sun et 
al., 2006).  GSH is important for proliferation, differentiation, and viability of neurons 
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during development since these are times where metabolic and oxidative demand is high 
(Dalton et al., 2004).  System xc-’s import of cystine is directly tied to GSH synthesis 
(Sagara et al., 1993a); therefore system xc- may play an important role in supplying 
developing neurons with the high levels of GSH they need.  In support of this idea, 
studies show that neuronal death induced by glutamate in immature neurons is a 
consequence of increased oxidative damage caused by a depletion of GSH resulting from 
system xc- inhibition  (Murphy et al., 1990; Shih et al., 2003; Shih et al., 2006). 
Astrocytes, fibroblasts, and meningeal cells cultured from both xCT knockout (xCT-/-) 
mice and mice with the subtle gray pigmentation mutant phenotype (sut/sut), a xCT loss 
of function mutation, are unable to proliferate in vitro and need the reducing agent β-
mercaptoethanol in order to grow (Sato et al. 2005; Shih et al. 2006). Similarly, our 
mixed cortical cultures do not survive if we apply sulfasalazine (SSZ), a system xc- 
inhibitor (Gout et al., 2001), on days in vitro 1-3 (data not shown). 
While these data support the hypothesis that system xc- activity is important 
during development, western blot analysis suggests that expression of xCT, the functional 
subunit of system xc-, is much lower in the developing brain compared to the adult brain  
(Shih et al., 2006; La Bella et al., 2007).  Also, differing effects of xCT knockout and 
xCT mutation on brain morphology have been reported; Shih et al. (2006) report that 
sut/sut mice show brain atrophy.  However, normal brain appearance has been reported in 
xCT-/- and sut/sut mice, suggesting that xCT is not critical for development in vivo  (Sato 
et al., 2005; Massie et al., 2015).  In the adult brain, a study by Liu et al. (2007) used 
sut/sut mice to assess cellular proliferation in the subventricular zone and dentate gyrus, 
two regions where neuronal development continues into adulthood.  The sut/sut mice 
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showed a small, non-significant, decrease in cell proliferation of the subventricular zone, 
but increased cell proliferation in the dentate gyrus. They concluded that xCT is not 
essential to cell proliferation in the adult brain.  Overall, it appears that system xc- is 
critical for the proliferation and survival of cells in vitro, but lack of system xc- may be 
able to be compensated for in vivo. 
System xc- might also play a role in aging.  The “free radical theory of aging” is 
one of the leading theories on the mechanism behind aging.  The basic idea is that aging 
occurs as a result of irreversible damage caused by an increase in reactive oxygen species 
(ROS) (Kregel and Zhang, 2007).  ROS increase with age in many organ systems, 
including the brain  (Driver et al., 2000; Kregel and Zhang, 2007).  Along with an 
increase in ROS, GSH levels decrease in many different cell types, including 
hippocampal neurons, during aging  (Lieshout and Peters, 1998; Erden-Inal et al., 2002; 
Parihar et al., 2008). In fact, overall GSH levels in the adult brain are significantly lower 
compared to the immature brain  (Lowndes et al., 1994; Shih et al., 2006).  System xc- 
plays a key role in GSH synthesis, therefore it is possible that it plays a role in the aging 
process.  One hypothesis would be that the decrease in GSH levels seen during aging is 
due to a decrease in system xc- activity.  In support of this hypothesis we observed a 
significant decrease in system xc- activity in the spinal cord slices of SOD1-G93A non-
transgenic littermates between the ages of 55 days and 70 days; this lower level of 
activity was maintained through 130 days (Albano et al., 2013).  Work in system xc- 
knockout mice may also support this hypothesis.  8-10 week old xCT-/- mice have a shift 
in their cystine/cysteine redox balance  (Sato et al., 2005).  They have higher levels of 
cystine in their plasma, but no change in cysteine plasma levels.  This shift in redox 
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balance is similar to what is seen in elderly patients  (Jones et al., 2002), which lead Sato 
et al. (2005) to speculate that aging may be accelerated in xCT-/- mice. 
While the role of system xc- during development and aging is still unknown, its 
role in maintaining balance between ROS and GSH is well known and makes it likely to 
be important in both of these life stages.  A more detailed study of different age ranges 
(embryonic, young pup, adolescent, middle-aged adult, aged) needs to be performed in 
order to have a better understanding of how system xc- changes with age. 
Cystine/Cysteine Redox Balance 
 
In chapter three of this thesis we provide evidence that suggests cysteine is a more 
important regulator of system xc- function than GSH levels.  System xc-’s functions of 
providing the cell with cystine for GSH synthesis and regulating extracellular glutamate, 
often masks its function of regulating the extracellular cystine/cysteine redox state that 
surrounds the cellular membrane.  Cystine taken up by system xc- is reduced to cysteine.  
Cysteine can then be used to synthesize GSH, which can leave the cell and contribute to 
the reduced extracellular environment (Wang and Cynader, 2000; Dringen and Hirrlinger, 
2003).  However, some of the cysteine is also directly exported from the cell via system 
ASC, which plays an important role in maintaining the extracellular redox environment 
independent of the GSH (Bannai and Ishii, 1982; Jones et al., 2002; Anderson et al., 
2007).  Given how important cysteine is to regulating the redox environment of the cell 
and how system xc- helps to maintain the cystine/cysteine balance, it is easy to see why 
cysteine would be an important regulator of system xc- function. 
A study by Banjac et al. (2008) lends support to our conclusions.  They found that 
expressing xCT in lymphoma cells, which normally take up little cystine, was able to 
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protect these cells from oxidative stress.  Interestingly however, expressing xCT did not 
increase GSH levels, rather it increased both intracellular and extracellular cysteine 
levels.  They concluded that the protection by xCT was not due to GSH as predicted; 
rather it was due to increased cysteine levels.  Similarly, glutamate-cysteine ligase (GCL) 
knockout cells, which are unable to synthesize GSH and therefore die within 48 hours, 
are able to proliferate if xCT is overexpressed due to high intracellular and extracellular 
cysteine levels (Mandal et al. 2010).   
The mechanism by which cysteine is downregulating system xc- still remains to 
be determined.  One possibility is that it is inhibiting the transcription factor nuclear 
factor erythroid-derived 2 (Nrf-2).  Nrf-2 is the main regulator of system xc- and 
increases transcription of xCT in response to oxidative stress (Ishii et al., 2000; Sasaki et 
al., 2002; Lewerenz et al., 2009).  Another possibility is that cysteine inhibits the 
phosphorylation of xCT by protein kinase A (PKA).  Inhibiting PKA has been shown to 
decrease system xc- activity in ex vivo striatal punches (Baker et al. 2002).  Future studies 
need to be performed in order to determine the mechanism behind cysteine regulation of 
system xc-. 
Neuronal Regulation 
 
 In our culture system we observed that astrocytes co-cultured with neurons that 
are killed (mixed cultures treated with 500µM NMDA) have a higher level of 14C-cystine 
uptake than astrocytes cultured without neurons (astrocyte-enriched glial cultures).  This 
observation suggests that when cultured together, neurons release a signal that contributes 
to the regulation of system xc- on astrocytes.  To determine if this hypothesis was correct 
we compared the function of system xc- in astrocyte-enriched glial cultures that were 
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treated with media from pure neuronal cultures (PNC) to those treated with media from 
other astrocyte-enriched glial cultures.  Astrocytes treated with PNC conditioned media 
for at least 24 hours had significantly higher 14C-cystine uptake than those treated with 
glial media (Figure 5.1A).  The system xc- inhibitors SSZ and (S)-4-
carboxyphenylglycine (CPG) blocked the increase in 14C-cystine uptake showing that it 
was through system xc- (Figure 5.1B).  To determine what the signal from neurons was 
that led to the increase in system xc- function, we tested receptor antagonists against 
factors that we know upregulate system xc- on astrocytes in our culture system; 
specifically, we tested antagonists against TGF-β1, FGF-2, and PACAP.  However, we 
were unable to block the increase in 14C-cystine uptake with any of the antagonists tested 
(data not shown).  While we were unable to determine the exact neuronal signal, we were 
able to determine that the neuronal signal mediates the increase in system xc- function 
through the MEK/ERK pathway (Figure 5.1C). 
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Figure 5.1 A) Astrocyte-enriched 
glial cultures treated with PNC 
media for 24 or 48 hours had 
significantly higher levels of 14C-
cystine uptake than those treated 
with glial media.  B) The system 
xc- inhibitors SSZ and CPG 
blocked the PNC media mediated 
increase in 14C-cystine uptake.  C) 
The increase in 14C-cystine uptake 
mediated by PNC media is 
blocked with the MEK/ERK 
pathway antagonist, PD98059.  
Results are expressed as 
mean±s.e.m. (n=8-16) after 
normalizing to untreated glial 
media uptake. * indicates 
significantly different from glial 
media; # indicates significant 
difference from PNC media, one-
way ANOVA (p < 0.05). 	
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 Recently, a study by Kong et al. (2016) found that inhibiting the PACAP receptor 
with PACAP6-38 blocked neuron-induced upregulation of system xc-.  Although this 
finding is in contrast to our observations there are some marked differences between the 
two studies.  First, they are using cortical cultures from rats, while we use mice.  Second, 
the culturing methods between the two studies are quite different.  Finally, while we also 
used the PACAP6-38 antagonist to try to block the neuronal signal, the Kong et al. 
(2016) study used a concentration of PACAP6-38 that can block multiple receptors; we 
applied a much lower concentration.  
Even though we were unable to determine the exact signaling molecule by which 
neurons regulate system xc- function on astrocytes, the observation that there is neuronal 
regulation is important.  As previously discussed, the neuron-astrocyte interaction plays a 
large role in synaptic transmission (Araque et al.,1999; Newman, 2003; Bridges et al., 
2012a).  For example, the glutamate released from system xc- into the extrasynaptic space 
is able to regulate the amount of glutamate released in the synapse, through mGluR2/3 
activation  (Baker et al., 2002).  Glutamate released by system xc- can also regulate 
synaptic strength by reducing the number of postsynaptic AMPA receptors (Williams and 
Featherstone, 2014). The ability for neurons to modulate the amount of glutamate 
released extrasynaptically through system xc- may be a way in which they are able to 
control synaptic strength and transmission. 
Not only are neuron-astrocyte interactions important for regulating synaptic 
transmission, but astrocytes also provide antioxidant support to neurons by 
supplying them with GSH precursors (Sagara et al., 1993a; Dringen et al., 1999; 
Wang and Cynader, 2000; Shih et al., 2003). The antioxidant support provided by 
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astrocytes begins with the transport of cystine into astrocytes through system xc- 
(Kranich et al., 1998).  Therefore, it is essential that neurons are able to signal 
astrocytes to increase system xc- function when they are in need of increased 
antioxidant support.  Determining the specific signal released by neurons is of 
importance because not only will it provide insight into specific situations when 
neuronal regulation of system xc- is necessary, but it may also provide a therapeutic 
target by which system xc- function can be up- or downregulated.  
TGF-β1 
 
TGF-β1 signaling is dysregulated in response to injury and several 
neurodegenerative diseases (Pratt and McPherson, 1997; Flanders et al., 1998; Vivien and 
Ali, 2006).  While it is mainly thought to be neuroprotective, some evidence suggests that 
it might potentiate neuronal injury (Prehn and Miller, 1996; Endo et al., 2015).  In 
chapter four of this thesis, we presented data showing that TGF-β1 increases system xc- 
function on astrocytes.  This effect requires the activation of two TGF-βR1 isoforms, 
ALK5 and ALK1, which in turn activate the MAPK/ERK pathway.  This novel action of 
TGF-β1 may provide further insight into its role in neuronal protection/death. 
TGF-β1, GSH, and Astrocyte Toxicity 
 
The import of cystine through system xc- activity is directly tied to GSH synthesis 
(Sagara et al., 1993a).  GSH is able to protect astrocytes from various insults (Kim et al., 
2003; Liddell et al., 2006).  However, when we compare the effects of TGF-β1 to the 
cytokine interleukin-1β (IL-1β) there are some marked differences in the way that GSH is 
regulated and its ability to protect astrocytes.  While both TGF-β1 and IL-1β increase 
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system xc- function on astrocytes  (Fogal et al., 2007; Jackman et al., 2010; Chapter IV), 
24-hour application of TGF-β1 decreases intracellular GSH levels in astrocytes, while IL-
1β increases intracellular GSH levels (He et al., 2015).  He et al. also shows that the IL-
1β-induced increase in GSH production protects astrocytes from ROS-inducing FeSO4 
and tert-butyl hydroperoxide (tBOOH) exposure.  Not only is TGF-β1 unable to protect 
astrocytes from rotenone-induced toxicity, it actually exacerbates its toxicity. 
Cytokines are known to have many diverse effects.  One possibility for the 
marked differences in TGF-β1 and IL-1β’s effects on astrocyte protection could be due to 
differential effects on GSH export.  While both TGF-β1 and IL-1β increase GSH export 
into the extracellular space (He et al., 2015; Chapter IV) they could regulate the GSH 
exporter, multidrug resistant protein 1 (MRP-1), differently.  IL-1β application does not 
change the expression (Ronaldson et al., 2010) or function (He et al., 2015) of MRP-1 in 
astrocytes.  The effects of TGF-β1 on MRP-1 expression are unknown, however, the 
MRP-1 inhibitor MK-571 brings intracellular GSH levels back up to control levels 
(Figure 5.2), suggesting TGF-β1 does not affect MRP-1 function.  Although MK-571 was 
not able to increase GSH levels when co-applied with TGF-β1 to the same level as MK-
571 under control conditions, we used a fairly low concentration of MK-571 (10µM). 
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Figure 5.2 The multidrug resistant protein 1 (MRP-1) inhibitor, MK-571 (10µM), 
blocked the decrease in intracellular GSH levels caused by TGF-β1.  Results are 
expressed as mean±s.e.m. (n=8-16) after normalizing to control. * indicates 
significant difference from control, # indicates significant difference from TGF-
β1, one-way ANOVA (p < 0.05). 
 
 
Oxidative stress could be another reason for the differential effects of TGF-β1 and 
IL-1β on astrocyte protection.  He et al. (2015) has shown that the GSH:GSSG ratio 
increases with time in the presence of IL-1β.  They use this ratio to show that IL-1β is not 
causing an increase in oxidative stress in their astrocytes.  An increase in oxidative stress 
caused by TGF-β1 application could lead to the decrease in intracellular GSH levels and 
account for the increase in rotenone-induced toxicity.  TGF-β1’s effects on oxidative 
stress are explored in the next section. 
TGF-β1 and Oxidative Stress 
 
 Studies show that TGF-β1 protects hippocampal neurons against oxidative insult 
(Prehn et al., 1994; Henrich-Noack et al., 1996).  However, TGF-β1 was found to 
increase mitochondrial ROS production in several cell types, leading to increased 
oxidative stress  (Liu and Desai, 2015).  It is also well established that oxidative stress 
	126	
can increase system xc- activity  (Kim et al., 2001; Dun et al., 2006; Mysona et al., 2009).  
In order to determine if the increase in system xc- activity induced by TGF-β1 was 
mediated by oxidative stress in astrocyte-enriched glial cultures we applied TGF-β1 
(100ng/mL) and measured ROS levels using the DCF assay.  Initially we saw an early 
increase (at hours 1 and 3) in ROS production after TGF-β1 application (data not shown).  
We were able to block the increase in ROS levels at 1 hour with the MAPK/ERK 
antagonist, U0126 (data not shown).  
These data suggest that TGF-β1 activates the MAPK/ERK pathway, which then 
leads to an increase in ROS production.  Since the increase in ROS production was seen 
after a 1-hour application of TGF-β1 but back down to control levels by 24 hours and the 
increase in 14C-cystine uptake through system xc- occurred 24 hours after application of 
TGF-β1, we hypothesized that the increase in oxidative stress was mediating the increase 
in system xc-.  However, we were unable to replicate the increase in ROS production with 
1-hour application of TGF-β1 (data not shown).  Also, in the 14C-cystine uptake assay we 
were unable to block the TGF-β1 mediated increase in system xc- activity with free 
radical scavengers. We tested other free radical scavengers, but were still unable to block 
the increase in system xc- activity.  Therefore, while TGF-β1 inducing an increase in 
oxidative stress, which leads to the upregulation of system xc- is an attractive hypothesis, 
we were not able to confirm that hypothesis.  Limitations of the DCF assay to measure all 
types of oxidative stress (Karlsson et al., 2010) and the inability of free radical 
scavengers to eliminate all ROS means that the hypothesis may be correct, but we were 
unable to confirm it. 
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THE EFFECT OF SYSTEM XC- FUNCTION ON NEURONAL DEATH 
 
TGF-β1’s Effects on Neuronal Death 
 
 Physiologically TGF-β1’s expression is very low under basal conditions; its 
expression and release are upregulated in many neurodegenerative diseases and in 
response to CNS injury (Pratt and McPherson, 1997; Flanders et al., 1998; Vivien and 
Ali, 2006).  Therefore, we were interested in TGF-β1’s effects on neuronal death in 
concert with an increase in oxidative stress, a hallmark of many neurodegenerative 
diseases.  Even though TGF-β1 caused astrocytes to export GSH, which should provide 
neuroprotection against the oxidative stress induced by rotenone, TGF-β1 exacerbated 
rotenone-induced neuronal death.  The AMPA receptor antagonist, NBQX (7.5µM), but 
not the NMDA receptor antagonist, memantine (10µM), was able to block the toxicity 
caused by the addition of TGF-β1.  These results suggest that TGF-β1 exacerbates 
rotenone-induced toxicity through an AMPA receptor-mediated excitotoxic mechanism.   
In order to determine if the excitotoxicity was caused by an increase in glutamate 
release due to TGF-β1’s increase in system xc- activity, blocking system xc- with an 
inhibitor would be the next logical experiment.  However, since rotenone toxicity is 
caused by increased oxidative stress (Li et al., 2003; Sherer et al., 2003) and blocking 
system xc- activity with an inhibitor would block GSH production, we found that the 
system xc- inhibitor SSZ greatly potentiated normal rotenone toxicity (data not shown).  
Therefore, due to the complexity of the experiment, we were unable to directly show that 
the increased excitotoxicity seen with TGF-β1 treatment during rotenone exposure was 
due to an increase in glutamate released through system xc-.  Another way to approach 
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answering this question would be to measure extracellular glutamate levels when TGF-β1 
is applied, using HPLC.  However, in our mixed cultures, which have high glutamate 
uptake, we have never been able to measure system xc- mediated glutamate release. 
Although we could not obtain direct evidence that the TGF-β1-induced increase 
in system xc- activity on astrocytes was responsible for the enhanced rotenone-induced 
neuronal death, a study by Brown (1999) lends support to this hypothesis.  Brown found 
that TGF-β1 causes excitotoxicity in cerebellar neurons only if astrocytes are present.  He 
concluded that TGF-β1 acted upon astrocytes to cause neuronal death through an increase 
in extracellular glutamate.  It is possible that the increase in glutamate was due to an 
increase in system xc-.  
TGF-β1 may also exert its effects through mechanisms other than system xc- that 
contribute to the excitotoxicity that Brown (1999) saw in cerebellar neurons and that we 
see with rotenone-induced toxicity in cortical neurons.  One such possibility is that TGF-
β1 causes excitotoxicity by decreasing the astrocytes’ ability to clear glutamate.  
However, along with others, we found that TGF-β1 did not affect astrocytes’ ability to 
clear extracellular glutamate through excitatory amino acid transporters (EAATs)  (Piani 
et al., 1993; Brown, 1999).   
Another possibility is that TGF-β1 could be affecting AMPA receptor expression 
and/or function.  TGF-β1 increases GluA2-containing AMPA receptor expression, but 
not GluA4-containing AMPA receptors in the hippocampus (Bae et al., 2011), which is 
consistent with our rotenone-enhanced excitotoxicity working through general AMPA 
receptors, but not Ca2+-permeable AMPA receptors.  The question still remains, however, 
why is TGF-β1 enhanced excitotoxicity AMPA-mediated and not NMDA-mediated?  
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Other studies show a similar mechanism for TGF-β1 mediated toxicity; TGF-β1 protects 
against NMDA toxicity but enhances AMPA toxicity (Prehn et al., 1993; Prehn and 
Miller, 1996; Buisson et al., 1998).  The mechanism of TGF-β1 protection against 
NMDA toxicity has been partially determined (Prehn and Krieglstein, 1994; Buisson et 
al., 1998), while the mechanism of TGF-β1exacerabtion of AMPA toxicity remains 
unclear. 
The Effect of Increasing System xc- Function on Neuronal Death 
 
The dual actions of system xc- and its ability to be regulated by a wide range of 
compounds and pathologies suggest that it can play an important role in neuronal 
protection and death.  System xc- takes up cystine from the extracellular space and uses it 
in the formation of GSH, which can protect cells from oxidative stress.  In fact, immature 
primary cortical neurons (Murphy et al., 1990), fetal brain cells  (Sagara et al., 1993b), 
and neuronal cell lines  (Miyamoto et al., 1989; Murphy et al., 1989), rely heavily on 
system xc- to protect them from oxidative glutamate toxicity.  Oxidative glutamate 
toxicity occurs when high levels of extracellular glutamate are applied to cells that lack 
glutamate receptors; instead of causing excitotoxicity, high levels of glutamate 
competitively inhibit the uptake of cystine through system xc-, causing GSH depletion, 
resulting in oxidative stress and cell death  (Murphy et al., 1989; Ratan et al., 1994).  
Overexpressing xCT or Nrf-2 in astrocytes protects immature neurons from oxidative 
glutamate toxicity (Shih et al., 2003; Shih et al., 2006).  Ceftriaxone, an antibiotic that 
upregulates system xc- activity through the Nrf-2 pathway, has also been shown to protect 
against oxidative glutamate toxicity in HT22 cells, which are not sensitive to 
excitotoxicity (Lewerenz et al., 2009).  
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System xc- can also protect against other types of oxidative stress.  Nrf-2 
overexpression in vitro protects immature neurons from hydrogen peroxide (H2O2) by 
increasing many genes involved in GSH sythesis, including xCT (Shih et al., 2003).  The 
growth factors insulin-like growth factor (IGF-1) and TGF-β1 increase system xc- activity 
on dental pulp cells, which leads to protection from oxidative stress induced by different 
dental materials (Pauly et al., 2011).  When exposed to diethyl maleate (DEM), which 
depletes cellular GSH, glioma cells increase xCT expression and system xc- activity  
(Kim et al., 2001).  System xc- activity is needed in order to maintain the high levels of 
GSH necessary for glioma cells to grow (Chung et al., 2005; Chung and Sontheimer, 
2009). 
While the above examples show increased system xc- function is protective 
against different types of oxidative stress, it is important to point out that immature 
neurons, dental pulp cells, and glioma cells, are not sensitive to excitotoxicity.  Mature 
neurons, however, are susceptible to glutamate-induced excitotoxicity and an increase in 
extracellular glutamate released through system xc- can cause excitotoxicity.  The growth 
factors TGF-β1 and fibroblast growth factor-2 (FGF-2) increase system xc- activity on 
astrocytes  (Liu et al., 2012; Liu et al. 2014; Chapter IV).  TGF-β1 enhances rotenone-
induced neuronal toxicity through AMPA receptors.  Similarly, long-term application of 
FGF-2 leads to AMPA receptor mediated neuronal death.  IL-1β also upregulates system 
xc- on astrocytes, which potentiates neuronal death induced by hypoxia and glucose 
deprivation (Fogal et al., 2007; Jackman et al., 2010; Jackman et al., 2012).  Upregulation 
of system xc- on microglia can also cause excitotoxicity in neurons.  Microglia activation 
by amyloid precursor protein (Barger and Basile, 2001) and aggregated amyloid beta 1-
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40 (Qin et al., 2006) increase glutamate released by system xc-, which leads to neuronal 
death.  Lipopolysaccharide (LPS) can also activate microglia and cause oligodendrocyte 
toxicity through increased system xc- (Domercq et al., 2007). 
While these studies suggest that increasing system xc- function has negative 
effects on neuronal death, there is no evidence that driving system xc- alone is lethal to 
neurons.  In fact, under basal conditions our culture media contains 100µM cystine, 
which is surely driving system xc- function.  Also applying TGF-β1 (Chapter IV), IL-1β 
(Fogal et al., 2005) or PACAP (Resch et al. 2014) alone for 24-48 hours, all of which 
increase system xc- function, does not lead to neuronal death.  In all of the above-
mentioned studies where upregulation of system xc- led to neuronal death, there was also 
another stressor involved: growth factor activation, rotenone, hypoxia, glucose 
deprivation, amyloid beta, or LPS. Taken together, the data suggests that while driving 
system xc- alone does not cause neuronal death, increased activity on non-neuronal cells, 
in concert with a stressor, can lead to neuronal death. 
System xc- in Amyotrophic Lateral Sclerosis 
 
 One of the most interesting results of this thesis is that system xc- function is 
significantly increased in the SOD1-G93A mutant mouse at 70 days of age (Albano et al., 
2013).  This was the first study to show that system xc- activity was dysregulated in an 
ALS model.  However, with system xc-’s ability to regulate both GSH production and 
glutamate release the key question remains: does the upregulation of system xc- at 70 
days promote neuronal protection or does it contribute to the neuronal death seen in the 
SOD1-G93A mutant mouse?  As discussed in chapter two of this thesis, elevated levels 
of oxidative stress have been seen in the spinal cord of SOD1-G93A mice starting at 60 
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days of age (Liu et al., 1998).  These data, along with changes in the GSH:GSSG ratio in 
the spinal cord of 80 day old SOD1-G93A mice (Chi et al., 2007) suggest that the 
elevated system xc- activity we found in 70 day old SOD1-G93A mice is induced by 
oxidative stress in order to increase GSH levels to protect against ROS.  
In line with this hypothesis that system xc- is upregulated in ALS in order to 
provide antioxidant protection, there are a few studies that have assessed the potential 
therapeutic effects of N-acetylcysteine (NAC) in models of ALS.  NAC is a cysteine pro-
drug that drives system xc- activity (Kupchik et al., 2012).  The results from studies using 
NAC to delay symptom onset and increase survival of SOD1-G93A mice have been 
mixed.  One study that administered NAC orally reported improved rotorod performance, 
which is indicative of delayed symptom onset, and increased survival  (Andreassen et al., 
2000).  However, another study that administered NAC orally in one set of animals and 
subcutaneously in another set of animals, did not report delayed symptom onset or 
increased survival in either group of animals  (Jaarsma et al., 1998).  The difference seen 
between these two studies may be due to variation in SOD1-G93A copy number.  The 
first study used SOD1-G93A mice with a fast symptom progression, which is due to a 
high number of SOD1-G93A copies.  The later study used mice with a lower number of 
SOD1-G93A copies, which resulted in a slower progression of the disease.   
There is one randomized, double-blind study in human ALS patients being treated 
with NAC.  Overall, NAC provided a small, non-significant increase in survival, with no 
evidence of reduction in disease progression  (Louwerse et al., 1995).  However, when 
divided into subgroups, NAC increased survival of patients with limb onset of the disease 
and decreased survival of patients with bulbar onset.  Interestingly, riluzole, a drug that 
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exerts antiglutamatergic actions and is the only FDA approved drug to treat ALS, also 
has different effects on these subgroups.  Riluzole increased survival in patients with 
bulbar onset but not patients with limb onset (Bensimon et al., 1994; Zoccolella et al., 
2007), suggesting that excitotoxicity plays a larger role in patients with bulbar onset.  It is 
possible that increased system xc- function may be particularly pronounced in ALS 
patients with bulbar onset, in which case driving system xc- with NAC could lead to 
excitotoxicity that overwhelms the benefit of increased cystine uptake.   
While system xc- may be upregulated in order to provide antioxidant protection, 
upregulation also leads to increased glutamate release and could have excitotoxic 
consequences.  A study using SOD1-G37R mutant mice, which phenotypically have a 
much slower progression of the disease than SOD1-G93A mice, observed an increase in 
xCT expression in microglia at the onset and symptomatic stages of disease progression 
(Mesci et al., 2015).  Using SOD1-G37R mice that lack xCT (SOD1-G37R:xCT-/- ) they 
found that although symptoms appeared earlier in SOD1-G37R:xCT-/- mice, the disease 
progressed more slowly.  During the symptomatic stage, SOD1-G37R:xCT-/-  mice 
maintained grip strength longer and lived longer then SOD1-G37R:xCT+/+  mice; they 
also had more surviving motor neurons at the end stage of the disease.  Mesci et al. 
hypothesize that SOD1-G37R:xCT-/- mice  have a slower disease progression due to less 
glutamate being released from microglia, since many studies have shown that activated 
microglia have increased glutamate release via system xc- (Piani and Fontana, 1994; 
Barger and Basile, 2001; Mesci et al., 2015).  However, they did not directly measure 
glutamate levels in the SOD1-G37R:xCT-/- mice. 
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With the dual nature of system xc- it is no surprise that it may play a very complex 
role in ALS.  System xc- function is upregulated in both SOD1-G93A and SOD1-G37R 
mice; however, we found that in SOD1-G93A mice it is upregulated at the 
presymptomatic stage, while in the SOD1-G37R mice it is upregulated at the onset and 
symptomatic stages (Albano et al., 2013; Mesci et al., 2015).  The differences in disease 
progression likely have a large impact on when system xc- is upregulated and the effects 
this upregulation has in the disease.  To this point, as previously described, treating 
SOD1 mutant mice and human ALS patients with NAC yielded different results.  The 
differences seen in all of these studies may be due to differences between the progression 
of the disease (in the mutant mice) and onset subgroup (in humans).  Further research into 
the role system xc- plays during the different stages of disease progression may aid in 
understanding the complexity of system xc- in ALS. 
Based on the available evidence, one might speculate that in SOD1 mutant mice 
system xc- may be initially upregulated in response to increased oxidative stress in order 
to provide antioxidant protection, but eventually it may contribute to the excitotoxicity of 
motor neurons through increased glutamate release.  Inhibiting system xc- at various time 
points in ALS disease progression and assessing disease onset, symptoms, and survival 
rate would be one way to determine if increasing system xc- is beneficial early on, but 
harmful at later stages of the disease.  The Food and Drug Administration (FDA) has 
approved the system xc- inhibitor SSZ for the treatment of inflammatory bowel disease. 
One potential problem with using SSZ is that blocking system xc- may lead to a decrease 
in GSH levels, which would mask any of its potentially protective effects.  The earlier 
symptom onset seen in SOD1-G37R:xCT-/- mice support this idea (Mesci et al., 2015).  
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SSZ administration in combination with L-2-oxo-4-thiazolidine carboxylate (OTC) may 
circumvent this problem.  OTC, also known as Procysteine, is an L-cysteine precursor; it 
increases cysteine levels in the brain by being taken up into cells and converted into L-
cysteine by the enzyme 5-oxoprolinase  (Anderson and Meister, 1989).  Since cysteine is 
the precursor to GSH, studies have shown that administration of OTC is able to increase 
GSH levels both in vitro and in vivo (Kranich et al., 1998; Mesina et al., 1989).  
Administering SSZ and OTC at the right time and in the correct dosage has the potential 
to block the excitotoxic effects the increase in system xc- might be having, while 
supplying the cells with the antioxidant support that blocking system xc- might remove. 
The ability of SSZ to reach the brain and spinal cord is another potential concern 
when considering its therapeutic potential.  Oral administration of SSZ is metabolized by 
bacteria found in the gut, into sulfapyridine and 5-aminosalicylic acid, which do not 
inhibit system xc-  (Azadkhan et al., 1982; Gout et al., 2001).  However, intraperitoneal 
injection of SSZ has been shown to suppress primary brain tumor growth by inhibiting 
system xc-  (Gout et al., 2001; Chung et al., 2005) and it has also been shown to dose-
dependently reduce extracellular glutamate levels in the prefrontal cortex (Lutgen et al., 
2014). Together these studies suggest that SSZ is able to cross the blood brain barrier and 
inhibit system xc- when administered intraperitoneally. 
Our findings in the SOD1-G93A mouse model of ALS add to a growing literature 
that shows dysregulation of system xc- function in many neurodegenerative diseases.  In 
most neurodegenerative diseases, with the exception of Huntington’s disease, system xc- 
function is increased; evidence suggests that this increase may contribute to the neuronal 
death seen in many of these diseases. Although in vivo evidence is still needed, the 
	136	
damage is likely caused by increased glutamate release into the extrasynaptic space, 
which leads to an overactivation of glutamate receptors and cell death.  In the EAE model 
of multiple sclerosis pharmacological inhibition of system xc- decreased disease severity 
(Evonuk et al., 2015); and in one study of the 6-OHDA model of Parkinson’s disease 
xCT-/- mice had decreased dopaminergic cell death (Massie et al., 2011).  These studies 
point to system xc- as a potential therapeutic target by which to slow progression of many 
neurodegenerative diseases. 
Increasing System xc- and Neuronal Death – A Summary 
 
 As previously discussed, there is no evidence that increasing system xc- activity 
alone leads to cell death.  However, upregulation of system xc- on non-neuronal cells, in a 
stressed or neurodegenerative diseased state can lead to neuronal death.  Figure 5.3 
summarizes the events that may be occurring in a stressed/diseased state, which may 
contribute to the neuronal death in these states.  In both non-stressed and 
stressed/diseased states, upregulation of system xc- leads to increased GSH production 
and increased glutamate release.  In a non-stressed state we hypothesize that increased 
GSH production helps protect neurons from oxidative stress caused by free radicals and 
EAATs are able to handle the increased glutamate being released.  In a stressed/diseased 
state, however, increased glutamate release can lead to excitotoxicity due to ionotrophic 
receptor overactivation.  The cause of AMPA and NMDA receptor overactivation is 
unknown, but may be due to receptor upregulation, recetpor phosphorylation, decreased 
EAAT function, or a combination of these events.  Decreased EAAT function may also 
decrease the uptake of cysteine into neurons, which would decrease GSH production in 
neurons leading to increased oxidative stress and contribute to neuronal death. 
	137	
 
Figure 5.3 Hypothetical role of system xc- in contributing to neuronal death 
in stressed/diseased states. C-C: cystine; Cys: cysteine; GSH: glutathione; Glu: 
glutamate; xc-: system xc-; E: excitatory amino acid transporter; A: AMPA 
receptor; N: NMDA receptor; M: metabotropic glutamate receptor; MRP-1: 
multidrug resistance protein 1 
 
 
LIMITATIONS IN STUDYING SYSTEM XC- 
 
Detecting System xc-  
 
One of the biggest challenges of studying system xc- is detecting its expression 
and pattern of distribution.  Three different xCT transcripts (12, 3.5, and 2.5kb), all easily 
induced by a variety of insults, have been detected in macrophages, fibroblasts, and HT22 
cells using Northern blot (Sato et al., 1999; Sato et al., 2001; Sato et al., 2002; Sato et al., 
2004; Sato et al., 2005; Lewerenz et al., 2006). The different transcripts are likely a result 
of alternative splicing or alternative polyadenylation sites.  Northern blot analysis of 
different types of tissue also show that the 12kb transcript is found in the brain, but is 
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absent from the heart, lungs, liver, and kidneys.  The 3.5 and 2.5kb transcripts are absent 
from all of the tissue tested, including brain tissue, suggesting that they are mainly found 
in cultured macrophages (Sato et al., 1999). 
Using RT-qPCR, we measured the change in xCT mRNA levels following TGF-
β1 application, using two different sets of primers.  Both sets of primers showed that 
TGF-β1 increased xCT mRNA levels in a time-dependent manner to a similar extent 
(data not shown).  Interestingly, our results also showed that the xCT mRNA detected 
with the first set of primers was significantly more abundant than that detected with the 
second set of primers under control conditions.  These results suggest that we are 
detecting two different splice variants of xCT.  
While using Northern blotting and RT-qPCR are useful, increased xCT mRNA 
does not always mean increased functional protein at the membrane.  A major hurdle for 
studying system xc- is the lack of a specific antibody to detect xCT protein. The amino 
acid sequence for xCT is predicted to be 502 amino acids long and have a relative 
molecular weight of 55.5kDa (Sato et al., 1999).  However, Western blotting with 
different antibodies has yielded results with multiple molecular masses.  A 50kDa band 
was detected in human glioma cells  (Kim et al., 2001), while a 45kDa band was detected 
in murine fibroblasts  (Lewerenz et al., 2009).  In Muller cells, both 50kDa and 40kDa 
bands were detected  (Mysona et al., 2009).  The 50kDa band was found both in the 
membrane and intracellularly.  The 40kDa band, on the other hand, was mainly found 
intracellularly; its expression increased in the membrane when the cells were in 
conditions of increased oxidative stress.  A 40kDa band was also found in human 
fibroblasts, and neurons and astrocytes cultured from rats (La Bella et al., 2007).  In 
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HT22 cells diethyl maleate increased the intensity of a band detected at 40kDa; and this 
band was gone following RNAi for xCT  (Burdo et al., 2006).  Finally, a 35kDa band has 
been detected in multiple brain regions in mice and rats  (Shih et al., 2006; Massie et al., 
2008; De Bundel et al., 2011; Liefferinge et al., 2016).  Some of these studies also show 
that the 35kDa band is not present in xCT knockout mice. 
A recent study done by Liefferinge et al. (2016) highlights some of the problems 
regarding xCT antibodies.  Out of 53 antibodies studied, only one was specific enough to 
be present in the xCT +/+ mouse and absent in the xCT -/- mouse when used for 
immunohistochemistry staining.  This was an antibody that was made in-house and it 
showed only one band at 35kDa with Western blotting.  Using this one specific antibody 
they were able to detect xCT expression in the cortex, striatum, hippocampus, midbrain, 
thalamus, and amygdala.  All of the other antibodies analyzed (including commercially 
available antibodies) detected multiple molecular masses with Western blotting and/or 
showed non-specific labeling with immunohistochemistry.  Liefferinge et al. (2016) also 
noted that the bands labeled with Western blot could change between different stocks of 
the same antibody.  Due to the unreliability of xCT antibodies, in this thesis we focused 
on analyzing system xc- function using radiolabeled uptake assays. 
Limitations Regarding the Translation of in vitro Studies in vivo 
 
In working with primary cortical cultures we have observed that system xc- is 
mainly found on astrocytes.  There are a couple of key pieces of evidence that support 
this observation.  First, 14C-cystine uptake through system xc- is much greater under 
control conditions in astrocytes-enriched glial cortical cultures than in either pure 
neuronal cultures or pure microglia cultures.  Also, when TGF-β1 is applied 14C-cystine 
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uptake is only increased in astrocyte-enriched glial cultures.  Similarly, other studies have 
found that IL-1β and PACAP increase 14C-cystine uptake and xCT mRNA expression in 
astrocytes, but not in neuronal or microglial cultures  (Jackman et al., 2010; Resch et al., 
2014).  Second, we observe similar levels of 14C-cystine uptake in mixed cortical 
cultures, which contain both neurons and glial cells, and mixed cortical cultures treated 
with 500µM NMDA, which effectively kills the neurons without killing the astrocytes. 
Taken together, this data suggests that in our culture system, system xc- is mainly found 
and upregulated on astrocytes.   
Other in vitro studies show that meninges have a higher rate of radiolabeled 
cystine uptake than astrocytes (Shih et al., 2006) and that system xc- is upregulated on 
microglia (Piani and Fontana, 1994; Qin et al., 2006; Barger et al., 2007).  System xc- 
activity has even been induced in culture on cells that do not show xCT expression in 
vivo  (Takada and Bannai, 1984; Watanabe and Bannai, 1987), which raises some 
concerns about translating in vitro studies in vivo.  Culturing conditions likely make cells 
much more reliant on system xc-, which makes its activity much higher in vitro than what 
may be found in vivo (Lewerenz et al., 2013).  For example, oxygen levels used in 
culturing conditions are higher than oxygen levels found in vivo.  Cells are normally 
cultured under 21% oxygen conditions, which leads to significantly higher levels of 
cystine uptake than cells cultured under only 2% oxygen (Bannai et al., 1989; Sato et al., 
2001).  Higher levels of oxygen lead to an increase in ROS (Halliwell, 2003) and in order 
to be protected, cells must synthesize more GSH.  Since cysteine found in the media is 
rapidly oxidized to cystine under normal cell culture conditions, in vitro cells rely heavily 
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on system xc- to be able to take up cystine from the media to convert it to GSH (Conrad 
and Sato, 2012). 
Within this thesis there is conflicting data regarding system xc- activity between 
work done using in vitro spinal cord glial cells cultured from 1-3 day old SOD1-G93A 
mice pups and work done in ex vivo slices from adult SOD1-G93A mice (Chapter II). In 
order to further study system xc- in SOD1-G93A mutant mice we cultured spinal cord 
glial cells from 1-3 day old pups.  Consistently culturing and getting healthy cells to grow 
in vitro from SOD1-G93A adult tissue is difficult, therefore it is common to culture cells 
from young SOD1-G93A mutant pups (Hensley et al., 2006; Bilsland et al., 2008; 
Cassina et al., 2008; Rabinovich-Toidman et al., 2015).  After culturing the glial cultures 
we insulted them with iron citrate, in order to mimic the increase in oxidative stress seen 
in vivo in SOD1-G93A mutant mice.  However, when we did this SOD1-G93A non-
transgenic littermates had higher levels of cystine uptake than SOD1-G93A mutant mice, 
which is the opposite of what we observed in adult spinal cord slices.  While in vitro 
studies reveal useful insight into the mechanistic and pharmacological characteristics of 
system xc-, the differences we see in system xc- activity between in vitro culture and ex 
vivo slice, along with the concerns regarding culture conditions, must be kept in mind 
when considering what is learned in vitro and translating it in vivo. 
Limitations of the DCF assay  
 
The DCF assay is the most commonly used assay to detect oxidative stress 
(Kalyanaraman et al., 2012). In this assay the cell-permeable probe, H2DCFDA is added 
to the media. Once inside the cell it is de-esterified to form a free acid (H2DCF) that can 
then be oxidized to the fluorescent product, DCF, which is easily detected using a 
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fluorescent plate reader. Originally thought to mainly detect hydrogen peroxide (H2O2) it 
is now known that H2DCF can be oxidized to DCF by the hydroxyl radical (OH-), NO2- 
formed from the nitrite system, hypochlorous acid (HOCl), and reactive species formed 
peroxynitrite decomposition (Kalyanaraman et al., 2012).  
Although easy to use, in our hands, we found that the DCF assay could give 
mixed results. As previously discussed, we used the DCF assay to detect the levels of 
oxidative stress inside astrocyte-enriched glial cell cultures following TGF-β1. Initially 
we observed an increase in DCF fluorescence following 1-hour TGF-β1 application, 
which indicated an increase in intracellular oxidative stress. However, in subsequent 
experiments the increase in oxidative stress was no longer detected by the DCF assay. 
The mixed results that we observe with the DCF assay may be a result of some of the 
assay’s caveats. One such caveat to the assay that may explain our mixed is that H2DCF 
is not directly oxidized by H2O2 (Kalyanaraman et al., 2012). A short (30 minute) 
exposure of cells to H2O2 only marginally increased DCF in a study by Karlsson et al. 
(2010). Therefore, it is possible that if TGF-β1 is increasing system xc- activity by 
increasing H2O2 production, the DCF assay may not be able to reliably detect the increase 
in H2O2 after only 1-hour.  
The DCF assay may also have some more major caveats. The study by Karlsson 
et al. (2010) suggests that H2DCF oxidation largely occurs as a result of its interaction 
with cytochrome c, a protein released from the mitochondria during apoptosis, and/or its 
interaction with iron released from lysosomes, which forms DCF in the presence of 
oxygen or H2O2. The study suggests that without the release of cytochrome c and/or iron 
only a weak cytosolic fluorescence will be observed, which is likely due to normal 
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mitochondrial production of H2O2. These caveats should also be taken into consideration 
when interpreting data from the DCF assay. 
CONCLUSIONS 
 
The function of system xc- allows it to be influential in determining a cell’s fate.  
Its dual nature allows it to protect neurons from oxidative stress but it may also lead to 
cell death by releasing too much glutamate into the extracellular space.  Although 
discovered over 30 years ago, the question still remains: Is upregulation of system xc- 
more likely to be neuroprotective or lead to cell death?  Unfortunately, because of the 
complexity of system xc- function and the diseases it is dysregulated in, there is no clear 
answer to this question.  However, this thesis was able to add to our knowledge about 
how system xc- is regulated and its contribution to cell death.   
Our study was the first to observe system xc- dysregulation in a model of ALS.  
We found that system xc- activity was increased in SOD1-G93A mutant mice at a time 
point just after increased oxidative stress was observed.  Given its function, this suggests 
that system xc- activity is increased in response to oxidative stress in order to provide 
antioxidant protection.  However, system xc- is increased in many neurodegenerative 
diseases and appears to have negative consequences on neuronal death in many of these 
diseases.  We also found cysteine to be a more important regulator of system xc- activity 
than GSH.  One of system xc-’s functions is to maintain the cystine/cysteine redox 
balance of the cellular membrane; therefore, cysteine’s ability to regulate system xc- is 
important, especially since levels of cysteine are more directly related to the uptake of 
cystine than levels of GSH.  Finally, we showed that TGF-β1 increased system xc- 
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activity on astrocytes and that this can have negative consequences on neurons when they 
are under increased oxidative stress.   
Collectively, there appear to be more studies showing negative consequences of 
increased system xc- function on neuronal death and our TGF-β1 study adds to this 
collection.  However, it is important to point out that most of these observations are seen 
in culture and occur when another stressor is involved.  Increasing system xc- activity in 
vivo may be beneficial in situations where excitotoxicity is limited, but oxidative stress is 
occurring.  Therapeutically increasing system xc- activity may also be useful in order to 
restore impaired glutamatergic signaling, as is seen in diseases like schizophrenia (Baker 
et al., 2008; Chen et al., 2010; Lutgen et al., 2014) and addiction (Baker et al., 2003; 
Madayag et al., 2007; Kau et al., 2008; Reichel et al., 2011); in which excitotoxicity is 
not likely to occur. 
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